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Background: Computerised cognitive behaviour therapy (cCBT) has been developed as an efficient form
of therapy delivery with the potential to enhance access to psychological care. Independent research is
needed which examines both the clinical effectiveness and cost-effectiveness of cCBT over the short and
longer term.
Objectives: To compare the clinical effectiveness and cost-effectiveness of cCBT as an adjunct to usual
general practitioner (GP) care against usual GP care alone, for a free-to-use cCBT program (MoodGYM;
National Institute for Mental Health Research, Australian National University, Canberra, Australia) and a
commercial pay-to-use cCBT program (Beating the Blues®; Ultrasis, London, UK) for adults with depression,
and to determine the acceptability of cCBT and the experiences of users.
Design: A pragmatic, multicentre, three-armed, parallel, randomised controlled trial (RCT) with concurrent
economic and qualitative evaluations. Simple randomisation was used. Participants and researchers were
not blind to treatment allocation.
Setting: Primary care in England.
Participants: Adults with depression who scored ≥ 10 on the Patient Health Questionnaire-9 (PHQ-9).
Interventions: Participants who were randomised to either of the two intervention groups received cCBT
(Beating the Blues or MoodGYM) in addition to usual GP care. Participants who were randomised to the
control group were offered usual GP care.
Main outcome measures: The primary outcome was depression at 4 months (PHQ-9). Secondary
outcomes were depression at 12 and 24 months; measures of mental health and health-related quality of
life at 4, 12 and 24 months; treatment preference; and the acceptability of cCBT and experiences of users.
Results: Clinical effectiveness: 210 patients were randomised to Beating the Blues, 242 patients were
randomised to MoodGYM and 239 patients were randomised to usual GP care (total 691). There was no
difference in the primary outcome (depression measured at 4 months) either between Beating the Blues
and usual GP care [odds ratio (OR) 1.19, 95% confidence interval (CI) 0.75 to 1.88] or between
MoodGYM and usual GP care (OR 0.98, 95% CI 0.62 to 1.56). There was no overall difference across all
time points for either intervention compared with usual GP care in a mixed model (Beating the Blues versus
usual GP care, p= 0.96; and MoodGYM versus usual GP care, p= 0.11). However, a small but statistically
significant difference between MoodGYM and usual GP care at 12 months was found (OR 0.56, 95% CI
0.34 to 0.93). Free-to-use cCBT (MoodGYM) was not inferior to pay-to-use cCBT (Beating the Blues)
(OR 0.91, 90% CI 0.62 to 1.34; p= 0.69). There were no consistent benefits of either intervention when
secondary outcomes were examined. There were no serious adverse events thought likely to be related to
the trial intervention. Despite the provision of regular technical telephone support, there was low uptake
of the cCBT programs. Cost-effectiveness: cost-effectiveness analyses suggest that neither Beating the
Blues nor MoodGYM appeared cost-effective compared with usual GP care alone. Qualitative evaluation:
participants were often demotivated to access the computer programs, by reason of depression. Some
expressed the view that a greater level of therapeutic input would be needed to promote engagement.
Conclusions: The benefits that have previously been observed in developer-led trials were not found in
this large pragmatic RCT. The benefits of cCBT when added to routine primary care were minimal, and
uptake of this mode of therapy was relatively low. There remains a clinical and economic need for effective
low-intensity psychological treatments for depression with improved patient engagement.
Trial registration: This trial is registered as ISRCTN91947481.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme.
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Effectiveness and Acceptability of
Computerised Therapy
SAE serious adverse event
SD standard deviation
SF-36v2 Short Form questionnaire-36 items
Health Survey® version 2
SF-6D Short Form questionnaire-6
Dimensions
SMD standardised mean difference
SUR seemingly unrelated regression
TSC Trial Steering Committee
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Plain English summary
Depression is a common mental health problem. An effective talking treatment for depression iscognitive behaviour therapy (CBT). Computerised CBT (cCBT) is a recently developed form of CBT
which is delivered by computer rather than by a face-to-face therapist. We conducted a fair test of
two cCBT programs compared with the usual care people receive from their general practitioner (GP) to
find out whether or not cCBT is effective in treating people with depression.
A total of 691 people with depression were allocated to one of three interventions: (1) a pay-to-use cCBT
program (called Beating the Blues®; Ultrasis, London, UK) added to usual GP care; (2) a free-to-use
cCBT program (called MoodGYM; National Institute for Mental Health Research, Australian National
University, Canberra, Australia) added to usual GP care; or (3) usual GP care alone. People received support
and encouragement to complete cCBT sessions via weekly telephone calls. People completed questionnaires
about general and mental well-being and symptoms of depression at 4, 12 and 24 months after the study
started. Some people were also interviewed to find out about their experiences of cCBT.
The cCBT programs were no more effective at reducing symptoms of depression than usual GP care alone
at 4 and 24 months, although there was a small benefit for MoodGYM compared with usual GP care
alone at 12 months. The free-to-use program was not inferior to the more costly program. The cCBT
programs were liked by some people and rejected by others, but the majority were ambivalent. We found
that usual GP care was better value for money than cCBT in addition to usual GP care.
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Scientific summary
Background
Depression is the most common mental health disorder in community settings and is estimated to become
the second largest cause of global disability by 2020. It is one of the most common reasons for consulting a
general practitioner (GP) and is associated with significant personal and economic burden. Antidepressant
medication is an important treatment option for depression; however, many patients and health-care
professionals would like to access psychological therapy as an alternative or adjunct to medication. A leading
evidence-supported form of brief psychological therapy for people with depression is cognitive behaviour
therapy (CBT), but unfortunately patient demand for CBT cannot be met from existing therapist resources.
There is a need to increase patient access to psychological therapy and one potential way of achieving this
might be the provision of CBT delivered via computer. The provision of computerised CBT (cCBT) is
recommended in the National Institute for Health and Care Excellence (NICE) guidelines as an initial
lower-intensity treatment for depression as part of a ‘stepped care’ approach in primary care. Much of
the existing evidence for the short-term clinical effectiveness of cCBT for depression comes from research
conducted by the developers of the cCBT programs. Research conducted by independent researchers is
needed to establish both the clinical effectiveness and the cost-effectiveness of cCBT in the short term and
over the longer term. Whether or not free-to-use cCBT programs are as effective as commercial pay-to-use
cCBT programs also needs to be determined. There is also a lack of research examining the acceptability
of cCBT, both to patients and health professionals, as well as the issue of patient preference and its
relationship to treatment uptake and effectiveness.
Objectives
The REEACT (Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy) trial
was a randomised controlled trial (RCT) of usual GP care versus the addition of one of two cCBT programs
for the treatment of depression in adults. This included concurrent qualitative and economic evaluations.
The specific objectives of the REEACT trial were:
1. to establish the clinical effectiveness and cost-effectiveness of cCBT in addition to usual GP care
compared with usual GP care alone over a 2-year trial follow-up period
2. to establish the acceptability (to patients and health professionals) of cCBT
3. to establish the differential clinical effectiveness and cost-effectiveness of a free-to-use cCBT program
(MoodGYM; National Institute for Mental Health Research, Australian National University, Canberra,
Australia) in comparison with a commercial pay-to-use cCBT program (Beating the Blues®; Ultrasis,
London, UK) over a 2-year and longer-term time horizon.
Method
Design
A pragmatic, multicentre, three-armed RCT with concurrent economic and qualitative evaluations.
The design included a fully randomised patient preference approach. Participants were randomised using
simple randomisation (1 : 1 : 1) with allocation concealed. Treatment allocation and outcome measurement
were not concealed.
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Setting
Participants were recruited from GP practices in Bristol, Manchester, Sheffield, York, Hull and the north-east
of England.
Participants
Potential participants were identified (1) by direct referral by a GP or health professional attached to a
GP practice or (2) following a written approach by the GP after identification via GP practice database
screening. Potential participants were eligible to participate in the trial if they were aged 18 years and over,
scored 10 or above on a validated depression severity instrument [Patient Health Questionnaire-9 (PHQ-9)]
and were not in receipt of cCBT or specialist psychological therapy.
Interventions
Participants were randomised to receive: (1) a free-to-use cCBT program (MoodGYM) plus usual GP care;
(2) a commercial pay-to-use cCBT program (Beating the Blues) plus usual GP care; or (3) usual GP care
alone. Given the pragmatic design of the trial, no restrictions were imposed on the range of treatments
that could be offered by a GP as part of usual care. Both intervention programs were based on CBT and
both have been endorsed by NICE in the initial treatment of depression in primary care. The cCBT
programs involved internet-based interactive therapy sessions, which could be accessed at the participant’s
home, in a central location close to the participant’s home or at the GP practice, depending on patient
preference and availability. Intervention participants received technical support and encouragement to
complete the cCBT program via weekly telephone calls.
Main outcome measures
The primary outcome was self-reported symptoms of depression, assessed by the PHQ-9 at 4 months post
randomisation. Secondary outcomes were: self-reported symptoms of depression (PHQ-9) at 12 and
24 months; global and generic measures of mental health, health-related quality of life and patient-level
resource use, each at 4, 12 and 24 months; treatment preference; and participants’ and health
professionals’ experiences of cCBT and perceptions of its acceptability.
Results
Clinical effectiveness: a total of 691 patients, aged 18–76 years, were recruited to the trial between
August 2009 and March 2011, with 210 participants randomised to receive pay-to-use cCBT (Beating
the Blues) plus usual GP care, 242 participants randomised to receive free-to-use cCBT (MoodGYM) plus
usual GP care and 239 participants randomised to receive usual GP care alone. Analyses used intention-to-
treat. There was no significant difference in depression at the primary outcome measured at 4 months for
either Beating the Blues versus usual GP care alone [odds ratio (OR) 1.19, 95% confidence interval (CI)
0.75 to 1.88] or MoodGYM versus usual GP care alone (OR 0.98, 95% CI 0.62 to 1.56). There was no
overall difference across all time points for either intervention compared with usual GP care alone in a
mixed model (Beating the Blues vs. usual GP care alone, p= 0.96; and MoodGYM vs. usual GP care alone,
p= 0.11). However, a small, but statistically significant, difference between MoodGYM and usual GP care
alone at 12 months was found (OR 0.56, 95% CI 0.34 to 0.93). In a non-inferiority analysis, free-to-use
cCBT (MoodGYM) was not shown to be inferior to pay-to-use cCBT (Beating the Blues) (OR 0.91, 90% CI
0.62 to 1.34; p= 0.69). There were no consistent benefits for either intervention when secondary
outcomes were examined. Participants showed a preference for cCBT prior to randomisation; however,
cCBT was equally ineffective for those with and without a strong preference. Despite the provision of
regular telephone calls for technical support and encouragement, there was low uptake of the cCBT
programs. There were no serious adverse events thought likely to be related to the trial intervention.
Cost-effectiveness: the trial-based cost-effectiveness analyses suggest that neither Beating the Blues nor
MoodGYM was cost-effective compared with usual GP care alone. Beating the Blues was more expensive
and resulted in fewer quality-adjusted life-years (QALYs) than usual GP care (dominated), and MoodGYM
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resulted in fewer QALYs but at lower cost. Usual GP care alone compared with either cCBT intervention was
also the cost-effective intervention in the majority of scenario analyses and was the intervention most likely to
be cost-effective at a £20,000 per QALY threshold (probabilities ranging across scenarios from 0.545 to 0.619).
Qualitative evaluation: when exploring the reasons for poor engagement of the cCBT programs, it was
found that depression often demotivated participants to access the computer programs in their own time
and when left to their own devices. Some said that a greater level of therapeutic input would be needed
to promote engagement. GPs did not believe that cCBT could be offered within primary care premises.
Conclusions
The benefits that have previously been observed in developer-led trials were not found in this large
pragmatic RCT conducted in routine UK primary care services. The benefits of cCBT when added to routine
primary care were minimal and there was relatively low uptake of this mode of therapy.
Implications for health care
l In this trial for patients with moderate or severe depression powered to detect non-inferiority,
technically supported cCBT in addition to usual GP care was no more effective than usual GP care
alone. Practice recommendations such as those offered by NICE and Improving Access to Psychological
Therapies stepped models of care might usefully be re-examined in the light of these findings.
l We consider that, where cCBT continues to be offered within the portfolio of low-intensity
psychological treatment, there should be early follow-up in primary care to identify patients for whom
the intervention may be unsuitable.
l Commissioners of services should take note of our findings that commercially produced products may
add little benefit to usual GP care.
l We found no substantial difference in outcomes between the commercially produced product (Beating
the Blues), when offered in addition to usual GP care, and the free-to-use product (MoodGYM), which
is clearly less costly for the NHS.
l Free-to-use products such as MoodGYM could be offered in response to patient choice. However, our
overall finding of the relative lack of benefit of these programs in addition to usual GP care should also
be taken into account in this context.
Recommendations for future research
There remains a clinical and economic need for effective low-intensity psychological treatments for
depression. Trials of alternative low-intensity treatments such as telephone-guided bibliotherapy,
telephone-guided self-help or more intensively guided cCBT are needed. All such studies should be
framed in primary care and conducted by researchers other than product developers. In the longer term,
if computers are to be used to deliver psychological treatment with minimal therapist input, then there
needs to be improved patient experience and engagement through greater personalisation of treatment
packages. This requires further research and innovation at the human–computer interface.
Trial registration
This trial is registered as ISRCTN91947481.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Depression
Depression is the most common mental health disorder in community settings and is estimated to become
the second largest cause of global disability by 2020.1 It is one of the most common reasons for consulting
a general practitioner (GP), and is associated with significant personal and economic burden.2
Psychological therapy for depression
Antidepressant medication is an important treatment option for depression; however, many patients and
health-care professionals would like to access psychological therapy as an alternative or adjunct to
medication.3 A leading evidence-supported form of brief psychological therapy for people with depression is
cognitive behaviour therapy (CBT).4,5 However, given that patient demand for CBT cannot be met from
existing therapist resources,6 there is a need to increase patient access to psychological therapy. One
potential way of achieving this might be the provision of CBT delivered via computer.7 In recent years, a
number of interactive programs have been developed which enable CBT to be delivered by computer. The
provision of computerised CBT (cCBT) is now recommended in the National Institute for Health and Care
Excellence (NICE) guidelines as an initial lower-intensity treatment for depression as part of a ‘stepped care’
approach in primary care.5 cCBT, if shown to be effective, has the potential to expand the provision of
psychological therapy in primary care and, as such, may represent an efficient and effective form of care
for depression.8
There are a number of interactive internet-based products that are available for those who decide to use
(or commission the provision of) cCBT. Some of these cCBT products are commercially produced whereas
others are free to use.7 A number of commercial products have been marketed to bodies such as the NHS
and have also been made available for patients to purchase directly. The free-to-use products have been
developed by the public sector or by research institutes and can be accessed at no direct purchase cost to
patients or health-care providers, although there may be costs associated with their support and use in
the NHS.
Evidence for computerised cognitive behaviour therapy
Computerised CBT represents an alternative form of therapy delivery that has the potential to enhance
access to psychological care. Existing research into cCBT has been summarised by Kaltenthaler
and colleagues in their 2006 Health Technology Assessment (HTA) review of clinical effectiveness and
cost-effectiveness.6 With respect to depression, three commercially produced computerised packages
available to the NHS were considered: Beating the Blues® (Ultrasis, London, UK), COPE and Overcoming
Depression. Of these, only one, Beating the Blues, had been evaluated in a randomised controlled trial
(RCT); the program was shown to be effective at reducing symptoms of depression.7 However, this
research was conducted by those who owned and held the intellectual copyright to Beating the Blues.
Among internet-based free-to-use packages, only one, MoodGYM (National Institute for Mental Health
Research, Australian National University, Canberra, Australia), has been evaluated in a randomised trial,
which was also conducted by the package developers.8 MoodGYM was found to be effective at reducing
depressive symptomatology.8 The overall conclusion of the HTA review was that ‘the efficacy but not
effectiveness of Beating the Blues had been established in comparison with treatment as usual’.6
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Recommendations for further research on the effectiveness of
computerised cognitive behaviour therapy
At the time of the commissioning and design of the REEACT (Randomised Evaluation of the Effectiveness
and Acceptability of Computerised Therapy) trial, several caveats applied and specific recommendations for
further research were made that are important with respect to the present trial.
l Computerised CBT had been shown to be effective in the short term, but trials rarely examined the
longer-term impact on depression compared with usual care. Trials with longer periods of follow-up
are needed.
l The cost-effectiveness of computerised packages is as yet unknown. More importantly, the
cost-effectiveness from the perspective of the UK NHS has not been sufficiently established and
the longer-term cost-effectiveness beyond the brief time horizon of existing trials is essentially unknown.
This is important, as commercial packages (such as Beating the Blues) will need to be purchased by
the NHS.
l Existing trials are based on populations who have been referred to specialist cCBT services and are
necessarily comfortable with information technology and willing to be offered computerised therapy as
a treatment option. Computer-delivered CBT uses a computer rather than a trained CBT therapist, and
the acceptability of the replacement of the therapist with a machine interface is largely unknown.
Patients with depression might show a strong preference for or against computer therapy, and this
might, in turn, be related to uptake and effectiveness. The acceptability and effectiveness of cCBT
among patients who are representative of people treated for depression in NHS primary care services
has not yet been established. There is, therefore, a need for pragmatic evaluations of cCBT based in UK
primary care that examine real-world effectiveness and the issue of patient preference.
l There are no trials of free-to-use cCBT packages versus pay-to-use cCBT packages. This is important,
as the effectiveness of free-to-use cCBT would need to be comparable to pay-to-use CBT if it were
to be a viable alternative within a stepped care pathway.9
l Evaluations of all the commercially available and free-to-use packages of cCBT have been conducted by
researchers responsible for their development. Although this does not invalidate the results, it does
raise concerns that a truly independent evaluation of the clinical effectiveness and cost-effectiveness of
cCBT is needed to inform NHS decision-making. In their 2006 HTA report, Kaltenthaler and colleagues
make this a core research recommendation and state that ‘Research needs to be carried out by
independent researchers. It should be carried out by those who are not associated with commercial or
product gains’.6
The present trial was designed to address these recommendations. A subsequent meta-analysis has
demonstrated that cCBT can be effective for depression, but there remains a need for longer-term
pragmatic studies and evaluations by researchers other than the product developers.10
The REEACT study represents a pragmatic evaluation of cCBT in a trial that is adequately controlled and
has appropriate statistical power.
BACKGROUND
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Research objectives
This was a fully randomised patient preference trial of usual GP care for depression versus the addition of
one of two cCBT packages to usual GP care. The REEACT study included a concurrent economic and
qualitative evaluation to meet the following specific aims:
l to establish the clinical effectiveness and cost-effectiveness of the addition of cCBT to usual GP care
compared with usual GP care alone over a 2-year trial follow-up period
l to establish the acceptability (to patients and health professionals) of cCBT
l to establish the differential clinical effectiveness and cost-effectiveness of a free-to-use computerised
package, in comparison with a commercial pay-to-use cCBT package over a 2-year and longer-term
time horizon.
Some of this text has been reproduced from Gilbody et al.11 © BMJ 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Chapter 2 Methods
Trial design
The REEACT trial was a pragmatic, multicentre, open, three-armed parallel RCT with simple randomisation. The
design included a fully randomised patient preference approach.12 Participants with depression [defined as a
score of ≥ 10 on the Patient Health Questionnaire-9 (PHQ-9) depression severity instrument]13 were randomised
(1 : 1 : 1) to receive:
l a commercial pay-to-use cCBT program (Beating the Blues) plus usual GP care or
l a free-to-use cCBT program (MoodGYM) plus usual GP care or
l usual GP care alone.
Approvals obtained
The Leeds (East) Research Ethics Committee (REC) approved the study on 10 July 2008 and approved the
substantial amendment to revise the trial design following advice from the funder on 22 September 2008
(see Chapter 3 for details of this substantial amendment). The details of the REC and Research and
Development Department approvals are provided in Appendix 1. The trial was registered as ISRCTN91947481;
EudraCT number 2007-007645-12; and UK Clinical Research Network Study Portfolio (UKCRN) identification
number 4115.
Trial sites
The trial was conducted in nine UK sites. Five sites were involved from the commencement of the trial,
and the remaining four sites were recruited throughout the duration of the trial. Details of the study sites
are provided in Appendix 2.
Participant eligibility
People with depression were eligible to take part in the trial. Both prevalent and incident cases of
depression were included.
Inclusion criteria
Potential participants were eligible for inclusion in the trial if they met the following criteria:
l They met the inclusion threshold of a score of ≥ 10 on the PHQ-9 depression severity instrument.13
This cut-off point is known to detect clinical depression (major depression) in a UK primary care
population with sensitivity of 91.7% and specificity of 78.3%.14
l They were not currently in receipt of cCBT or specialist psychological therapy (including therapy from
a psychologist), and were not currently under care from a local Improving Access to Psychological
Therapies (IAPT) service.
l They were aged 18 years or over.
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Potential participants who met the above inclusion criteria were not excluded if:
l They had a comorbid physical illness (such as diabetes).
l They had a comorbid non-psychotic functional disorder (such as anxiety).
l They were in receipt of antidepressant medication.
l They had previous treatment experience of CBT.
Exclusion criteria
Potential participants were excluded if they met any one of the following criteria:
l They were actively suicidal.
l They were suffering a psychotic illness (as ascertained by the GP).
l They had recently suffered bereavement (bereavement was classed as having lost a mother, father,
partner, husband, wife, son or daughter in the last year).
l They were depressed in the postnatal period (the postnatal period was classed as having had a baby in
the last year).
l They were suffering from psychotic depression (this decision was based on NICE guidance in which
computerised therapy is not recommended for people with psychotic depression).15
l They had a primary diagnosis of alcohol or drug abuse.
l They were not able to read and write in English.
Recruitment into the trial
All researchers participating in the study received training in all aspects of the trial including trial
recruitment, eligibility criteria, trial protocol, adverse event reporting procedures, participant risk
assessment and reporting procedures, trial database and trial documentation. Each researcher received
a researcher manual detailing these procedures in order to standardise the running of the study across
researchers and trial sites. All researchers also undertook Good Clinical Practice training.
Potential participants were referred to the trial through GP practices. All GP practices were provided with a
GP practice manual. This provided details of key trial contacts and site information, information about cCBT
and the trial intervention cCBT programs, a GP information sheet (see Appendix 3), and procedures and
forms for recruiting participants via the various recruitment routes (described in Recruitment routes) and for
reporting serious adverse events (SAEs). The manual also contained copies of trial documentation including
the trial protocol, participant information sheet and patient consent form (see Appendix 4). GP practices
were also provided with participant study information packs containing a study invitation/cover letter, a
participant information sheet and a permission form for release of personal details (see Appendix 4).
In line with recommendations from a HTA-funded primary care depression trial by Peveler and colleagues,16
GP practices were reimbursed for the additional time involved in recruitment of patients to the trial via
service support costs. An additional GP practice incentive was the use of the Quality and Outcomes
Framework (QOF).17 As the PHQ-9 was a validated assessment measure incentivised for the Depression 2
indicator in the QOF during the trial’s recruitment period, all GPs were provided with participants’ PHQ-9
scores at recruitment.
METHODS
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Recruitment routes
Potential participants were identified through one of four main recruitment routes:
General practitioner-initiated recruitment (direct referral)
General practitioners identified potential participants who presented with depression during patient
consultations (both prevalent and incident cases of depression). GPs were asked to introduce the study to
potential participants. For patients who were immediately interested in the trial, GPs completed a referral
form stating that the patient matched the study criteria and provided the patient with a study cover
letter and the participant information sheet. Patients were asked to complete a ‘permission for release of
personal details form’ which included their contact details. The GP or a member of the GP practice staff
would then fax the referral form and permission form to the local research team. For those patients who
expressed a wish to consider the study over a longer period, GPs were asked to provide the patient with a
study information pack which included an invitation letter explaining how to contact the research team.
Patients interested in taking part in the study completed the ‘permission for release of personal details
form’ and sent this back to the local research team. Patients were advised by their GP that they should
expect to hear from a study researcher within 2 working days of the research team receiving their
permission form.
Recruitment initiated by health professionals attached to a general
practitioner practice (direct referral)
Practice-attached nurses and primary care mental health workers identified potential participants who
presented with depression during patient visits. These health professionals were asked to introduce the
study to potential participants and provide interested patients with the study information pack. They were
also able to complete a referral form, ask patients to complete the ‘permission for release of personal
details form’ and fax these forms to the local research team in the same way that a GP would. They would
then notify the patient’s GP that a referral to the trial had been made.
Record screening (database screening)
General practitioner practice staff, with agreement from the lead research GP, reviewed patient records in
accordance with a pre-specified protocol to identify a list of potential study participants (presenting
prevalent cases of depression). This protocol contained a list of read codes which described a range
of inclusion and exclusion criteria to search for over pre-specified time frames. GPs reviewed the list of
potential participants and identified any patients who they felt were not suitable to take part in the trial.
GP practices were supplied with study information packs to send out to potential participants on this list;
alternatively, the GP could consider the patient for the trial at their next GP appointment. The frequency
of these record searches was agreed between individual GP practices and the REEACT research team.
Interested participants who received the study information pack in the post completed the ‘permission for
release of personal details form’ and sent this back to the local research team.
Waiting room screening
Where a GP practice agreed, REEACT researchers would screen patients in the GP practice waiting room
with a simple two-question screening instrument.18 GPs were immediately notified of any patients who
screened positive for possible depression so that the GP could consider introducing the study to them
during their appointment. Although this recruitment route was available it was not implemented in any of
the recruiting GP practices.
The number of participants recruited to the trial via direct referral and database screening recruitment
routes is detailed in Appendix 5.
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Researcher contact following trial referral
See Appendix 6 for a summary of participant involvement in the trial.
Following receipt of a completed ‘permission for release of personal details form’, the REEACT researcher
would contact the patient to discuss the study and to pre-screen for eligibility using the PHQ-9 depression
instrument. Initial contact was made within 1 or 2 working days of receiving the permission form, to allow
the patient a minimum of 24 hours to read the information sheet and consider participation. If the patient
scored ≥ 10 on the PHQ-9 during the pre-screen, the researcher arranged a face-to-face visit with the patient,
at which the researcher would confirm the patient’s eligibility after obtaining written informed consent (part 1)
by readministering the PHQ-9. If the patient scored ≥ 10 at this point, the researcher would obtain the
patient’s written informed consent (part 2) to participate in the trial, administer the baseline measurements and
ascertain treatment preference. The researcher would then ascertain and inform the patient of treatment
allocation and make arrangements to initiate cCBT if this was the allocation. Arrangements would be made for
the researcher to collect follow-up measures after 4 months. Following recruitment, participants’ GPs (and
referrers, if the referrer was not their GP) were notified of the outcome of the referral, including treatment
allocation and PHQ-9 score for participants who had been randomised to the study.
Baseline assessment
After written informed consent (parts 1 and 2) had been obtained, baseline data were collected on
participants prior to randomisation using several self-report baseline questionnaires. The following data
were collected.
Depression severity and symptomatology
Participants completed the PHQ-9 self-report questionnaire13 to confirm their eligibility to participate in the
trial and to assess baseline depression severity and symptomatology.
Participants also completed a diagnostic gold standard lay-administered computer-based interview
[Clinical Interview Schedule – Revised, (CIS-R)],19 which assesses depression severity and diagnosis and other
common mental health disorders, such as anxiety, according to the International Classification of Diseases,
Tenth Edition (ICD-10) criteria.20
Biographical data
Participants completed a bespoke biographical questionnaire which recorded data on ethnicity, education,
employment status, marital status, living arrangements, previous episodes of depression and
treatment preference.
Ethnicity
The ethnicity of participants was recorded.
Education
Participants were asked to indicate their highest educational qualification.
Employment status
Information relating to participants’ current employment status was recorded. Participants who classed
themselves as employed or self-employed indicated if they were currently off work sick because of
their depression. Participants who described themselves as unemployed were asked to record the duration
of their unemployment. Participants also indicated the type of position held in their most recent job.
Marital status
The marital status of participants was recorded.
METHODS
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Living arrangements
Married participants were asked to indicate if their spouse lived with them. The number of other people
living with each participant, including the number of people under the age of 18 years, was recorded.
Previous episodes of depression
Whether or not participants had experienced a previous episode of depression for which they had sought
help was recorded. Further information was recorded for those participants who indicated that they had
experienced a previous episode of treated depression; this included the number of previous episodes of
treated depression, if antidepressants had been prescribed, if participants had ever seen anyone for help
with their depression other than their GP and, if so, who they had seen.
Treatment preference
The participant’s treatment preference was recorded on the biographical questionnaire (see Appendix 7) to
allow us to explore the influence of patient preference prior to randomisation and the differential impact
of preference on the relative effectiveness of cCBT versus usual GP care.
Generic and global mental health
Participants completed the Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM)
questionnaire21,22 to assess their baseline generic and global mental health.
Health-related quality of life
Participants completed two self-report questionnaires to assess baseline health-related quality of life
(HRQoL) and health-state utility. These were the Short Form questionnaire-36 items Health Survey®
version 2 (SF-36v2)23,24 (QualityMetric Incorporated, Lincoln, RI, USA) and the European Quality of Life-5
Dimensions (EQ-5D).25,26
Resource use data
Participants completed an adapted version of the Client Service Receipt Inventory (CSRI)27 to assess baseline
resource utilisation.
Randomisation
Participants were randomised 1 : 1 : 1 between the three trial arms: cCBT (Beating the Blues) plus usual
GP care; cCBT (MoodGYM) plus usual GP care; and usual GP care alone. In view of the large number
of participants to be recruited to the study, stratification by depression severity was not required.
Randomisation was simple and, therefore, not restricted in any way. Simple randomisation reduces the risk
of any possible subversion associated with restricted randomisation methods and has been shown to
produce equally precise results28 as stratified randomisation, which improves treatment precision in trials
with fewer than 50 participants. However, simple randomisation can lead to unequal group sizes by
chance alone. To maintain allocation concealment, the generation of the randomisation sequence and
subsequent treatment allocation were performed by an independent, secure, remote telephone or
web-based randomisation service. The computerised randomisation sequence was checked periodically
during the trial following standard operating procedures. Owing to the nature of the trial design and the
intervention, it was not possible to conceal treatment allocation from either the participant or the
REEACT researcher.
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Sample size
We needed to know if cCBT represented a clinically effective addition to usual GP care and whether or not
the free-to-use computerised program (MoodGYM) represented a less effective (non-inferior) choice of
therapy for patients compared with the commercial pay-to-use computerised program (Beating the Blues).
We therefore powered our trial both to capture any benefit of cCBT over usual GP care alone and to test
the non-inferiority of free-to-use cCBT. We based our sample size calculation on the usual care arm of our
own primary care trial of collaborative care for depression, where the proportion of patients responding
to usual care was in the region of 0.6;29 a response rate similar to that found in a UK HTA trial of
antidepressants in primary care16 and a US pragmatic depression trial.30 We regarded a response rate of
not more than 0.15 below this rate as being acceptable, given the additional care options that are
available to patients who do not initially respond to cCBT within a stepped care framework. Our original
sample size calculation of 600 participants (200 participants in each of the three arms) gave us in excess
of 80% power to detect non-inferiority using the percentage success in both groups as 60%, with a
non-inferiority margin of 15% and allowing for 25% attrition. However, the sample size was re-estimated
as, despite better levels of recruitment than anticipated, levels of attrition were slightly higher than
originally expected (see Chapter 3). In order to retain similar levels of power to detect non-inferiority
between the free-to-use and commercial cCBT packages with 5% probability, while allowing for 35%
attrition, 690 participants were recruited (230 participants in each of the three arms). The trial also
retained 80% power to detect a difference of 15% between the usual GP care arm and either of the two
cCBT arms using a conventional power analysis (α=0.05; two-sided significance).
Trial interventions
Participants were randomised to receive a commercial pay-to-use cCBT program (Beating the Blues) plus
usual GP care, a free-to-use cCBT program (MoodGYM) plus usual GP care, or usual GP care alone.
Experimental interventions
Participants randomised to either of the two intervention arms each received cCBT (Beating the Blues or
MoodGYM) in addition to usual GP care. Given that this was a pragmatic trial design, we imposed no
restrictions on usual GP care, including the use of antidepressant drugs or the addition of drug treatment
to cCBT in the two intervention arms.
Location of computerised cognitive behaviour therapy access
In order to maximise participant accessibility and flexibility, while respecting the importance of patient
choice, cCBT was offered in one of three locations, according to patient choice and local availability:
(1) in the participant’s own home (if the participant already had a computer and a broadband connection
at home); (2) in a central location close to the participant’s home – this could be in a psychotherapy
department, a local library or a large GP practice (where a standalone computer in a private room
operating on a weekly booking system would be provided); or (3) in the GP practice (provided the
participant’s GP practice was able to provide a broadband-connected computer in a private room on a
fixed weekly basis).
Telephone support calls
All participants in the two intervention arms were provided with support in the form of regular (weekly)
telephone calls, conducted by telephone support staff. The purpose of these telephone calls was to
provide participants with technical support with using the cCBT programs (such as how to access the cCBT
programs and resetting passwords) and to encourage them to engage with the cCBT programs. The
supportive telephone calls were not intended to offer any form of psychotherapy. The telephone support
staff completed each of the two cCBT programs in order to familiarise themselves with the nature and
content of these programs. As a way of ensuring standardisation of the telephone support calls, telephone
support staff worked to specific and standardised instructions regarding what should be covered during
METHODS
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each telephone call to ensure delivery of ‘support’ rather than ‘therapy’. Telephone support staff were
provided with the skills required to respond to common questions which would inevitably arise during the
telephone calls. The option of support e-mails was offered to those participants who specifically requested
contact via e-mail or who found it difficult to respond to telephone calls. A record was made of all
participant contacts, including a brief summary of the content of the contact and an estimate of the
duration of the telephone calls. In order to supervise the telephone support staff, and as a means of
ensuring quality control, the telephone calls were recorded. All participants were asked for their verbal
informed consent to record each telephone call and participants were not excluded from the trial if they
withheld their consent to the recording. Telephone support staff were aware that calls were being
recorded, where participant consent had been given. Telephone support staff underwent regular
supervision with the chief investigator or other senior study co-investigators.
Experimental group: Beating the Blues (pay-to-use computerised
cognitive behaviour therapy program) plus usual general practitioner care
Beating the Blues (www.ultrasis.com) is an interactive, multimedia, cCBT program developed by Ultrasis
comprising a 15-minute introductory video followed by eight therapy sessions of approximately 50 minutes’
duration each, with homework exercises between sessions. It was used via the internet. Beating the Blues
has been shown to be effective in reducing symptoms of depression.7 In addition, all participants were
offered usual GP care, and no restrictions were placed on GPs in their ability to prescribe medication or refer
participants to other forms of psychological therapy (including IAPT services).
Experimental group: MoodGYM (free-to-use computerised
cognitive behaviour therapy program) plus usual general practitioner care
MoodGYM (http://moodgym.anu.edu.au) is a free-to-use, internet-based, interactive CBT program for
depression developed and copyrighted at the National Institute for Mental Health Research of the
Australian National University. It consists of five interactive modules of approximately 30–45 minutes’
duration, with revision of all aspects of the program in the sixth session. The program includes a personal
workbook containing exercises and assessments, and ‘characters’ to represent patterns of ‘dysfunctional’
thinking, and provides patients with CBT techniques to overcome this.31 MoodGYM has been shown to be
effective in reducing symptoms of depression in a developer-led trial.8 At the commencement of the study,
MoodGYM was being used in the UK, with 20.5% of the registrants on MoodGYM being from the UK. In
addition, all participants were offered usual GP care, and no restrictions were placed on GPs in their ability to
prescribe medication or refer participants to other forms of psychological therapy (including IAPT services).
Control group: usual general practitioner care
Participants randomised to the control arm received usual care by their GP. In line with the overall
pragmatic approach of the trial, we replicated ‘usual GP care’ by making no specific patient-level
recommendation or requirement to alter usual GP care by participating in the trial. However, GPs were
reminded of the existence of NICE guidance on the management of depression,15 including the
prescription of antidepressants, where this is indicated. Participants in the control arm were given no
specific encouragement to access cCBT but this remained an option if the GP chose to suggest this
treatment or if it was offered in the context of a local IAPT service.
Participant follow-up
Participants were followed up at three time points following randomisation: 4 months, 12 months and
24 months. During the first 6 months of the trial follow-up period, participants completed their follow-up
questionnaires with a REEACT researcher during face-to-face interviews or telephone interviews,
according to participant preference. In order to improve follow-up rates, participants were later given the
additional option of completing and returning follow-up questionnaires in the post (see Chapter 3). The
participant information sheet was revised to reflect this additional method of follow-up completion, and
participants already recruited to the trial were advised of this option and received a copy of the revised
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participant information sheet at their next scheduled follow-up. As a further means of improving our
retention rates, participants received an unconditional £5 voucher with their follow-up as an
acknowledgement for their taking part in the study and completing the questionnaires. The £5 voucher
either accompanied their appointment letter for face-to-face or telephone interviews, or was sent along
with postal questionnaires.
Trial completion
Participants were deemed to have exited the trial when:
l The participant had completed the 24-month follow-up.
l The participant wished to exit the trial fully.
l The participant’s GP withdrew him or her from the trial.
l The participant died.
Instead of withdrawing fully from the trial, participants had the option of:
l withdrawing only from receiving the trial intervention (applicable only to participants randomised to
receive either of the two cCBT programs).
Participants who elected to withdraw from the trial intervention (cCBT programs) and follow-ups were
deemed to be full withdrawals (trial exit). REEACT researchers were able to indicate any change in
the patient’s level of participation by registering this information on the trial database, which immediately
notified the co-ordinating centre (University of York) of this change. REEACT researchers notified the
patient’s GP when a participant elected to withdraw fully from the trial.
Measurement and verification of primary outcome
The primary outcome measure was depression severity and symptomatology as measured by the PHQ-913
questionnaire at 4 months. Participants completed the primary outcome measure during face-to-face
interviews or telephone interviews with REEACT researchers, or as a postal questionnaire, according to
their preference.
The PHQ-9 is a nine-item self-report questionnaire which records the core symptoms of depression based
on the Diagnostic and Statistical Manual of Mental Disorders diagnostic criteria for major depressive
disorder.32 Each item is rated on a scale of 0 to 3 based on the frequency of depressive symptoms (0= ‘not
at all’ to 3= ‘nearly every day’). Scores range from 0 to 27, with higher scores indicating a greater degree
of depression severity. It has the added advantage that it can be reliably administered over the telephone.33
There are extensive US and non-US validation and sensitivity to change data using the PHQ-9. It has
been validated in a UK primary care population14 and has become the instrument of choice in the
management of depression in UK primary care, including monitoring symptom change,34,35 and in the
fulfilment of QOF routine depression measurement.36 It has also been shown to be sensitive to change
over time.37,38
Measurement and verification of secondary outcomes
A variety of disease-specific and generic outcome measures were administered to ascertain clinical
effectiveness. Cost-effectiveness was determined by obtaining measures of HRQoL and resource utilisation
using self-report questionnaires, along with objective data collection from participants’ GP medical records.
METHODS
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Outcome measures completed by participants were administered at each follow-up – 4 months, 12 months
and 24 months – and were completed during face-to-face interviews or telephone interviews with REEACT
researchers, or as a postal questionnaire, according to participant preference. Objective data from
participants’ GP medical records were obtained after participants had completed their 24-month follow-up.
The following data were collected.
Depression severity and symptomatology
Participants completed the PHQ-913 self-report questionnaire to assess depression severity and
symptomatology at each follow-up (see section on Measurement and verification of primary outcome for
detailed information on this instrument).
Global and generic mental health
The CORE-OM21 questionnaire was completed by participants at each follow-up. The CORE-OM is a
34-item generic instrument which measures common mental health problems (including four items
measuring depression), subjective well-being, functional capacity and risk.21,22 It has been validated in a UK
primary care population14 and is a widely used outcome measure for psychological therapies21,39 and in
research.40,41 It shows reliable sensitivity to change over time.39
Health-related quality of life
Participants completed two generic questionnaires about their HRQoL (SF-36v2) and health-state utility
(EQ-5D) at each follow-up in order to measure participants’ perceptions of health outcome during the
study. Generic instruments of health status are useful for comparing different groups of participants, while
also having a broad capacity for use in economic evaluations. Their generic nature also makes them
potentially responsive to side effects or unforeseen effects of treatment.
Each participant’s perception of his or her general health was assessed using the SF-36v223,24 and the
EQ-5D.25,26 The SF-36v2 is a reliable and well-validated generic HRQoL measure. It has been validated for
use in UK primary care42,43 and has been used as an outcome measure in a wide variety of patient groups,
including patients with depression.44 It measures health on eight dimensions covering functional status,
well-being and overall evaluation of health, with scores ranging from 0 (worst HRQoL) to 100 (best
HRQoL). It also yields two summary scores assessing physical and mental components, which have been
shown to be reliable and valid measures of HRQoL.45 It can also be used to generate a Short Form
questionnaire-6 Dimensions (SF-6D) score, which is a preference-based generic HRQoL measure suitable to
be used as an outcome in economic evaluation.46,47
The EQ-5D is a generic preference-based measure of health state that covers five dimensions: mobility,
self-care, usual activity, pain/discomfort and anxiety/depression.25 Patients indicate their health state by rating
each dimension according to three possible levels of severity: no problems, some problems and major problems.
This response will identify one among the 243 mutually exclusive health states defined by the combination of
dimensions and levels, plus two additional health states referring to ‘death’ and ‘unconsciousness’, yielding a
total of 245 health states.26 HRQoL weights for these health states have been previously elicited by Dolan et al.48
using a time trade-off technique from a representative sample of the UK population. A score of 1 represents
perfect health and a score of 0 represents death. The EQ-5D has been validated in UK populations and has
been used to measure HRQoL in patients with depression in primary care.49–51
Resource use data
Information relating to participants’ resource utilisation was obtained via two measures: completion of a
self-report questionnaire (an adapted CSRI) and objective data collection from GP medical records.
Resource use data were used in the assessment of cost-effectiveness and allowed us to assess whether or
not participants randomised to the two cCBT arms experienced differing levels of resource use from the
usual GP care alone group. Given the significant overlap between the content of the adapted CSRI and
service use data collected from GP medical records, preference was given to the use of GP record data to
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inform resource use, as GP records were considered the more consistent and reliable source of data. At the
outset of the trial, the logistical issues of collecting data from GP medical records were not clear and so
the adapted CSRI was retained and was planned to be used in the event of difficulties in accessing these
records. In the final analysis, only resource data from GP medical records were used because of the high
proportion of patients in whom service records were obtained and the degree of completeness.
Questionnaire data
The CSRI is a self-report questionnaire which asks participants about their use of health and social care
services and employment.27
Participants completed an adapted version of the CSRI at each follow-up (see Appendix 7). Participants
were asked about their use of services in the previous 6 months (including inpatient and outpatient hospital
services, community-based day services and primary and community care contacts) and whether or
not they had incurred any additional costs associated with their depression in the previous 6 months
(e.g. medication or drug costs, child-care costs, travel costs). Participants were asked about their current
occupational status, including information about type of occupation, weekly hours worked, days absent
from work and reason and duration for unemployment. Participants were also asked to record their
use of any medication to help with their depression, including medication name, dose and duration taken
(however, participants were asked this medication question only at the 24-month follow-up, as it was not
included on previous versions of the questionnaire).
In addition, participants were asked to indicate their use of any cCBT since their last REEACT follow-up,
allowing us to determine self-reported level of engagement with the two cCBT programs, or any other
cCBT packages, for those participants randomised to the two intervention arms, and to examine whether
or not participants in the control arm (usual GP care alone) made use of any cCBT packages. Participants
were also asked to record their use of other self-help materials (such as self-help books for depression)
since their last REEACT follow-up.
Data collected from general practitioner medical records
A range of data were obtained directly from participants’ GP medical records, provided participants had
given their informed consent for us to access this information. Data were collected from 2 months before
randomisation until the 24-month follow-up, or the date the participant was de-registered from his or her
recruiting GP practice, if this occurred before their 24-month follow-up. The data were obtained across
three time frames: (1) from 2 months before randomisation to the date of randomisation (representing
a 2-month period); (2) from the date of randomisation to 12-month follow-up (‘year 1’, representing a
12-month period); and (3) from 12-month follow-up to 24-month follow-up (‘year 2’, representing
a 12-month period).
Data were not collected for those participants who had withdrawn fully from the trial before completion of
their 24-month follow-up (see section on Trial completion). Data were recorded by either REEACT researchers
or GP practice staff using a data collection form.
Data were collected on the following.
General practitioner consultations
The number of consultations with a GP (including face-to-face, telephone and home consultations) was
recorded. The number of these consultations that were clearly related to depression was also recorded.
Nurse appointments
The number of appointments with a practice nurse was recorded, along with the type of nurse seen,
if known (e.g. practice nurse, treatment nurse, midwife, health-care assistant).
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Health problems
Information about participants’ health problems was recorded. This included mental health problems
(specifically depression and anxiety/panic), chronic illness (e.g. diabetes, hypertension, asthma), myocardial
infarction, accident/life events (e.g. bereavement, divorce, birth of a baby), drug/alcohol disorders and any
other health conditions.
Medication
Information about prescribed depression-related medication was recorded, including medication type,
dosage, and prescription start and end dates. Medication type included antidepressants, antipsychotics,
mood stabilisers, sleeping tablets and anxiety medication.
Referrals
General practitioner referrals were recorded. This included referrals to various mental health services
[e.g. inhouse counsellor, community mental health teams (CMHTs), IAPT, psychologist and psychiatry
services] and ‘other’ referrals for all other conditions. The date of referral was recorded, along with the
number of sessions received for any mental health services accessed, if known.
Hospital stays
Hospital inpatient stays were recorded, including number of inpatient nights, area of specialty and reason
for admission.
Hospital outpatient appointments
Hospital outpatient appointments were recorded, including the appointment date, specialty and reason.
Emergency contacts
The date and reason for visits to accident and emergency departments (for mental health concerns and
‘other’ concerns) and contacts made with out-of-hours services were recorded.
Adverse events
An adverse event was defined as ‘any undesirable clinical occurrence in a subject, whether it is considered
to be caused by or related to treatment or not’.
Adverse events were identified during participant recruitment and follow-up by REEACT researchers or at
any point during the participant’s involvement in the trial by the participant’s GP. In addition, participants
completed a Health Events Questionnaire at each follow-up (see Appendix 7). This asked participants if
they had experienced any health problems since their last follow-up, with particular reference to any
problems or events that may be related to their depression. Participants were asked to describe their
health problems, including when the problem or event happened. Adverse events were also identified via
the adapted CSRI questionnaire, which was administered at each follow-up and asked participants about
their use of inpatient hospital services during the previous 6 months.
Adverse events were categorised as serious or non-serious. A serious adverse event (SAE) was defined as
an event that resulted in death, was life-threatening, required inpatient hospitalisation or prolonging of
existing hospitalisation, resulted in persistent or significant disability or incapacity, resulted in a congenital
anomaly or birth defect or was deemed medically significant by the reporter.
Adverse events that were felt to be serious were reported to the trial co-ordinating team either by REEACT
researchers or by the participant’s GP. The reporter was asked to complete a ‘serious adverse event/reaction
form’ (see Appendix 7) for all those adverse events he or she judged to be serious, indicating why, in the
reporter’s opinion, the event was considered to be serious and the relationship of the adverse event to
treatment. Reporters were asked to report any SAEs to the trial co-ordinating team within 24 hours of the
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event occurring, or within 24 hours of becoming aware of the event. All adverse events judged to be serious
were reviewed by at least two members of the Trial Management Group. SAEs felt to be related to treatment
in some way were reviewed by the Data and Ethics Monitoring Committee (DMEC) and the Trial Steering
Committee (TSC). SAEs that were felt to be unrelated to treatment were reviewed by the DMEC and TSC at
the next scheduled meeting.
The trial co-ordinating team regularly reviewed participant outputs reported on the Health Events
Questionnaire. A SAE/reaction form was completed for any reported health problems/events considered to
be serious and/or related to treatment. Health problems/events reported by participants that were felt to
be non-serious by the trial co-ordinating team were reviewed by the DMEC and the TSC at the next
scheduled meeting.
Statistical analysis of the REEACT clinical effectiveness data
All analyses were conducted on an intention-to-treat basis, including all participants in the groups to
which they were randomised. For superiority comparisons, two-sided significance tests at the 5%
significance level were used. Analyses were conducted in Stata version 13 (StataCorp LP, College Station,
TX, USA).
Overview of analyses
All outcome measures were assessed separately among the following groups of participants:
1. Beating the Blues versus usual GP care alone (superiority)
2. MoodGYM versus usual GP care alone (superiority)
3. MoodGYM versus Beating the Blues (non-inferiority).
For each group comparison, similar analyses were applied depending on the type of comparison (superiority
or non-inferiority) and the inclusion of potentially important covariates. It was aimed to minimise the number
of models applied to each outcome to avoid issues arising from multiple comparisons. The non-inferiority
comparison was undertaken only for the dichotomised PHQ-9 scores, with the primary outcome being at
4 months. To assess non-inferiority between Beating the Blues and MoodGYM, we computed two-sided 90%
confidence intervals (CIs). Using this method, the free-to-use cCBT program MoodGYM was not inferior to the
commercial pay-to-use cCBT program Beating the Blues at the 5% level if the upper boundary was below
the pre-specified margin of non-inferiority [0.15 difference in proportions, which translated to 1.44 for the
odds ratio (OR)].
Baseline data
All baseline data were summarised by treatment group and described descriptively. No formal statistical
comparisons were undertaken. Continuous measures were reported as means and standard deviations
(SDs; with medians and minimum and maximum values where appropriate), whereas the categorical data
were reported as counts and percentages.
Primary analysis
The primary outcome was depression status at 4 months using a cut-off point of 10 on the PHQ-9. The
PHQ-9 was scored if at least eight out of the nine questions were completed. If there was a missing
response for one item, then the mean of the other eight responses was imputed. Groups were compared
using a logistic regression model with adjustments for gender, age, baseline depression severity, depression
duration and level of anxiety. From this model, we obtained ORs and corresponding 95% CIs.
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Secondary analyses
Patient Health Questionnaire-9 dichotomised
The primary analysis was repeated for the 12- and 24-month dichotomised PHQ-9 data using the same
methods as described above. In addition, all time points were analysed in a single model rather than
individual analyses at each time point, using a repeated measures multilevel logistic regression model.
The outcome measures were the values at 4, 12 and 24 months, and baseline PHQ-9 score, age, gender,
depression duration, level of anxiety, treatment group and time were included as fixed effects. The model
also included an interaction between treatment and time. Participants were treated as random effects
(to allow for clustering of data within individual participants). Different covariance patterns were calculated
for the repeated measurements within participants: unstructured, independent, exchangeable and identity.
Models were compared and the model with the smallest Akaike information criterion (AIC) value was
selected for the final model for each comparison. Model assumptions for the final models were checked for
all comparisons. Overall ORs and corresponding 95% (or 90% for non-inferiority) CIs and individual ORs at
each time point (4, 12 and 24 months) were estimated from these models.
Subgroup analyses
An a priori subgroup analysis was performed for the dichotomised PHQ-9 scores at 4 months only. The
primary analysis was repeated, including an interaction term between the baseline factor and treatment
comparison as described in the previous section. As this study has not been powered to detect
interactions, a statistical significance level of 10% (p< 0.10) was used. The subgroup analysis was based
on baseline pre-randomised patient preference in relation to cCBT.
Patient Health Questionnaire-9 continuous
The PHQ-9 outcome was also analysed in its continuous form using a repeated measures multilevel linear
mixed model following a similar procedure to those outlined above for the dichotomised PHQ-9 scores.
The model made adjustments for the same covariates.
Clinical Outcomes in Routine Evaluation – Outcome Measure
The CORE-OM was analysed using a repeated measures multilevel linear mixed model following a similar
procedure to that outlined above for the dichotomised PHQ-9 scores. The model adjusted for the same
covariates but included the baseline CORE-OM score and not the baseline PHQ-9 score. If there was a
missing response for no more than three items, then the overall score was still calculated by summing the
valid responses and dividing by the number of valid responses.
Short Form questionnaire-36 items Health Survey version 2
The HRQoL was measured using the SF-36v2 questionnaire at baseline and 4, 12 and 24 months.
The scores for the individual SF-36v2 health components (physical functioning, role-physical, bodily pain,
general health, role-emotional, vitality, social functioning and mental health) were summarised at each
time point by group. For statistical analysis purposes, only the physical component summary (PCS) scores
and mental component summary (MCS) scores were analysed to prevent problems caused by multiple
testing. The SF-36v2 PCS and MCS scores were analysed using a repeated measures multilevel linear
mixed model following a similar procedure to that outlined above for the dichotomised PHQ-9 scores.
The model adjusted for the same covariates but included the baseline SF-36v2 score and not the baseline
PHQ-9 score.
Adverse events
The number of adverse events and the number of participants experiencing those events were summarised
overall and by group for non-serious adverse events (NSAEs) and SAEs separately. No statistical comparisons
were undertaken.
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Economic analysis of the REEACT cost-effectiveness data
Overview
A within-trial economic analysis was conducted to evaluate the cost-effectiveness of cCBT programs when
added to usual GP care in patients with depression. Costs and health benefits expressed in terms of
quality-adjusted life-years (QALYs) were estimated over a time horizon of 2 years for each treatment group.
Incremental analyses of costs and QALYs were then performed to provide estimates of the incremental
cost-effectiveness of a commercial pay-to-use cCBT program (Beating the Blues) plus usual GP care and a
free-to-use cCBT program (MoodGYM) plus usual GP care compared with usual GP care alone. The analysis
was conducted on an intention-to-treat basis from the perspective of the UK NHS and Personal Social
Services, in line with current UK guidelines for a cost-effectiveness analysis.52 All costs were considered at a
2011–12 price base. Main analyses were conducted on multiply imputed data sets because of the presence
of missing data in the trial.53 A sensitivity analysis was performed to explore and quantify uncertainty in
the cost-effectiveness results. The sensitivity analysis included: (1) scenario analyses testing different
assumptions in terms of costs, HRQoL and missing data; and (2) a probabilistic sensitivity analysis.54 Similar
to the clinical analyses, a subgroup analysis was performed. The planned subgroup analysis aimed to assess
the influence of participants’ treatment preference for treatment allocation on outcomes. Finally,
exploratory analyses were conducted to integrate trial findings on a wider evidence base, and to include
other psychological therapies as comparators in the cost-effectiveness analyses. All analyses were
undertaken in Stata version 12.0 (StataCorp LP, College Station, TX, USA).
Health-care resource use
Health-care resource use data were based on GP medical records. Data were collected for the following
periods: 2 months prior to randomisation, from randomisation to 12 months after randomisation and from
12 to 24 months after randomisation. Use of health care was recorded for the following categories
(see earlier section on Resource use data for a detailed description): GP visits (including telephone call
appointments), including the number of GP contacts that were specifically related to depression; nurse
visits (including telephone call appointments); out-of-hours GP services; hospital inpatient stays; hospital
outpatient visits; other community services visits (including counsellors, psychologists, psychiatrists, CMHT
and IAPT services); and depression-related medication (including antidepressants, antipsychotics, mood
stabilisers, sleeping tablets and anxiety medication).
Costs
Costs were estimated in UK pounds sterling based on the financial year 2011–12. Unit costs were
obtained from routinely published national cost sources, namely the British National Formulary,55 the
Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care56 and the NHS
reference costs.57 Costs accrued from 12 to 24 months were discounted at a 3.5% discount rate, in line
with current UK guidance.52
Appendix 8 provides sources and details of key unit costs. Total costs include the costs of cCBT, GP visits,
nurse visits, out-of-hours GP services, hospital inpatient stays, outpatient visits, other community services
and depression-related medication. Mental health services included visits to counsellors, psychologists,
psychiatrists, CMHT and IAPT services.
Mean total costs were estimated per treatment group using regression analysis to control for patients’
covariates, including costs incurred in the 2 months prior to randomisation (henceforth referred to as
baseline costs), and used as a primary outcome measure in the economic analysis.
An alternative costing scenario was considered, in which only costs related to depression were included in the
cost analysis. Total depression-related costs included depression-related costs of GP and nurse visits, other
community services attendances and depression-related medication costs. As depression-related nurse visits
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were not collected in this trial, this cost category was estimated by assuming that the proportion of nurse visit
costs which were depression related was the same as for GP visits. Depression-related nurse visits costs per
time period were estimated by applying to total nurse visits costs the ratio between mean depression-related
GP visit costs and mean total GP visit costs. It was not possible to identify which hospital services costs were
related to depression and, therefore, they were excluded entirely from the depression-related costs analysis.
Costs of computerised cognitive behaviour therapy
The costs associated with the provision of cCBT are shown in Table 1. These costs include the licence fee
(applicable only to Beating the Blues) and the cost of support in the form of telephone calls to provide
technical support and to encourage participants to engage with the computerised therapy. All costs related
to the provision of cCBT were assumed to be incurred in the first year of follow-up.
The licence fee for Beating the Blues was obtained from the software website, and corresponds to £250
per five treatments.58 The cost of the Beating the Blues licence per patient can be a maximum of £250
(if only one patient takes the treatment) and a minimum of £50 (if all five treatments are used by
five patients). This is in contrast with a previous HTA report,6 where the cost of the Beating the Blues licence
fee was a fixed cost per purchase at the GP practice level, with cost per patient depending on assumptions
of the patient throughput at the practice. For the purpose of this evaluation, the cost of £50 per patient
was used, as it was considered plausible that all five treatments permitted under each licence purchase
were taken, given that the previous HTA estimated an annual patient throughput of 25 to 50 per practice.6
The cost of telephone support calls was estimated based on mean duration and mean number of support
calls recorded as part of the study and assuming the support was provided by a clinical support worker.
The support calls aimed to provide technical support and to encourage participants to engage with the
cCBT programs. In the REEACT trial, support was mostly provided by telephone support staff (grade 4).
Hardware and overhead costs associated with the provision of the computerised therapies at the GP
practice were not included in the cost of any of the two interventions. Although the trial protocol allowed
the use of the cCBT programs at the GP practice, only nine patients accessed the cCBT programs at their
GP practice throughout the 2 years of trial follow-up. Therefore, it was assumed that use of the cCBT
programs at the GP practice is likely to be minimal and that the exclusion of related costs was unlikely to
affect the results of the cost-effectiveness analysis.
Health-related quality of life
The HRQoL was assessed using responses to the EQ-5D questionnaire applied at baseline, 4, 12 and
24 months. The EQ-5D is a generic preference-based measure of health state that covers five dimensions
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression) that can be rated according to
three levels of severity to define unique health states.25 HRQoL weights for these health states have been
previously elicited by Dolan et al.48 using a time trade-off technique from a representative sample of the
UK population. A score of 1 represents perfect health and a score of 0 represents death.
TABLE 1 Elements of costs associated with the delivery of cCBT
cCBT package
Licence fee cost
per patient (£)
Support cost
Mean duration
(minutes)
Mean number
of calls
Unit cost
per hour (£) Details
Beating the Blues 50 6.2 0.2 21 Based on clinical support
worker nursing hour
(Community – Band 2)MoodGYM Free software 6.5 0.3 21
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The SF-6D was used as an alternative instrument to obtain estimates of HRQoL. SF-6D scores were
estimated from responses to the SF-36v224,59 applied at baseline, 4, 12 and 24 months. The SF-6D
instrument uses the participant’s responses to 11 items from the SF-36v2 to identify one health state from
the 18,000 possible health states. Health states are defined by the different combinations of six attributes
(physical functioning, role limitations, social functioning, pain, mental health and vitality) and four to
six levels.46,47 The classification score was based on standard gamble utility measurements on a
representative sample of the UK population.46,60
The EQ-5D scores were used to estimate patient-specific QALYs using the area under the curve method.61
Mean QALYs measured by EQ-5D were estimated per treatment group using regression analysis to control
for patients’ covariates, including baseline EQ-5D score,62 and were used as a primary outcome measure
in the economic analysis. QALYs were also estimated using the SF-6D scores as an alternative to EQ-5D
scores. Regression analysis was used in a similar way to estimate mean QALYs measured by SF-6D per
treatment group, controlling for baseline SF-6D score and the same patient covariates as in the analysis
with EQ-5D estimated QALYs. QALYs accrued from 12 to 24 months were discounted at a 3.5% discount
rate, in line with current UK guidance.52
Missing data
The existence of missing data is a common problem when economic evaluation relies on patient-level
data. The use of complete case analysis not only can reduce the power of the analysis, but may also lead
to biased estimates if there is an underlying relationship between missing values and any observed or
unobserved variables, that is if values are not missing completely at random.63 Available case analysis will
only partially address the problem. Despite not reducing the power of the analysis like complete case
analysis, in available case analysis sample size will vary across analysis, reducing comparability.63
Alternative ways to deal with missing data include imputation techniques, where missing values are
replaced by estimates based on observable variables.63 Multiple imputation by chained equations (MICE)
was selected to handle missing data in this analysis.53,64,65 This method’s central assumption is that data are
missing at random, conditional on the values of observed variables in the data set and not on other
unobserved variables. Another important feature of this method is that it allows incorporation of the
uncertainty associated to the imputation method in the estimates that replace the missing values.66
As complete case analysis requires stricter assumptions regarding the nature of missing data and is more
likely to yield biased and less efficient estimates, and given the previously discussed advantages of multiple
imputation, it was decided prior to the analysis that MICE would be used to handle missing data.
Multiple imputation by chained equations was performed for a total of 10 imputations (m), as previous
research has suggested that three to five m are sufficient to provide adequate estimates but that
increasing m improves efficiency.67 EQ-5D and SF-6D scores were imputed at every follow-up time point
(baseline, 4, 12 and 24 months), while costs were imputed for the same time intervals as resource use was
collected (the 2 months prior to randomisation, from randomisation to 12 months, and from 12 to 24 months)
for each resource use category that was collected on the trial. The independent variables specified in the
imputation were baseline EQ-5D score, baseline SF-6D score, age, gender, anxiety level at baseline, depression
level at baseline and depression duration at baseline.
Costs and utility scores distributions can accrue some difficulties to the analysis, as the former are bounded at 0
and tend to be positively skewed, whereas the latter are bounded between –0.594 and 1 for EQ-5D and
between 0 and 1 for SF-6D. Failure to account for this while imputing the data sets can lead to predicting
values that lie outside the bounds for each variable. To overcome this difficulty, predictive mean matching was
used. In predictive mean matching, observed data are used to estimate a predictive model (using the
MICE-specified covariates), but, instead of replacing missing values with the model predicted values, the
nearest observed value is used to fill the missing value. Imputed values are, thus, sampled from values in the
original data set and will not lie outside the bounds of the original data distribution.66
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Cost-effectiveness analysis
The cost-effectiveness of the two cCBT programs, Beating the Blues and MoodGYM, when added to usual
GP care in patients with depression, was assessed by comparing costs and QALYs in each cCBT treatment
arm with costs and QALYs in the usual GP care alone arm, while controlling for baseline patient covariates.
Costs and QALYs accrued from 12 to 24 months were discounted at a 3.5% discount rate, in line with
current UK guidance.52
All categories of health-care costs were included in the base-case analysis and QALYs estimated from EQ-5D
scores were considered. Incremental estimates of costs and QALYs were obtained through regression
methods, adjusting for the baseline characteristics of age, anxiety level, baseline depression severity,
depression duration and gender (in accordance with the statistical analysis plan). Difference in QALYs
measured by EQ-5D was also controlled for baseline EQ-5D, as it is likely to be a strong predictor of
follow-up QALYs, and failure to adjust for this covariate may bias estimates in the presence of a EQ-5D
baseline score imbalance between the treatment groups.62 Similarly, differences in costs were also adjusted
for baseline costs.
The regression model selected for the analysis of costs in the base case was a generalised linear model
(GLM). This type of model was preferred to an ordinary least squares (OLS) regression, as cost data tend to
be heavily skewed and follow a non-normal distribution,68 which leads to violations of the OLS assumptions.
GLM models impose a specific distribution function (F ) on the dependent variable, to account for the
relation between its mean and variance conditional on the covariates, and a link function (g(.)) to define the
relationship between the mean (µi) and covariates (xji).69 This allows the selection of a distribution that better
fits cost data and enables issues with heteroscedasticity (i.e. non-constant variance of the error term in a
regression) to be addressed, as mean and variance are modelled simultaneously. The model is described by
the equation
g(µi)= β0þΣJ1βjxji, yi∼ F69, (1)
where j is the total number of independent covariates in the model. For the analysis of costs (and also in
subsequent scenario and subgroup analysis), a gamma family distribution was selected. Selection of the family
distribution was based on the modified Park’s test70 performed on each imputed data set and complete case
data set. An identity link function was selected, thus assuming an additive effect of covariates on costs.69
The model was adjusted for the patient characteristics of age, gender, anxiety level at baseline, depression
severity at baseline and depression duration at baseline. Adjustment was also made for baseline costs.
Incremental QALYs estimation was performed through OLS regression, as this method has been
recommended for the estimation of QALYs in economic evaluation.71 The distribution of QALYs was also
inspected through histograms to assess distribution shape. QALYs distribution appeared to resemble
normal distributions for both EQ-5D- and SF-6D-calculated QALYs (the latter used on scenario analyses).
The regression model was adjusted for age, gender, anxiety level at baseline, depression severity at
baseline and depression duration at baseline, as well as EQ-5D score at baseline (or the SF-6D score at
baseline for the SF-6D scenario analysis).
Seemingly unrelated regressions (SURs; a bivariate regression model)72 of costs and QALYs were also
considered as an alternative regression model to jointly estimate outcomes. In this bivariate model,
incremental costs and QALYs were simultaneously estimated from two separate OLS regressions, assuming
correlation between the error terms in each regression. The bivariate model was adjusted using the same
covariates for costs and QALYs as in the main analysis. Although the bivariate approach allows the
simultaneous estimation of costs and QALYs, and can increase the precision of estimates if there is a
correlation between outcomes, it assumes an underlying normal distribution of error terms.73 As the
modified Park’s test suggested that a gamma distribution, rather than the normal distribution, is likely to
provide a better fit for the error terms in the costs regression, SUR was not the preferred model.
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Standard decision rules74 were used to evaluate the incremental cost-effectiveness of the two cCBT
programs, Beating the Blues and MoodGYM, when added to usual GP care, compared with GP usual care
alone. An intervention that generates greater mean QALYs and lower mean costs can be considered
dominant. Where no dominance arises, the interventions can be compared by calculating the ratio
between incremental costs and QALYs to establish the incremental cost-effectiveness ratio (ICER) between
each cCBT intervention plus usual GP care and usual GP care alone. The cost-effectiveness of the
interventions was assessed by comparing ICERs against a cost-effectiveness interval ranging from £20,000
to £30,000 per QALY, in line with NICE cost-effectiveness thresholds for the UK.52
Uncertainty surrounding the decision was assessed using probabilistic sensitivity analysis and presented
through cost-effectiveness acceptability curves (CEACs) which graphically represent the probability of an
intervention being cost-effective across a range of cost-effectiveness thresholds.75 CEACs do not aim to
identify which is the optimal strategy for a particular decision problem.75 The estimation of probabilities of
cost-effectiveness is nevertheless important to quantify the uncertainty surrounding the decision, and whether
or not it is worth conducting further research to reduce this uncertainty.75,76 In order to plot the CEAC, the
variance–covariance matrices from the costs and QALYs regressions (one matrix for each, except in the SUR
model) were extracted and the corresponding Cholesky decompositions used to obtain correlated draws from
a multivariate normal distribution.54 This approach is commonly used to ensure that parameters taken from a
regression framework remain correlated when the probabilistic sensitivity analysis is performed (and CEACs
are plotted), but it has the disadvantage of imposing normality on the sampling distribution.
Sensitivity analyses
Sensitivity analyses were conducted by performing a number of alternative scenario analyses, where
assumptions underlying the base-case analysis were varied. The aim of the sensitivity analyses was to
assess the robustness of base-case results to alternative assumptions in terms of costs, HRQoL and nature
of missing data. Table 2 illustrates which elements were varied in each scenario analysis.
The use of EQ-5D to measure HRQoL is recommended by NICE as part of the preferred base case for
HTA52 and, therefore, EQ-5D-estimated QALYs were included in the base-case analysis. NICE also accepts
the use of alternative instruments to measure HRQoL, such as the SF-6D, when EQ-5D-measured utilities
are not available.52 Nevertheless, it has been demonstrated that, despite the convergence of measurements
by EQ-5D and SF-6D, the two instruments are not interchangeable.60 As the data collected in the REEACT
trial allowed estimating QALYs as measured by SF-6D data, it was possible to explore in scenario 2 how
sensitive the results of the base-case analysis were to the choice of HRQoL instrument. Similar to the
base-case analysis, incremental QALYs were estimated through an OLS regression adjusted for age,
gender, anxiety level at baseline, depression severity at baseline and depression duration at baseline, as
well as SF-6D score at baseline.
TABLE 2 Key elements of the base-case analysis and the variation used in sensitivity analysis
Scenario Element Base case Variation for the sensitivity analysis
1 Source of
HRQoL
EQ-5D instrument used to estimate
QALYs
SF-6D instrument used to estimate QALYs
2 Costs All cost categories included Only depression-related costs included
3 Missing data Data assumed to be missing at
random; analysis therefore
conducted on imputed data
Data assumed to be missing completely at random;
therefore, analysis conducted on the complete case
data
4 Missing data
and source of
HRQoL
Data assumed to be missing at
random. EQ-5D instrument used to
estimate QALYs
Data assumed to be missing completely at random;
therefore, analysis conducted on the complete case
data. SF-6D instrument used to estimate QALYs
5 Missing data
and costs
Data assumed to be missing at
random. All cost categories included
Data assumed to be missing completely at random;
therefore, analysis conducted on the complete case
data. Only depression-related costs included in the
analysis
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In principle, only costs that differ as a result of the treatments being considered should be included, so as
not to introduce additional variability in the analysis that will make relevant differences in costs more
difficult to detect.77 Nevertheless, the identification of which costs are relevant can be difficult, and it may
be preferable to include a wider range of costs in the analysis. Uncertainty regarding which costs are
relevant can be explored by testing the impact on cost-effectiveness analysis results of including a more
restricted set of costs. In scenario 1, the categories of costs included in the estimation of total costs per
treatment group was limited to those considered to be related to depression, that is depression-related
GP and nurse visits, other community service attendances and depression-related medication. The
regression model used to estimate incremental costs for scenario 2 was similar to the base case, that is,
a GLM model with a gamma distribution and identity link function, adjusted for age, gender, anxiety
level at baseline, depression level at baseline and depression duration at baseline. Adjustment was also
made for baseline depression-related costs.
In scenario 3, the base-case analysis is performed on an alternative data set, obtained by excluding from
the available case data set all observations for which data on costs, EQ-5D scores, age, gender, anxiety
level at baseline, depression level at baseline and depression duration at baseline were missing (i.e. the
complete case data set). Analyses on the complete case data set assume that data are missing completely
at random and not conditional on any covariates (observable or unobservable).63 Scenarios 4 and 5 are
parallel to scenarios 1 and 2, respectively, assuming, similarly to scenario 3, that data are missing completely
at random. These two scenarios aim to verify whether or not varying costs and HRQoL assumptions on
complete case data set impact similarly on cost-effectiveness results when these variations were performed
on the imputed data sets. Regression models corresponding to those fitted to the imputed data sets were
used in the complete case data sets scenario. It should be noted that the complete case data set (n= 265)
for scenario 4 is not an exact match to the complete case data set (n= 290) in scenarios 3 and 5, given that
questionnaire rate of completion was lower at each time point for the SF-36v2 than for EQ-5D.
Subgroup analyses
Heterogeneity of treatment impact on costs and QALYs was explored through a subgroup analysis based
on participant preference for allocation to a cCBT treatment group. The aim of the subgroup analysis was
to identify whether or not the cost-effectiveness of the cCBT treatments plus usual GP care compared with
usual GP care alone in the overall patient population is likely to change for specific patient subgroups.
The preference subgroup analysis explored the influence of participants’ treatment preference for
allocation to a cCBT treatment group on outcomes. This analysis was conducted by including participant’s
treatment preference as a covariate and an interaction term (between treatment allocation and
participant’s treatment preference) on both the base-case costs and QALYs’ regression models.
Extrapolation and evidence synthesis
The within-trial economic evaluation has been criticised by Sculpher and colleagues78 as a limited
framework to inform decision-making. Duration of trial follow-up is frequently insufficient to capture the
time over which all relevant costs and benefits may differ between the competing interventions and has
been identified as one of the reasons for lack of appropriateness to inform decision-making in within-trial
analyses. Decision-analytic models are used to overcome this (and other) limitation(s), allowing the
extrapolation of trial results over longer and potentially more relevant time horizons. However, it is worth
noting that there are circumstances under which any within-trial cost-effectiveness results are unlikely to
change regardless of how long the time horizon is extended. For example, if no difference between
treatment arms in terms of HRQoL is detected for the duration of the trial, there is no basis for inferring
that these changes will occur in the future. Another circumstance where extrapolation will be unnecessary
is when a given intervention is dominated by the comparator (i.e. is more costly and less effective) and
extending the time horizon will only make that dominance more evident. Similarly, if no changes in costs
and QALYs are plausibly expected to occur past the trial period, then extrapolation would be redundant.
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The within-trial analysis traditional framework is also not amenable to the incorporation of other relevant
sources of evidence, nor does it usually allow the comparison of all relevant comparators.78 The
incorporation of other sources of evidence in cost-effectiveness can be accomplished with decision-analytic
models, where parameters are informed from multiple studies or evidence synthesis outputs. However,
modelling would require imposing a formal decision model structure which may not be consistent with the
within-trial analyses and result. Therefore, to maintain consistency with the trial analyses, a novel approach
to evidence synthesis has been used here. Estimates of the impact of changes in depression severity from
the trial on costs and QALYs of patients are combined with estimates of the impact of alternative
treatment on changes in depression from the wider literature to estimate what the incremental difference
would be of these alternative treatments on costs and QALYs in patients from the REEACT study.
In this evidence synthesis approach, regression analyses similar to those outlined previously were used to
determine the impact of changes in depression, measured by change in PHQ-9 from baseline, rather than
treatment arm on costs and excluding intervention costs, and QALYs measured in the trial. The coefficients
on the change in PHQ-9 from the regression equations estimate the impact of changes in PHQ-9 on costs
and QALYs for patients within the trial. Two meta-analyses were identified, one on the effectiveness of
internet-based treatments for depression in adults10 and another on other psychological therapies for
patients with depression.79 These reported the effect of the interventions compared with usual care in
terms of a standardised mean difference (SMD). SMD is calculated as the difference between the average
scores on the depression severity measurement instrument of the control group and treatment group at
post-test divided by the pooled SDs of the two groups. These SMDs can be converted back onto the scale
of change in PHQ-9 (ΔPHQ-9) by multiplying them by the standard deviation (SD) in ΔPHQ-9 observed in
the trial, so as to estimate the incremental impact of the two interventions on costs and QALYs in the trial
population compared with usual GP care alone.
The above analyses can then be combined along with estimates of the intervention specific costs to
estimate the cost-effectiveness of cCBT and other psychological therapies compared with usual GP care in
patients from the REEACT study.
Qualitative study of the acceptability to patients and health
professionals of computerised therapy
A concurrent qualitative study was undertaken to examine the acceptability and experiences of patients
and health professionals in relation to computerised therapy.
Design of qualitative study
Patient interviews
We explored patient experience of cCBT in a sample of trial participants who were randomised to receive
either of the two cCBT programs (Beating the Blues or MoodGYM). Informed by prior literature on
engagement and uptake, we aimed to explore the:
l experience of using the program, including perceptions of the content, accessibility and
perceived effectiveness
l reported barriers to engagement and perceived limitations of the cCBT intervention, particularly in
comparison with face-to-face interventions
l experience of using the cCBT programs in routine care, specifically if primary care staff were involved in
providing support or follow-up.
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Sampling and recruitment for the qualitative study
We had originally planned to conduct 10 focus groups each consisting of 7–10 participants, with
participant sampling based on expressed preference for cCBT prior to randomisation; on randomisation to
Beating the Blues, usual GP care alone, or MoodGYM; and on whether cCBT was accessed at home or
from a central location. However, a number of factors (e.g. pragmatic difficulties in arranging the focus
groups, but, furthermore, the fact that individual interviews may be more appropriate given the individual
nature of the cCBT programs and initial follow-up data indicating that participants struggled to complete
the cCBT programs, and also that the majority of participants were accessing the cCBT programs from
home independently rather than working in any group or social format – see Chapter 3) led us to revise
our design and sampling framework. In addition, in order to explore whether or not treatment refusal may
relate to perceived unacceptability or unsuitability of the cCBT program, we received ethical approval to
recruit participants who declined to take part in the trial before randomisation (see Chapter 3).
We therefore aimed to conduct individual semistructured interviews with 30–40 participants, sampling for
expressed preference for cCBT prior to randomisation (assessed by one question in the Biographical
Questionnaire, which asked participants if they would prefer to receive cCBT – see Appendix 7) and
self-reported engagement with the cCBT program (assessed by the number of sessions of cCBT completed
as reported on the adapted CSRI – see Appendix 7). We also aimed to conduct individual semistructured
interviews with participants who indicated that their primary reason for refusal to participate in the trial
prior to randomisation was concern over using cCBT. We aimed to recruit 8–10 participants in this group.
Although we wished to consider preference and engagement, we adopted a convenience sampling method
to ensure adequate recruitment rather than using an a priori sampling theme, and instead attended to
preference and engagement in the topic guides and in the analysis. The first 80 participants to complete
their 4-month follow-up at each of the four main trial sites (including the additional five trial sites recruited
through the University of York) were invited by letter to participate (320 participants in total). Participants
who responded to the invitation letter (see Appendix 9) were contacted by telephone to discuss taking part.
Participants who opted to take part in the qualitative study received a participant information sheet and
completed a consent form (see Appendix 9). Face-to-face interviews were then arranged with a qualitative
researcher at a time and location convenient to participants. Interviews were conducted separately from any
outcome assessments to avoid bias and to ensure that the interaction felt open and exploratory (in contrast
to the pre-defined nature of the outcome assessments.) We assessed completed analysis of the interviews
for data saturation in order to decide whether or not to initiate a second round of recruitment (which was
agreed to be unnecessary). Owing to a slowing in overall trial recruitment, we were unable to recruit any
participants to the qualitative study who had declined participation to the trial on the expressed basis of an
unwillingness to try cCBT.
Patient interviews were conducted by three research associates, one based at the University of Manchester
(SK) and two based at the University of Bristol (HT, EA). The researchers were all experienced in qualitative
interviewing and had backgrounds in psychology. The topic guides were adapted iteratively as the study
progressed to ensure that emergent themes were attended to and that interviews were sensitive to new
areas or topics being discussed (see Appendix 10). Within the interviews, topic guides were used to
suggest areas of discussion but we avoided using them as a definite framework to limit or explicitly
focus conversations.
Health professional interviews
We explored health professionals’ views of referring patients for computerised therapy as part of the
REEACT trial. We aimed to explore:
l the degree to which health professionals targeted referral or ‘matched’ the interventions to particular
patients, exploring perceptions about which patients cCBT would be most suitable for
l if cCBT could be implemented within GP practices
l if health professionals provided support or structured follow-up for patients using cCBT and whether or
not this was considered feasible.
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Sampling and recruitment for the qualitative study
In the original protocol, we aimed to conduct individual semistructured interviews with a purposive
sample of up to 25 health professionals (GPs and practice managers) in order to explore perceptions of
implementing cCBT within GP practices. However, given that GP practices involved in the trial did not
provide on-site access to the cCBT programs, and as a result of patient reports indicating that GPs did
not play a significant part in monitoring or supporting their use of the cCBT programs, we aimed instead
to interview a minimum of 10 GPs to explore perceptions of referring patients to cCBT (with the intention
of extending recruitment if GPs reported, contrary to the patient interviews, that they had been significantly
involved with the cCBT programs. However, GPs confirmed that they had minimal input into patients’
experience of the cCBT programs, as further discussed in Chapter 5). We specifically attended to whether
or not data saturation was achieved in this smaller sample, however, in order to determine whether further
interviews were necessary.
Once participant trial recruitment was completed, invitation letters (see Appendix 11) were sent to all those
GP practices that had recruited participants to the trial via the Universities of Manchester, York and Bristol
(70 GP practices in total). GP practices that recruited participants via the University of Sheffield (13 GP
practices in total) were not included because of local NHS restructuring, delaying the necessary study
approvals. Health professionals who responded to the invitation were sent an information sheet about the
qualitative study and completed a consent form (see Appendix 11).
Interviews were conducted by a qualitative researcher based at the University of Manchester (SK).
All interviews were conducted by telephone and followed a topic guide (see Appendix 10). GP practices
were offered reimbursement for their time participating in the interviews.
Qualitative analysis
Patient interviews
Patient interviews and subsequent analyses were undertaken before the clinical results of the study were
known. Interviews were conducted face to face and were transcribed verbatim.
Data were analysed using the constant comparative method as described by Boeije.80 One researcher (SK)
analysed all the transcripts and three co-investigators (PB, KL and HL) analysed a subset of 16 interview
transcripts. Significant phrases in the transcripts were noted and used to generate initial codes, which were
then discussed to reach consensus on themes. Analysis consisted of two key processes, fragmenting and
connecting.80 Fragmenting refers to exploring the separate themes that emerge within each interview,
to code items relevant to the individual research questions. Connecting emphasises the interview as a
whole, to understand the themes together in context. These processes were conducted first within single
interviews, then between interviews in the same group and finally across the sample as a whole.
Disagreements on themes were discussed until agreement was reached.
In the original protocol we stated our aim to use Normalisation Process Theory (NPT) to guide analysis in
order to understand barriers and facilitators of cCBT being embedded within practices (which was an initial
plan prior to the trial commencing). As very few practices provided on-site access and most participants
accessed the packages alone from home, we decided to reconsider if NPT was appropriate. We aimed
instead to conduct an inductive analysis (as previously described) and then consider if NPT was still valuable
in adding understanding to the emergent themes. Consensus was reached within the qualitative team that
NPT did not add significantly to the primary analysis in this case.
METHODS
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Professional interviews
Interviews with health professionals were conducted by telephone and were transcribed verbatim.
Data were analysed using the constant comparative method as previously described.80 All transcripts were
analysed by a qualitative researcher (SK) and emergent themes discussed and clarified with two of the
study co-investigators (PB and KL). Analysis was also informed by the thematic findings from the patient
interviews to enable cross-comparison and to identify consistencies or differences between patient and
professional reports.
Patient and public participation
The REEACT trial received patient and public participation input at the design, conduct, analysis and
interpretation stages. We received input from those with lived experience of depression in the design of all
research materials. The REEACT trial received oversight via committee membership from members with
lived experience of common mental health problems and a representative of a user-led self-help
organisation. A user-led organisation (Anxiety UK and Self-Help Services via its Chief Executive) acted as
co-applicant and collaborator on the REEACT trial.
Some of this text has been reproduced from Gilbody et al.11 © BMJ 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Chapter 3 Protocol changes
Research objectives/trial design
In the original protocol the primary research objective was to establish the clinical effectiveness and
cost-effectiveness of two cCBT programs – Beating the Blues and MoodGYM – versus antidepressant
medication over a 2-year follow-up period. All participants were to receive usual GP care, with the key
comparison being in the selection of initial treatment for depression, where the comparison would be
between antidepressants and a non-drug alternative in the form of cCBT. Participants who were
randomised to either of the two cCBT programs would receive computerised therapy rather than
medication in the first instance, with the addition of drug treatment to cCBT if the participant’s GP felt
that the patient was failing to respond to computerised therapy. Participants randomised to the control
group – usual GP care alone – would be prescribed antidepressants by their GP. Although no specific
patient-level recommendations were to be made about which medication to prescribe or the dosage,
GPs were asked to follow the NICE recommendations on the prescription of antidepressants15 and the
British National Formulary dosage recommendations.55
Following ethical approval of our original protocol (10 July 2008), we received notification from the
Medicines and Healthcare products Regulatory Agency that our design qualified our trial as a clinical trial
of an investigational medicinal product. We sought advice from our funders, who advised against using
this trial design and recommended that all participants receive ‘care as usual’ and that participants’
medication use should not in any way be altered by participating in the trial.
In light of this advice, the basic design of the trial was revised. The revised design maintained the original
structure of a three-armed trial but with slight changes to the content of each arm. The control arm was
revised to be usual GP care. The two intervention arms were amended to include the addition of usual GP
care to one of two cCBT programs (usual GP care plus Beating the Blues and usual GP care plus MoodGYM).
The revised trial design now meant that all participants would receive usual GP care. Usual GP care might
include antidepressant medication but also might not. As a result, the original exclusion criterion that
participants already in receipt of antidepressants would be ineligible to participate in the trial was removed.
This change in trial design meant our primary research objective was now to establish the clinical
effectiveness and cost-effectiveness of the addition of cCBT to usual GP care over a 2-year follow-up period.
On the basis that all participants would be receiving care as usual, the trial was no longer classified as a
clinical trial of an investigational medicinal product but as a non-interventional trial. We received ethical
approval (22 September 2008) for this revised trial design before the study commenced.
Outcome measures
Primary outcome measure
In our original protocol we had defined our primary outcome measure as depression severity and
symptomatology as measured by the PHQ-913 and a self-report computer-administered diagnostic interview
(CIS-R)19 at 4 months. However, we were advised by the study co-investigators that participants in other
studies they were involved in had found the CIS-R interview prohibitively onerous. In the light of this we
decided that the burden of the CIS-R interview was not justified by its usefulness as a follow-up measure
and therefore removed this measure from each of the follow-up time points, although it remained as a
baseline measure. The primary outcome measure was, therefore, measured by only the PHQ-9 at
4 months.
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Telephone support calls
During early trial meetings (and prior to the first participant being randomised) we decided to introduce regular
telephone support calls to those participants who were randomised to use either one of the two cCBT
programs in order to ensure uptake and to be in line with good clinical practice. These telephone calls were
undertaken by telephone support staff who would deal with any technical problems the participants might
experience and would try to encourage them to engage with the cCBT programs. The telephone calls were not
intended to offer any form of psychotherapy. This protocol change was implemented following information
that cCBT interventions are usually implemented in practice with this kind of support, and so this change
allowed us to reflect current practice and maintain the pragmatic design of the trial.
In addition, the protocol was adapted to include supervision of the telephone support staff. Telephone
support staff were required to work to specific and standardised instructions on what should be covered
during each telephone call to ensure the delivery of ‘support’ rather than ‘therapy’ and to provide the
telephone support staff with the skills needed to respond to the common questions that would inevitably
arise during the telephone calls. Therefore, as a means of ensuring standardisation and quality control, we
gained ethical approval to record the telephone calls. All participants were asked for their informed
consent to record each telephone call and participants were not excluded from the trial if they withheld
their consent to the recordings. All telephone support staff were aware that telephone calls were being
recorded where participant consent was given. Regular supervision with the chief investigator or other
senior study co-investigators was provided to the telephone support staff.
These protocol changes were implemented before the first participant was randomised.
Exclusion criteria
It was decided to add two additional exclusion criteria when considering potential trial participants. It was
felt by the study investigators that patients who have a primary diagnosis of alcohol or drug abuse and
patients who are not able to read and write in English would be highly unlikely to benefit from cCBT. This
protocol change was implemented before the first participant was randomised.
Trial referrals
In our original protocol, direct referrals to the trial could be made only by a patient’s GP. Practice nurses
could identify potential participants with depression but would need to advise the patient to make an
appointment with his or her GP and notify the GP of the patient’s potential eligibility for the trial. However,
during the first 3 months of recruitment we received numerous requests from those health professionals
attached to a GP practice (primary care-based mental health workers and practice-attached nurses)
participating in REEACT to allow them to directly refer patients to the trial. Following discussions with GPs,
practice-attached nurses and members of the primary care mental health team, we decided it was
reasonable to allow the latter two groups of staff to check participant eligibility and refer directly to the trial,
with the understanding that the referrer would need to inform the patient’s GP of the trial referral. The
REEACT researcher would then need to inform both the referrer and the patient’s GP of the outcome of
the referral. This method of direct referral was permitted only following discussions with and agreement
from individual GP practices and all practice staff involved. This recruitment method was available from
November 2009.
PROTOCOL CHANGES
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Pre-screening for trial eligibility
Problems with the process of REEACT researchers confirming trial participant eligibility led us to change
our protocol. During the first 4 months of trial recruitment, we were finding that approximately 40% of
participants who had provided their permission for us to contact them had a depression score below the
inclusion threshold (PHQ-9 ≥ 10) when assessed for eligibility during face-to-face visits. This meant that,
because of the large geographical areas covered by each centre, researchers were travelling long
distances to see ineligible patients. In addition, there seemed to be a level of disappointment among
otherwise willing participants when they were told they were ineligible to take part in the trial following
a face-to-face meeting.
We therefore extended the eligibility protocol to allow REEACT researchers to administer the PHQ-9 over
the telephone to pre-screen for baseline eligibility before arranging a face-to-face meeting. The PHQ-9 has
been shown to be reliable when administered over the telephone.33 Those participants who scored ≥ 10
on the PHQ-9 during the pre-screen would receive a face-to-face meeting where the PHQ-9 eligibility
check would be repeated to confirm eligibility at the actual point of entry into the trial. Those participants
who proved to be ineligible following the pre-screen were advised that their symptoms did not match the
symptoms under investigation in the trial and were advised to continue to see their GP as normal. This
process of pre-screening for trial eligibility was implemented from November 2009.
Postal questionnaires
During the first 6 months of the follow-up period it became apparent that our current retention rate of
approximately 65% at 4-month follow-up – the point at which our primary outcome measure was
collected – was falling below our target retention rate of 75%. REEACT researchers were finding it difficult
to contact participants to arrange follow-up interviews. It was felt that this might in part be a result of
participants having returned to their normal daily activities following their recruitment into the trial, as they
might find it more difficult to spare the additional time required to be interviewed.
In an attempt to improve our retention rates, we gained ethical approval to give participants the option of
completing and returning follow-up questionnaires by post, in the hope that this method might make it
easier for participants to fit completing the questionnaires into their daily lives. The participant information
sheet was revised to reflect the additional option of postal questionnaire completion. Participants were still
provided with the option of completing their follow-up through a face-to-face or telephone interview as
described in the original participant information sheet. Participants already in the trial were given the
option of postal questionnaire completion at their next follow-up and received a copy of the updated
participant information sheet. The suicide protocol was also revised to describe the procedure to follow if a
potential suicide risk was identified on return of a postal questionnaire. Participants recruited to the trial
following implementation of this protocol change were asked to provide their consent to us informing
their GP about potential risk if this was deemed necessary. The addition of postal questionnaires as a
completion method was implemented in August 2010.
Qualitative study
We revised our plans for evaluating the acceptability of cCBT from those detailed in our original protocol.
The original protocol stated that the qualitative data would be collected during 10 focus groups each with
7–10 participants. However, because of pragmatic difficulties in arranging group sessions across the four
recruitment centres, our qualitative researcher was concerned that participants might be excluded from the
qualitative study if they were unable to find convenient times to attend the focus groups. We also considered
that individual interviews might be more appropriate given the individual nature of the intervention and might
better enable us to explore how the individual patients experienced the independent computerised therapy.
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Therefore, in order to increase the accessibility of the study, and in the light of considerations about the
nature of the individual experience, we decided instead to collect the qualitative data through individual
semistructured interviews, which could be arranged at times and locations to suit each participant.
We also revised our patient-sampling frame. In the original protocol, we planned to sample participants
based on expressed preference for cCBT prior to randomisation; on randomisation to Beating the Blues,
usual GP care, or MoodGYM; and on whether cCBT was accessed at home or from a central location.
However, data collected from participants during the first 8 months of the follow-up period indicated that
many participants were struggling to complete the cCBT programs and that the majority of participants
were accessing the cCBT programs at home. Treatment completion is a significant issue in patient
acceptability and we felt it was important to explore reasons for discontinuing or continuing treatment.
As a result, the patient sampling frame was changed so that participants would be sampled based on their
expressed preference for cCBT prior to randomisation and on whether they completed the course of cCBT
or not. This allowed us to identify both positive and negative experiences of the treatment. We planned to
recruit between 30 and 40 participants, with the group reflecting a roughly equal balance of preference
and completion.
In the original protocol we were not able to explore the views of participants who did not think
computerised therapy was acceptable and who did not wish to be randomised into one of the trial groups.
Non-acceptability – refusal to begin treatment – is a noted problem in the literature on cCBT81 and it is
likely to be especially relevant in routine primary care, where not all individuals are likely to be willing to try
cCBT.82 We therefore revised our original protocol to allow us to explore reasons for treatment refusal in
an attempt to understand perceived barriers to using cCBT and to identify how treatment uptake can be
improved. We thus amended the original protocol. Participants who spontaneously expressed an
unwillingness to try cCBT as the reason why they did not wish to join the trial would be asked if they
would consider being interviewed. Those participants who agreed would be sent an information sheet
before being contacted again. We aimed to recruit between 8 and 10 participants in this group.
Finally, in the light of the finding that the majority of participants did not access the cCBT programs in
their GP practices as previously expected, we revised the interview topic guides and information sheet to
be used in the planned qualitative interviews with health professionals. However, data would still be
collected on professionals’ opinions of the feasibility of providing cCBT on site and their perceptions of the
acceptability of home and central access for patients.
These protocol changes were implemented from September 2010.
Sample size
Early in the trial we noticed lower than expected follow-up rates at 4-month follow-up (the point at
which our primary outcome was measured). This led us to increase our recruitment target from 600
(200 participants in each of the three groups) to 690 participants (230 participants in each of the three
groups). In our original protocol we had allowed for a loss to follow-up of 25% to retain 80% power to
detect superiority between the usual GP care group and either of the two cCBT groups and non-inferiority
between commercial (Beating the Blues) and free-to-use (MoodGYM) cCBT.
To calculate the most effective sample size we modelled the effects of follow-up rates on power. We
subsequently gained ethical approval to over-recruit by 30 participants in each arm (an overall increase of
90 participants), which allowed for a loss to follow-up of 35% while retaining 80% power to detect
superiority between the usual GP care group and either of the two cCBT groups, and non-inferiority
between commercial and free-to-use cCBT. This protocol change was implemented from September 2010.
PROTOCOL CHANGES
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Questionnaire response rates
As previously mentioned, we experienced lower than expected follow-up rates. As a way of improving our
follow-up response rate, we received ethical approval to send a £5 voucher as a token ‘thank you’
payment to participants at each follow-up time point. This token payment was not mentioned in the
participant information sheet so that the risk of this being interpreted as a financial incentive to take part
in, or continue with, the study was minimised. Receipt of a £5 voucher at follow-up was not conditional
on participants completing their follow-up questionnaires. For follow-ups completed during face-to-face
visits or telephone interviews, participants received a £5 voucher with their appointment letter. Follow-up
questionnaires that were posted out to participants for them to complete and return were accompanied by
a £5 voucher. This approach was based on the findings of a systematic review investigating ways of
increasing response rates to postal questionnaires.83 This protocol change was implemented from
February 2011.
Long-term follow-up
Given that this study allowed us to assemble one of the largest groups of people with depression in UK
primary care, we took the opportunity to investigate the impact of depression and treatment over the longer
term. We therefore gained ethics approval to develop a primary care depression cohort of trial participants
over a follow-up period of 10 years, with additional follow-ups taking place at 3, 5, 7 and 10 years.
Participants were provided with information about these additional follow-ups and those interested were
asked to provide their consent to take part. Although the development of a primary care depression cohort
represented an extension of our original research objectives, it was not an objective for which we received
funding. Therefore, although the primary care depression cohort is referred to in the protocol, it will not be
discussed within this report.
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Chapter 4 Clinical results
This chapter presents the statistical analysis of the clinical results of REEACT. In the first section of thechapter the trial recruitment, baseline participant characteristics and clinical data are summarised in
tables and narratively described. In the second section the outcome data are summarised and results from
the statistical models fitted to the data are presented.
Trial recruitment
Four main sites across the UK co-ordinated recruitment to the study. These were the University of Bristol,
the University of Manchester, the University of Sheffield and the University of York. In addition, the
University of York site was responsible for co-ordinating recruitment at an additional five sites (Durham
and Darlington, Gateshead, Hull, North of Tyne and South of Tyne). Table 3 shows the number of
participants recruited at each site. Participants were recruited through GP practices, with each site
recruiting between 4 and 21 GP practices. Eighty-three out of 100 participating GP practices recruited at
least one trial participant (recruitment of participants per GP practice ranged from 1 to 56). Recruitment
was staggered, with GP practices participating at different time points during the course of the study.
Further details of recruiting sites and GP practices are presented in Appendix 12.
Recruitment of participants began in August 2009 and ended in March 2011. In total, 1273 individuals
were screened as potential participants and, of these, 691 (54.3%) were randomised. The overall rate of
recruitment is shown in Figure 1. Figure 2 shows the Consolidated Standards of Reporting Trials (CONSORT)
flow chart of participants through the trial. The follow-up period began in December 2009 and ended in
April 2013.
TABLE 3 Number (%) of participants recruited by group and by site
Site
Beating the Blues
(n= 210)
MoodGYM
(n= 242)
Usual GP care alone
(n= 239)
Total
(n= 691)
University of Bristol 51 (24.29) 68 (28.10) 64 (26.78) 183 (26.48)
University of Manchester 32 (15.24) 37 (15.29) 32 (13.39) 101 (14.62)
University of Sheffield 30 (14.29) 33 (13.64) 36 (15.06) 99 (14.33)
University of York 38 (18.10) 41 (16.94) 38 (15.90) 117 (16.93)
Durham and Darlington 8 (3.81) 9 (3.72) 7 (2.93) 24 (3.47)
Gateshead 8 (3.81) 11 (4.55) 12 (5.02) 31 (4.49)
Hull 28 (13.33) 30 (12.40) 29 (12.13) 87 (12.59)
North of Tyne 11 (5.24) 11 (4.55) 15 (6.28) 37 (5.35)
South of Tyne 4 (1.90) 2 (0.83) 6 (2.51) 12 (1.74)
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Follow-up
Follow-up at 4 months, n = 165
• Lost to follow-up, n = 33
• Withdrawn from intervention, n = 15
• Full withdrawal, n = 12
Follow-up at 12 months, n = 153
• Lost to follow-up, n = 35
• Full withdrawal, n = 10
Follow-up at 24 months, n = 145
• Lost to follow-up, n = 39
• Full withdrawal, n = 4
• Incomplete primary outcome, n = 2
Analysis
Analysis at 4 months, n = 165
Analysis at 12 months, n = 153
Analysis at 24 months, n = 143
Randomised
(n = 691)
Allocated to Beating the Blues and
usual GP care, n = 210
Received Beating the Blues, n = 210
Excluded
(n = 582)
Not meeting inclusion criteria, n = 234
Declined to participate, n = 348
Assessed for eligibility
(n = 1273)
Allocation
Enrollment
Follow-up at 4 months, n = 179
• Lost to follow-up, n = 47
• Full withdrawal, n = 13
Follow-up at 12 months, n = 166
• Lost to follow-up, n = 48
• Full withdrawal, n = 12
Follow-up at 24 months, n = 158
• Lost to follow-up, n = 54
• Full withdrawal, n = 2
Analysis at 4 months, n = 179
Analysis at 12 months, n = 166
Analysis at 24 months, n = 158
Allocated to usual GP care, n = 239
Follow-up at 4 months, n = 182
• Lost to follow-up, n = 48
• Withdrawn from intervention n = 9
• Full withdrawal, n = 12
Follow-up at 12 months, n = 165
• Lost to follow-up, n = 56
• Full withdrawal, n = 9
Follow-up at 24 months, n = 160
• Lost to follow-up, n = 59
• Full withdrawal, n = 2
Analysis at 4 months, n = 182
Analysis at 12 months, n = 165
Analysis at 24 months, n = 160
Allocated to MoodGYM and
usual GP care, n = 242
Received MoodGYM, n = 242
FIGURE 2 The REEACT trial CONSORT diagram. Reproduced from Gilbody et al.11 © BMJ 2015. This is an Open
Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Baseline data
Baseline patient characteristics
In total, 691 eligible participants were recruited to the study: 210 were randomised to receive the cCBT
program Beating the Blues plus usual GP care (Beating the Blues), 242 were randomised to receive the
cCBT program MoodGYM plus usual GP care (MoodGYM) and 239 were randomised to receive usual GP
care (usual GP care alone). The baseline demographic characteristics are shown in Tables 4–6. The mean
age of the participants in the study was 39.86 years (SD 12.65 years) and randomisation resulted in groups
that were well balanced for age, gender, ethnicity, educational qualification, employment variables and
marital status. The majority of participants in the study were white British (95.1%), and more females
(66.9%) than males were included. The majority of participants in the study were employed: 61.8% of
participants were employed on a full-time or part-time basis or were self-employed. Of those participants
who were employed, 26.2% were on sick leave because of depression. The proportion of participants who
were on sick leave because of depression was well balanced across the three groups.
Table 7 shows the baseline clinical data for both groups. This demonstrates the nature of depression and
anxiety in this population at baseline. Participants experiencing previous episodes of depression for which
they sought help were high (n= 491, 71%), with 51% (n= 249) of participants having one or two previous
treated episodes of depression and 14% (n= 70) categorising themselves as being chronically depressed.
TABLE 4 Summary of baseline participant characteristics
Characteristic
Beating the Blues
(N= 210)
MoodGYM
(N= 242)
Usual GP care
alone (N= 239)
Age (years), mean (SD) 39.61 (12.34) 39.43 (12.96) 40.52 (12.64)
Gender, n (%) n = 210 n = 242 n = 239
Female 142 (67.62) 157 (64.88) 163 (68.20)
Ethnicity, n (%) n = 210 n = 242 n = 239
White – British 199 (94.76) 230 (95.04) 228 (95.40)
White – Irish 0 (0.00) 0 (0.00) 1 (0.42)
Any other white background 3 (1.43) 8 (3.31) 5 (2.09)
Mixed – white and black Caribbean 2 (0.95) 1 (0.41) 0 (0.00)
Mixed – white and black African 1 (0.48) 0 (0.00) 0 (0.00)
Any other mixed background 0 (0.00) 1 (0.41) 0 (0.00)
Asian or Asian British – Indian 1 (0.48) 0 (0.00) 1 (0.42)
Asian or Asian British – Pakistani 0 (0.00) 1 (0.41) 0 (0.00)
Chinese 3 (1.43) 0 (0.00) 1 (0.42)
Other 1 (0.48) 1 (0.41) 3 (1.26)
Marital status, n (%) n = 210 n = 242 n = 239
Married 75 (35.71) 87 (35.95) 92 (38.49)
Living with a partner 34 (16.19) 43 (17.77) 38 (15.90)
Divorced/separated 30 (14.29) 37 (15.29) 36 (15.06)
Widowed 3 (1.43) 3 (1.24) 4 (1.67)
Single/never married 65 (30.95) 71 (29.34) 67 (28.03)
Other 3 (1.43) 1 (0.41) 2 (0.84)
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TABLE 5 Summary of baseline education
Characteristic
Beating the Blues
(N= 210)
MoodGYM
(N= 242)
Usual GP care
alone (N= 239)
Educational qualification, n (%) n = 210 n = 242 n = 239
GCSE/O level 41 (19.52) 53 (21.90) 48 (20.08)
GCE A/AS level or Scottish Higher 31 (14.76) 21 (8.68) 31 (12.97)
NVQ/SVQ levels 1–3 21 (10.00) 30 (12.40) 24 (10.04)
GNVQ (Advanced) 6 (2.86) 5 (2.07) 2 (0.84)
B Tec Certificate 3 (1.43) 6 (2.48) 4 (1.67)
B Tec Diploma 6 (2.86) 7 (2.89) 9 (3.77)
National Certificate or Diploma (ONC/OND/HNC/HND) 15 (7.14) 19 (7.85) 14 (5.86)
Qualified Teacher Status 3 (1.43) 3 (1.24) 11 (4.60)
Higher Education Diploma 7 (3.33) 6 (2.48) 17 (7.11)
Degree (First Degree/Ordinary Degree) 27 (12.86) 46 (19.01) 32 (13.39)
Post Graduate Certificate 7 (3.33) 5 (2.07) 3 (1.26)
Post Graduate Diploma 8 (3.81) 2 (0.83) 8 (3.35)
Masters Degree 14 (6.67) 10 (4.13) 7 (2.93)
Other 16 (7.62) 19 (7.85) 21 (8.79)
Don’t know 1 (0.48) 2 (0.83) 3 (1.26)
No response 4 (1.90) 8 (3.31) 5 (2.09)
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TABLE 6 Summary of baseline employment status
Characteristic
Beating the Blues
(N= 210)
MoodGYM
(N= 242)
Usual GP care
alone (N= 239)
Employment, n (%) n = 210 n = 242 n = 239
Employed part-time 43 (20.48) 45 (18.60) 37 (15.48)
Employed full-time 59 (28.10) 101 (41.74) 95 (39.75)
Self-employed 21 (10.00) 12 (4.96) 14 (5.86)
Retired 10 (4.76) 11 (4.55) 21 (8.79)
Looking after family or home 15 (7.14) 8 (3.31) 11 (4.60)
Not employed but seeking work 12 (5.71) 15 (6.20) 12 (5.02)
Not employed but not seeking work because of ill health 23 (10.95) 31 (12.81) 29 (12.13)
Not employed but not seeking work for some other reason 7 (3.33) 3 (1.24) 3 (1.26)
Full-time student 16 (7.62) 14 (5.79) 15 (6.28)
Other 4 (1.90) 2 (0.83) 2 (0.84)
Employed but on sick leave because of depression, n (%) n = 123 n = 158 n = 146
Yes 34 (27.64) 37 (23.42) 41 (28.08)
No 89 (72.36) 120 (75.95) 105 (71.92)
Don’t know 0 (0.00) 1 (0.63) 0 (0.00)
Unemployment (duration) , n (%) n = 42 n = 49 n = 44
< 3 months 7 (16.67) 10 (20.41) 9 (20.45)
4–12 months 11 (26.19) 12 (24.49) 13 (29.55)
1–2 years 7 (16.67) 4 (8.16) 6 (13.64)
2–5 years 8 (19.05) 7 (14.29) 6 (13.64)
> 5 years 7 (16.67) 13 (26.53) 10 (22.73)
No response 2 (4.76) 3 (6.12) 0 (0.00)
Job details, n (%) n = 210 n = 242 n = 239
Foreman/supervisor 13 (6.19) 8 (3.31) 11 (4.60)
Manager 37 (17.62) 44 (18.18) 41 (17.15)
Self-employed with employees 5 (2.38) 5 (2.07) 10 (4.18)
Self-employed without employees 21 (10.00) 13 (5.37) 18 (7.53)
Other employee 125 (59.52) 165 (68.18) 154 (64.44)
Never been in paid employment 6 (2.86) 5 (2.07) 4 (1.67)
No response 3 (1.43) 2 (0.83) 1 (0.42)
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TABLE 7 Summary of baseline clinical data11
Characteristic
Beating the Blues
(N= 210)
MoodGYM
(N= 242)
Usual GP care
alone (N= 239)
Previous episodes of depression, n (%) n = 210 n = 242 n = 239
Yes 144 (68.57) 169 (69.83) 178 (74.48)
No 65 (30.95) 72 (29.75) 60 (25.10)
Don’t know 1 (0.48) 1 (0.41) 0 (0.00)
No response 0 (0.00) 0 (0.00) 1 (0.42)
Number of episodes of depression, n (%) n = 144 n = 169 n = 178
1 42 (29.17) 44 (26.04) 49 (27.53)
2 34 (23.61) 31 (18.34) 49 (27.53)
3 12 (8.33) 23 (13.61) 21 (11.80)
4 10 (6.94) 14 (8.28) 7 (3.93)
5+ 22 (15.28) 22 (13.02) 24 (13.48)
Chronically depressed 19 (13.19) 30 (17.75) 21 (11.80)
Don’t know 4 (2.78) 5 (2.96) 7 (3.93)
No response 1 (0.69) 0 (0.00) 0 (0.00)
Previously prescribed antidepressants, n (%) n = 144 n = 169 n = 178
Yes 129 (89.58) 149 (88.17) 152 (85.39)
No 14 (9.72) 20 (11.83) 26 (14.61)
Don’t know 1 (0.69) 0 (0.00) 0 (0.00)
Seen anyone other than GP for depression, n (%) n = 104 n = 132 n = 129
Psychiatrist 25 (24.04) 31 (23.48) 37 (28.68)
Psychologist 21 (20.19) 35 (26.52) 21 (16.28)
Counsellor 79 (75.96) 95 (71.97) 99 (76.74)
Community psychiatric nurse 15 (14.42) 19 (14.39) 26 (20.16)
Social worker 2 (1.92) 1 (0.76) 3 (2.33)
Citizens Advice Bureau 2 (1.92) 2 (1.52) 1 (0.78)
Other statutory/voluntary agency 11 (10.58) 9 (6.82) 17 (13.18)
Don’t know 1 (0.96) 1 (0.76) 1 (0.78)
Level of anxiety, n (%) n = 208 n = 239 n = 238
0 (no problem recorded) 43 (20.67) 52 (21.76) 45 (18.91)
1 (+ 1 if anxious for > 3 days in past week) 32 (15.38) 38 (15.90) 41 (17.23)
2 (+ 1 if causes feeling of unpleasantness) 39 (18.75) 30 (12.55) 41 (17.23)
3 (+ 1 if causes physical symptoms) 39 (18.75) 43 (17.99) 43 (18.07)
4 (+ 1 if anxious > 3 hours in any day) 55 (26.44) 76 (31.80) 68 (28.57)
continued
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The majority of participants had previously been prescribed antidepressants for their depression (n= 430,
88%) and 365 (74%) had sought help with their depression from someone other than their GP (counsellor
75%, psychiatrist 25% and psychologist 21%). Participants’ current profile of depression and anxiety were
obtained at baseline for a total of 685 participants using a diagnostic gold standard (CIS–R).19 Data for
six participants were lost because of file corruption (two in the Beating the Blues group, one in the usual
GP care group and three in the MoodGYM group). There were approximately equal numbers of participants
in each of the levels of depression (scored from no problem recorded to unable to be cheered up) and
anxiety categories (scored from no problem recorded to anxious for more than 3 hours per day). There were
two spikes for the duration of anxiety recorded and the duration of depression recorded in the categories
of being present for 2 weeks to 6 months and being present for over 2 years. Randomisation resulted in
well-balanced groups across all baseline clinical data.
TABLE 7 Summary of baseline clinical data11 (continued )
Characteristic
Beating the Blues
(N= 210)
MoodGYM
(N= 242)
Usual GP care
alone (N= 239)
Duration of anxiety n = 208 n = 239 n = 238
0 (no problem recorded) 31 (14.90) 33 (13.81) 33 (13.87)
1 (present for < 2weeks) 6 (2.88) 6 (2.51) 5 (2.10)
2 (present for 2weeks to 6months) 57 (27.40) 63 (26.36) 79 (33.19)
3 (present for 6months to 1 year) 32 (15.38) 34 (14.23) 41 (17.23)
4 (present for 1 to 2 years) 24 (11.54) 32 (13.39) 21 (8.82)
5 (present > 2 years) 58 (27.88) 71 (29.71) 59 (24.79)
Level of depression, n (%) n = 208 n = 239 n = 238
0 (no problem recorded) 14 (6.73) 24 (10.04) 17 (7.14)
1 (+ 1 if less/no enjoyment with life during past week) 17 (8.17) 20 (8.37) 27 (11.34)
2 (+ 1 depressed for > 3 days in past week) 43 (20.67) 45 (18.83) 46 (19.33)
3 (+ 1 if depressed for > 3 hours in any day of past week) 50 (24.04) 64 (26.78) 56 (23.53)
4 (+ 1 if unable to be cheered up) 84 (40.38) 86 (35.98) 92 (38.66)
Duration of depression n = 208 n = 239 n = 238
0 (no problem recorded) 9 (4.33) 14 (5.86) 13 (5.46)
1 (present for < 2weeks) 3 (1.44) 2 (0.84) 0 (0.00)
2 (present for 2weeks to 6months) 67 (32.21) 79 (33.05) 96 (40.34)
3 (present for 6months to 1 year) 49 (23.56) 43 (17.99) 46 (19.33)
4 (present for 1 to 2 years) 24 (11.54) 37 (15.48) 30 (12.61)
5 (present > 2 years) 56 (26.92) 64 (26.78) 53 (22.27)
Presence of phobia (phobia flag), n (%) n = 208 n = 239 n = 238
Only anxiety 59 (28.37) 70 (29.29) 76 (31.93)
Specific fear 149 (71.63) 169 (70.71) 162 (68.07)
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Patient Health Questionnaire-9
To be included in the study participants had to score 10 or more on the PHQ-9 at baseline. A cut-off point
of 10 has been shown to detect clinical depression in UK primary care.14 A cut-off point of 10 was used to
categorise participants as depressed or not depressed at 4 months, 12 months and 24 months (PHQ-9
≥ 10= depressed, PHQ-9 < 10= not depressed). The descriptive statistics for the PHQ-9 by group across all
time points are presented in Table 8 and displayed in Figure 3.
As previously stated, to be eligible for the study participants had to score 10 or above on the PHQ-9 at
baseline. The mean PHQ-9 score at baseline was 16.65 (SD 4.25) and randomisation resulted in balance
across the three groups. The mean PHQ-9 score at 4 months was 9.71 (SD 6.35), at 12 months was 7.99
(SD 5.98) and at 24 months was 8.33 (SD 6.19). If we dichotomise the PHQ-9 using a cut-off point of 10,
the number of participants depressed at 4 months was 250 (47.53%), at 12 months was 170 (35.12%)
and at 24 months was 176 (38.18%).
TABLE 8 Patient Health Questionnaire-9 summary by duration of follow-up and treatment group11
Characteristic Beating the Blues MoodGYM Usual GP care
Baseline n = 210 n = 242 n = 239
Depressed (PHQ-9 ≥ 10), n (%) 210 (100.00) 242 (100.00) 239 (100.00)
4 months n = 165 n = 182 n = 179
Depressed (PHQ-9 ≥ 10), n (%) 83 (50.30) 89 (48.90) 78 (43.58)
12 months n = 153 n = 165 n = 166
Depressed (PHQ-9 ≥ 10), n (%) 54 (35.29) 50 (30.30) 66 (39.76)
24 months n = 143 n = 160 n = 158
Depressed (PHQ-9 ≥ 10), n (%) 60 (41.96) 55 (34.38) 61 (38.61)
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FIGURE 3 Bar chart of the proportion of patients who are depressed by group. (a) Beating the Blues;
(b) MoodGYM; and (c) usual GP care alone.
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Primary outcome
At 4 months, 83 of the 165 (50.30%) participants in the Beating the Blues group, 78 of the 179 (43.58%)
participants in the usual GP care group and 89 of the 182 (48.90%) participants in the MoodGYM group
scored 10 or more on the PHQ-9. The logistic regression results at 4 months highlighted that there was little
or no evidence of a difference between Beating the Blues and usual GP care alone (OR 1.19, 95% CI 0.75
to 1.88) or between MoodGYM and usual GP care alone at 4 months (OR 0.98, 95% CI 0.62 to 1.56;
Table 9).
The non-inferiority comparison between MoodGYM and Beating the Blues found the OR at 4 months was
0.91 (90% CI 0.62 to 1.34, p= 0.69). The upper limit of the 90% CI for the OR was 1.34, thus satisfying
statistical criteria for non-inferiority of MoodGYM compared with Beating the Blues.
Secondary outcomes
Patient Health Questionnaire-9: results from the logistic regression at 12 and
24 months
At 12 months, 54 of the 153 (35.29%) participants in the Beating the Blues group, 66 of the 166 (39.76%)
participants in the usual GP care group and 50 of the 165 (30.30%) participants in the MoodGYM group
scored 10 or more on the PHQ-9. At 24 months, 60 of the 143 (41.96%) participants in the Beating the
Blues group, 61 of the 158 (38.61%) participants in the usual GP care group and 55 of the 160 (34.38%)
participants in the MoodGYM group scored 10 or more on the PHQ-9. The logistic regression results
revealed that there was little or no evidence of a difference between Beating the Blues and usual GP care
across any of the time points (12 months OR 0.77, 95% CI 0.47 to 1.26; 24 months OR 1.00, 95% CI 0.60
to 1.68; Table 9). There was some evidence of a difference between MoodGYM and usual GP care at
12 months (OR 0.56, 95% CI 0.34 to 0.93) but this was no longer evident at 24 months (OR 0.68, 95% CI
0.41 to 1.15; Table 9). For the non-inferiority comparison between MoodGYM and Beating the Blues at
12 months, the OR was 0.77 (90% CI 0.50 to 1.18, p= 0.31) (Table 9 and Figure 4) and at 24 months was
TABLE 9 Results from the logistic regression models fitted at each individual time point11
Comparison OR
95% CI
p-valueLower Upper
4 months
Beating the Blues vs. usual GP care alone 1.19 0.75 1.88 0.46
MoodGYM vs. usual GP care alone 0.98 0.62 1.56 0.95
MoodGYM vs. Beating the Blues 0.91 0.62a 1.34a 0.69
12 months
Beating the Blues vs. usual GP care alone 0.77 0.47 1.26 0.29
MoodGYM vs. usual GP care alone 0.56 0.34 0.93 0.02
MoodGYM vs. Beating the Blues 0.77 0.50a 1.18a 0.31
24 months
Beating the Blues vs. usual GP care alone 1.00 0.60 1.68 0.99
MoodGYM vs. usual GP care alone 0.68 0.41 1.15 0.15
MoodGYM vs. Beating the Blues 0.72 0.47a 1.11a 0.21
Odds are being presented as ‘odds of being depressed’; model adjusted for gender, age, baseline depression severity,
depression duration and level of anxiety.
a 90% CI for the non-inferiority comparison.
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FIGURE 4 Mean PHQ-9 score over time by trial arm comparison. Means are predicted means and 95% CIs,
estimated from the mixed model and adjusted for gender, age, baseline PHQ-9 score, duration of depression and
level of anxiety as fixed effects. The model also included an interaction between month and treatment. Raw
unadjusted means are presented for baseline. (a) Beating the Blues vs. usual GP care; and (b) MoodGYM vs. usual
GP care. Reproduced from Gilbody et al.11 © BMJ 2015. This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/.
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0.72 (90% CI 0.47 to 1.11, p= 0.21) (Table 9 and Figure 4). At both time points, the upper limit of the
90% CI for the OR satisfied statistical criteria for non-inferiority of MoodGYM compared with Beating the
Blues. For the non-inferiority comparison between MoodGYM and Beating the Blues at 24 months, the OR
was 0.72 (90% CI 0.47 to 1.11, p= 0.21) (Table 9 and Figure 4). The upper limit of the 90% CI for the
OR was 1.11, thus satisfying statistical criteria for non-inferiority of MoodGYM and Beating the Blues.
Patient Health Questionnaire-9 dichotomised: results from the mixed model
We also fitted a repeated measures multilevel logistic regression model to the PHQ-9 scores, and Table 10
shows the results of this analysis. The values at 4, 12 and 24 months were the outcome measures, and
the baseline PHQ-9 score, age, gender, depression duration, level of anxiety, treatment group and time
were included as fixed effects; an interaction between treatment and time was also included in the model.
Different covariance patterns were assessed for the repeated measurements within participants and, as
the results were similar, the model with the smallest AIC was chosen for each comparison (independent
for all comparisons). For the Beating the Blues versus usual GP care and MoodGYM versus usual GP care
comparison there was no evidence of an overall difference between the two groups (p= 0.96 and p= 0.11,
respectively). The results are similar to those from the logistic regression models at each individual time-point
presented in Table 9. However, the results did change for the non-inferiority comparison between
MoodGYM and Beating the Blues at 4 months: the OR was 0.94 (90% CI 0.57 to 1.55, p= 0.84). The upper
limit of the 90% CI for the OR was 1.55, thus no longer satisfying statistical criteria for non-inferiority of
MoodGYM and Beating the Blues (Figure 5).
Subgroup analysis
Patient preference
Treatment preferences and the strength of these preferences were recorded at baseline in advance of
randomisation and are summarised in Tables 11 and 12. Approximately two-thirds of the participants had
a preference for the cCBT interventions, and less than 2% of participants did not know if they had a
TABLE 10 Result of mixed model for the dichotomised PHQ-911
Comparison OR
95% CI
p-valueLower Upper
4 months
Beating the Blues vs. usual GP care alone 1.27 0.70 2.28 0.43
MoodGYM vs. usual GP care alone 1.13 0.61 2.10 0.70
MoodGYM vs. Beating the Blues 0.94 0.57a 1.55a 0.84
12 months
Beating the Blues vs. usual GP care alone 0.66 0.32 1.34 0.24
MoodGYM vs. usual GP care alone 0.44 0.22 0.88 0.02
MoodGYM vs. Beating the Blues 0.73 0.40a 1.32a 0.39
24 months
Beating the Blues vs. usual GP care alone 1.16 0.44 3.05 0.77
MoodGYM vs. usual GP care alone 0.62 0.30 1.29 0.20
MoodGYM vs. Beating the Blues 0.60 0.29a 1.26a 0.26
Odds are presented as ‘odds of being depressed’; multilevel model adjusted for gender, age, baseline depression severity,
depression duration and level of anxiety as fixed effects. The model also included an interaction between month
and treatment.
a 90% CI for the non-inferiority comparison.
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FIGURE 5 Results from the logistic regression and mixed models for the non-inferiority comparisons between
MoodGYM and Beating the Blues.
TABLE 11 Patient preference at baseline by trial arm
Prefer to be randomised
to receive cCBT
Beating the Blues
(n= 210)
MoodGYM
(n= 242)
Usual GP care
(n= 239)
Total
(n= 691)
Yes 133 (63.33) 163 (67.36) 153 (64.02) 449 (64.98)
No/Don’t mind 74 (35.24) 75 (30.99) 80 (33.47) 229 (33.14)
Don’t know 3 (1.43) 4 (1.65) 6 (2.51) 13 (1.88)
TABLE 12 Strength of preference at baseline
Strength of preference
Beating the Blues
(n= 133)
MoodGYM
(n= 163)
Usual GP care
alone (n= 153)
Total
(n= 449)
Not particularly strong 23 (17.29) 37 (22.70) 39 (25.49) 99 (22.05)
Quite strong 61 (45.86) 75 (46.01) 65 (42.48) 201 (44.77)
Very strong 35 (26.32) 27 (16.56) 28 (18.30) 90 (20.04)
Extremely strong 14 (10.53) 23 (14.11) 21 (13.73) 58 (12.92)
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preference to be randomised to receive cCBT. Of the participants who expressed a preference to be
randomised to receive cCBT, 12.92% had an extremely strong preference, 20.04% had a very strong
preference, 44.77% had a quite strong preference and 22.05% had a not particularly strong preference.
The primary analysis was repeated with the addition of patient preference measured at baseline and its
interaction with trial arm as additional covariates. There was no evidence of an interaction between patient
preference and allocated treatment across any of the comparisons (Beating the Blues vs. usual GP care,
p= 0.47; MoodGYM vs. usual GP care, p= 0.35).
Patient Health Questionnaire-9 scores: results from the mixed model
The PHQ-9 questionnaire was used to assess depression severity at baseline and at 4, 12 and 24 months.
Descriptive statistics of the PHQ-9 scores are presented in Table 13. The minimum, and best, score possible
was 0 and the maximum was 27. The mean PHQ-9 score decreased over time across all trial arms but
increased slightly at 24 months in the two cCBT groups.
We fitted a repeated measures multilevel linear regression model to the PHQ-9 scores. The values at 4, 12
and 24 months were the outcome measures, and the baseline value, treatment group and time were
included as fixed effects; an interaction between treatment and time was also included in the model.
Different covariance patterns were assessed for the repeated measurements within participants and, as
the results were similar, the model with the smallest AIC was chosen for each comparison (independent
for Beating the Blues vs. usual GP care and unstructured for MoodGYM vs. usual GP care). For the Beating
the Blues versus usual GP care comparison there was no evidence of an overall difference between the
two groups (p= 0.81) and the mean PHQ-9 score (over all follow-up assessments) was 8.06 (95% CI 6.92
to 9.20) for Beating the Blues and 7.93 (95% CI 6.74 to 9.13) for usual GP care. For the MoodGYM versus
usual GP care comparison there was no evidence of an overall difference between the two groups
(p= 0.09) and the mean PHQ-9 score (over all follow-up assessments) was 8.49 (95% CI 7.26 to 9.72)
for MoodGYM and 9.30 (95% CI 8.00 to 10.60) for usual GP care. Table 14 and Figure 4 display the
results of the mixed model for each time point individually.
Clinical Outcomes in Routine Evaluation – Outcome Measure
The CORE-OM questionnaire was measured at baseline and at 4, 12 and 24 months. Descriptive statistics
of the CORE-OM scores are presented in Table 15. The mean CORE-OM scores decreased over time across
all trial arms but increased slightly at 24 months in the two cCBT groups.
TABLE 13 Patient Health Questionnaire-9 summary by duration of follow-up and treatment group
Characteristic Beating the Blues MoodGYM Usual GP care alone
Baseline n = 210 n = 242 n = 239
Mean (SD) 16.78 (4.21) 16.87 (3.99) 16.32 (4.52)
Median (minimum to maximum) 17 (10 to 27) 17 (10 to 26) 16 (10 to 27)
4 months n = 165 n = 182 n = 179
Mean (SD) 10.30 (6.35) 9.70 (6.36) 9.17 (6.34)
Median (minimum to maximum) 10 (0 to 26) 9 (0 to 26) 9 (0 to 27)
12 months n = 153 n = 165 n = 166
Mean (SD) 8.13 (6.13) 7.39 (5.51) 8.45 (6.28)
Median (minimum to maximum) 7 (0 to 27) 6 (0 to 24) 7 (0 to 25)
24 months n = 143 n = 160 n = 158
Mean (SD) 8.93 (6.09) 7.75 (5.81) 8.36 (6.62)
Median (minimum to maximum) 8 (0 to 25) 7 (0 to 26) 7 (0 to 25)
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TABLE 14 Result of the linear mixed model for PHQ-911
Comparison
Intervention,
mean (95% CI)
Usual GP care,
mean (95% CI) Difference (95% CI) p-value
4 months
Beating the Blues vs. usual GP
care alone
9.18 (7.94 to 10.42) 8.46 (7.18 to 9.73) 0.72 (– 0.46 to 1.90) 0.23
MoodGYM vs. usual GP care
alone
9.86 (8.55 to 11.18) 9.80 (8.42 to 11.18) 0.06 (– 1.09 to 1.22) 0.91
12 months
Beating the Blues vs. usual GP
care alone
7.20 (5.94 to 8.46) 7.83 (6.53 to 9.13) – 0.63 (– 1.87 to 0.62) 0.33
MoodGYM vs. usual GP care
alone
7.63 (6.31 to 8.95) 9.22 (7.83 to 10.60) – 1.59 (– 2.75 to –0.42) 0.008
24 months
Beating the Blues vs. usual GP
care alone
7.79 (6.47 to 9.12) 7.52 (6.16 to 8.88) 0.28 (– 1.10 to 1.65) 0.69
MoodGYM vs. usual GP care
alone
7.97 (6.61 to 9.33) 8.88 (7.45 to 10.30) – 0.91 (– 2.16 to 0.35) 0.16
Multilevel model adjusted for gender, age, baseline depression severity, depression duration and level of anxiety as fixed
effects. The model also included an interaction between month and treatment.
TABLE 15 Clinical Outcomes in Routine Evaluation – Outcome Measure summary by duration of follow-up and
treatment group
Characteristic Beating the Blues MoodGYM Usual GP care alone
Baseline n = 209 n = 242 n = 237
Mean (SD) 19.23 (5.22) 18.65 (5.75) 18.63 (5.59)
Median (minimum to maximum) 19.12 (7.94 to 34.12) 18.97 (4.41 to 32.94) 18.53 (4.12 to 34.41)
4 months n = 155 n = 170 n = 167
Mean (SD) 13.81 (7.19) 12.85 (7.37) 13.03 (8.28)
Median (minimum to maximum) 13.82 (0.88 to 33.24) 11.91 (0.59 to 30.00) 12.94 (0.29 to 34.41)
12 months n = 137 n = 155 n = 150
Mean (SD) 11.07 (7.42) 10.10 (6.72) 11.75 (7.99)
Median (minimum to maximum) 10.59 (0.29 to 31.18) 9.12 (0 to 31.47) 10.58 (0 to 31.47)
24 months n = 124 n = 143 n = 139
Mean (SD) 12.76 (7.68) 10.57 (6.97) 11.48 (8.05)
Median (minimum to maximum) 11.76 (0.29 to 32.65) 9.41 (0 to 30.59) 10.29 (0 to 33.24)
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We fitted a repeated-measures multilevel linear regression model to the CORE-OM scores. The values at 4,
12 and 24 months were the outcome measures, and the baseline value, treatment group and time were
included as fixed effects; an interaction between treatment and time was also included in the model.
Different covariance patterns were assessed for the repeated measurements within participants and, as the
results were similar, the model with the smallest AIC was chosen for each comparison (independent for
both comparisons). For the Beating the Blues versus usual GP care comparison there was little or no
evidence of an overall difference between the two groups (p= 0.50) and the mean CORE-OM score
(over all follow-up assessments) was 11.74 (95% CI 10.27 to 13.21) for Beating the Blues and 12.18
(95% CI 10.64 to 13.71) for usual GP care. For the MoodGYM versus usual GP care comparison there was
some evidence of an overall difference between the two groups (p= 0.05) and the mean CORE-OM score
(over all follow-up assessments) was 11.98 (95% CI 10.47 to 13.50) for MoodGYM and 13.14 (95% CI
11.55 to 14.73) for usual GP care. Table 16 and Figure 6 display the results of the mixed model for each
time point individually.
Short Form questionnaire-36 items Health Survey version 2
The SF-36v2 questionnaire was used to assess self-reported HRQoL at baseline and at 4, 12 and 24 months.
Descriptive statistics of the domain scores and the PCS scores and MCS scores are presented in Tables 17
and 18. Only the PCS scores and MCS scores have been analysed, all other components are presented
descriptively. Figures 7 and 8 show the mean MCS scores and PCS scores (and 95% CI) by trial arm,
over time. This shows that, for the PCS, there was little difference between the treatment groups at any time
and no clear pattern of improvements over time. For the MCS, the mean scores for Beating the Blues
increased between 4 and 12 months and then decreased slightly at 24 months, but this score was still higher
than at 4 months. For MoodGYM the scores increased between 4 and 12 months and then remained
constant, whereas for usual GP care scores remained similar over all time points.
We fitted a repeated measures multilevel regression model to the PCS scores and MCS scores. The values
at 4, 12 and 24 months were the outcome measures, and the baseline value, treatment group and time
were included as fixed effects. An interaction between treatment and time was also included in the model.
Different covariance patterns were assessed for the repeated measurements within participants and, as the
results were similar, the model with the smallest AIC was chosen for each component score and
TABLE 16 Results of the linear mixed model for CORE-OM11
Comparison
Intervention,
mean (95% CI)
Usual GP care,
mean (95% CI)
Difference
(95% CI) p-value
4 months
Beating the Blues vs. usual GP
care alone
12.87 (11.31 to 14.43) 12.75 (11.14 to 14.36) 0.12 (– 1.33 to 1.57) 0.87
MoodGYM vs. usual GP care
alone
13.61 (12.01 to 15.20) 13.69 (12.02 to 15.36) – 0.09 (– 1.44 to 1.27) 0.90
12 months
Beating the Blues vs. usual GP
care alone
10.51 (8.91 to 12.11) 12.00 (10.34 to 13.66) – 1.49 (– 3.04 to 0.06) 0.06
MoodGYM vs. usual GP care
alone
10.87 (9.25 to 12.48) 12.98 (11.28 to 14.68) – 2.12 (– 3.54 to – 0.69) 0.004
24 months
Beating the Blues vs. usual GP
care alone
11.84 (10.13 to 13.55) 11.78 (10.05 to 13.51) 0.06 (– 1.68 to 1.80) 0.95
MoodGYM vs. usual GP care
alone
11.48 (9.80 to 13.16) 12.74 (11.00 to 14.49) – 1.27 (– 2.80 to 0.27) 0.11
Multilevel model adjusted for gender, age, baseline CORE-OM score, duration of depression and level of anxiety as fixed
effects. The model also included an interaction between time point (month) and treatment.
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FIGURE 6 Mean CORE-OM scores over time by trial arm comparison. (a) Beating the Blues vs. usual GP care; and
(b) MoodGYM vs. usual GP care.
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TABLE 17 Short Form questionnaire-36 items Health Survey version 2 summary scores by duration of follow-up and
treatment group
Characteristic
Beating the Blues MoodGYM Usual GP care alone
n Mean score (SD) n Mean score (SD) n Mean score (SD)
Physical functioning
Baseline 210 48.39 (9.90) 242 49.25 (9.32) 239 49.55 (9.78)
4 months 155 48.06 (10.65) 170 49.53 (10.02) 167 49.86 (9.41)
12 months 137 48.51 (10.77) 156 49.53 (10.34) 151 49.69 (10.27)
24 months 123 47.23 (11.77) 143 47.61 (12.13) 139 49.78 (9.87)
Role-physical
Baseline 210 43.17 (11.94) 242 42.85 (12.67) 239 45.24 (12.35)
4 months 155 44.37 (11.31) 170 45.56 (11.95) 167 46.35 (11.59)
12 months 137 45.82 (11.38) 156 45.91 (11.75) 151 45.45 (11.92)
24 months 124 44.75 (12.84) 143 44.97 (12.41) 139 46.19 (11.11)
Bodily pain
Baseline 210 43.29 (10.95) 242 43.89 (10.70) 239 44.48 (10.52)
4 months 155 45.00 (11.94) 170 46.77 (11.67) 167 47.14 (11.41)
12 months 137 46.94 (12.05) 156 46.92 (12.49) 151 47.84 (11.26)
24 months 123 45.45 (12.95) 142 46.30 (13.02) 137 47.81 (12.04)
General health
Baseline 210 37.84 (10.43) 242 39.49 (11.08) 239 39.47 (10.20)
4 months 155 39.63 (11.74) 169 41.93 (11.55) 167 41.48 (11.65)
12 months 136 42.39 (12.53) 156 44.04 (12.07) 150 43.27 (11.18)
24 months 124 40.17 (13.18) 141 43.93 (12.75) 139 42.80 (11.41)
Vitality
Baseline 210 32.01 (8.10) 242 32.39 (7.70) 239 33.61 (8.05)
4 months 155 38.60 (10.63) 170 40.55 (11.49) 166 40.36 (10.92)
12 months 137 41.77 (11.24) 156 42.58 (11.67) 151 41.51 (11.23)
24 months 124 40.13 (12.05) 143 42.91 (11.81) 139 41.51 (11.57)
Social functioning
Baseline 209 30.39 (10.47) 242 29.47 (10.83) 238 31.05 (10.00)
4 months 155 36.37 (12.68) 170 38.18 (12.11) 167 39.21 (11.91)
12 months 136 41.69 (13.22) 156 41.43 (12.64) 151 40.96 (12.29)
24 months 123 38.71 (13.53) 143 41.02 (13.25) 137 41.32 (12.23)
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TABLE 18 Short Form questionnaire-36 items Health Survey version 2 PCS scores and MCS scores by duration of
follow-up and treatment group
Characteristic Beating the Blues MoodGYM Usual GP care alone
Baseline n = 209 n = 242 n = 238
PCS score, mean (SD) 50.31 (11.55) 51.20 (10.08) 51.94 (10.40)
MCS score, mean (SD) 22.81 (9.96) 22.22 (10.55) 23.51 (9.64)
4 months n = 155 n = 169 n = 166
PCS score, mean (SD) 48.45 (11.72) 50.08 (11.22) 50.29 (10.39)
MCS score, mean (SD) 32.85 (13.27) 34.50 (14.20) 34.79 (14.01)
12 months n = 135 n = 156 n = 150
PCS score, mean (SD) 48.24 (12.46) 48.80 (11.91) 49.80 (10.88)
MCS score, mean (SD) 39.56 (12.59) 40.16 (13.05) 37.28 (14.93)
24 months n = 122 n = 140 n = 137
PCS score, mean (SD) 47.45 (13.19) 47.96 (12.99) 49.92 (10.70)
MCS score, mean (SD) 36.11 (13.95) 40.36 (13.04) 37.79 (14.07)
SF-36v2 higher score is better in health.
TABLE 17 Short Form questionnaire-36 items Health Survey version 2 summary scores by duration of follow-up and
treatment group (continued )
Characteristic
Beating the Blues MoodGYM Usual GP care alone
n Mean score (SD) n Mean score (SD) n Mean score (SD)
Role-emotional
Baseline 210 28.34 (11.26) 242 28.57 (12.12) 239 29.79 (11.07)
4 months 155 36.49 (13.12) 170 37.31 (13.13) 167 38.10 (13.06)
12 months 137 43.00 (12.06) 156 42.55 (12.75) 151 40.02 (14.02)
24 months 124 39.08 (13.88) 143 41.82 (12.47) 139 40.86 (13.18)
Mental health
Baseline 210 28.73 (7.98) 242 28.11 (9.01) 239 29.05 (8.78)
4 months 155 36.15 (11.31) 170 38.15 (12.45) 166 38.25 (13.19)
12 months 137 41.11 (12.05) 156 42.67 (11.88) 151 40.17 (13.18)
24 months 124 38.55 (12.81) 143 42.19 (12.16) 139 40.32 (13.08)
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FIGURE 7 Short Form questionnaire-36 items Health Survey version 2 MCS scores over time trial arm comparison.
(a) Beating the Blues vs. usual GP care; and (b) MoodGYM vs. usual GP care.
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FIGURE 8 Mean SF-36v2 PCS scores over time trial arm comparison. (a) Beating the Blues vs. usual GP care; and
(b) MoodGYM vs. usual GP care.
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comparison (independent for Beating the Blues vs. usual GP care alone and unstructured for MoodGYM
vs. usual GP care alone for both component scores). For the Beating the Blues versus usual GP care
comparison, there was little or no evidence of an overall difference between the two groups for the MCS
(p= 0.40) or for the PCS (p= 0.22), and the mean SF-36v2 MCS score (over all follow-up assessments) was
38.52 (95% CI 35.77 to 41.27) for Beating the Blues and 37.50 (95% CI 34.62 to 40.38) for usual GP
care and for the PCS was 48.66 (95% CI 47.05 to 50.28) for Beating the Blues and 49.55 (95% CI 47.86
to 51.23) for usual GP care. For the MoodGYM versus usual GP care comparison, there was evidence of an
overall difference between the two groups for the MCS (p= 0.009) but little or no evidence for the PCS
(p= 0.14). The mean SF-36v2 MCS score (over all follow-up assessments) was 38.98 (95% CI 36.03 to
41.92) for MoodGYM and 35.99 (95% CI 32.88 to 39.11) for usual GP care and for the PCS was 48.87
(95% CI 47.11 to 50.63) for MoodGYM and 49.91 (95% CI 48.05 to 51.76) for usual GP care. Tables 19
and 20 and Figures 7 and 8 display the results of the mixed model for each time point individually.
Adverse events
A total of 745 NSAEs were reported from 302 participants: 264 events (from 93 participants) in the
Beating the Blues group, 240 events (from 99 participants) in the MoodGYM group and 241 events (from
110 participants) in the usual GP care alone group. Table 21 summarises the NSAEs by trial arm and
Table 22 summarises the SAEs by trial arm. There were 49 SAEs reported from 39 participants. Of these
SAEs, 39 events were classified as unrelated to treatment and nine were classified as unlikely to be
related to treatment, with the final event being unable to classify. Five of the reported SAEs were
referred to the DMEC for further discussion and two were referred to the REC. Of the 49 SAEs reported,
40 (81.6%) involved inpatient hospitalisation, seven were deemed life-threatening and two resulted
in participants dying.
Data on computerised cognitive behaviour therapy usage
Data were obtained on participants’ engagement with the two cCBT programs. This included data relating
to participants’ progression through the cCBT programs on a session-by-session basis. Following
randomisation, a total of 175 (83%) Beating the Blues participants and 186 (77%) MoodGYM participants
went on to access the programs at least once.
TABLE 19 Results of the Linear Mixed Model for the SF-36v2 for MCS11
Comparison
Intervention,
mean (95% CI)
Usual GP care,
mean (95% CI) Difference (95% CI) p-value
4 months
Beating the Blues vs. usual
GP care alone
35.23 (32.28 to 38.17) 36.33 (33.29 to 39.37) – 1.10 (– 3.85 to 1.64) 0.43
MoodGYM vs. usual GP care
alone
35.07 (31.90 to 38.23) 34.87 (31.54 to 38.20) 0.20 (– 2.60 to 2.99) 0.89
12 months
Beating the Blues vs. usual
GP care alone
41.58 (38.55 to 44.60) 38.25 (35.11 to 41.39) 3.32 (0.37 to 6.28) 0.03
MoodGYM vs. usual GP care
alone
40.91 (37.77 to 44.05) 36.66 (33.33 to 40.00) 4.25 (1.47 to 7.02) 0.003
24 months
Beating the Blues vs. usual
GP care alone
38.76 (35.52 to 41.99) 37.92 (34.62 to 41.22) 0.84 (–2.49 to 4.17) 0.62
MoodGYM vs. usual GP care
alone
40.95 (37.68 to 44.23) 36.44 (33.03 to 39.86) 4.51 (1.51 to 7.51) 0.003
Adjusted for gender, age, baseline depression severity, depression duration and level of anxiety.
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TABLE 20 Result of the linear mixed model for the SF-36v2 for PCS11
Comparison
Intervention,
mean (95% CI)
Usual GP care,
mean (95% CI) Difference (95% CI) p-value
4 months
Beating the Blues vs. usual
GP care alone
49.18 (47.44 to 50.92) 49.85 (48.05 to 51.64) – 0.67 (– 2.33 to 0.99) 0.43
MoodGYM vs. usual GP care
alone
49.86 (47.97 to 51.75) 50.21 (48.23 to 52.19) – 0.35 (– 2.04 to 1.33) 0.68
12 months
Beating the Blues vs. usual
GP care alone
48.61 (46.80 to 50.43) 49.73 (47.86 to 51.61) – 1.12 (– 2.95 to 0.71) 0.23
MoodGYM vs. usual GP care
alone
48.85 (46.96 to 50.73) 50.06 (48.07 to 52.05) – 1.21 (– 2.91 to 0.49) 0.16
24 months
Beating the Blues vs. usual
GP care alone
48.19 (46.17 to 50.22) 49.06 (47.02 to 51.10) – 0.87 (– 3.06 to 1.32) 0.44
MoodGYM vs. usual GP care
alone
47.89 (45.82 to 49.97) 49.45 (47.30 to 51.60) – 1.56 (– 3.61 to 0.50) 0.14
Adjusted for gender, age, baseline depression severity, depression duration and level of anxiety.
TABLE 21 Summary of NSAEs11
Summary
Beating the Blues
(n= 210)
MoodGYM
(n= 242)
Usual GP care
alone (n= 239)
Total
(n= 691)
Total number of NSAEs 264 240 241 745
Number of participants
with one or more NSAEs
93 (44.3) 99 (40.9) 110 (46.0) 302 (43.7)
NSAEs per patient
1 27 (29.0) 36 (36.4) 49 (44.5) 112 (37.1)
2 30 (32.3) 21 (21.2) 31 (28.2) 82 (27.2)
3 14 (15.1) 22 (22.2) 13 (11.8) 49 (16.2)
4 6 (6.5) 12 (12.1) 7 (6.4) 25 (8.3)
5 5 (5.4) 6 (6.1) 6 (5.5) 17 (5.6)
6 or more 11 (11.8) 2 (2.0) 4 (3.6) 17 (5.6)
DOI: 10.3310/hta191010 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 101
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Littlewood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
In terms of progression through the programs, the median number of Beating the Blues sessions
completed was two [interquartile range (IQR) 0–5] and the most frequent number of sessions was one.
The median number of sessions completed for MoodGYM was one (IQR 0–2) and the most frequent
number of sessions was one. Of the 175 participants who started Beating the Blues, 31 (18%) participants
completed all eight sessions of the program; and of the 186 participants who started MoodGYM, a total
of 29 (16%) participants completed all six sessions of the program. The average length of time spent using
the cCBT programs (from initial access to last session accessed) was 67 days (median 40 days, IQR 1–98 days)
for Beating the Blues and 34 days (median 8 days, IQR 1–50 days) for MoodGYM participants.
TABLE 22 Summary of SAEs11
Summary
Beating the Blues
(N= 210)
MoodGYM
(N= 242)
Usual GP care
(N= 239)
Total
(N= 691)
Total number of SAEs 19 11 19 49
Number of participants with one or
more SAEs
15 (7.1) 9 (3.7) 15 (6.3) 39 (5.6)
Events per patient
1 12 (80.0) 7 (77.8) 11 (73.3) 30 (76.9)
2 2 (13.3) 2 (22.2) 4 (26.7) 8 (20.5)
3 1 (6.7) 0 (0.0) 0 (0.0) 1 (2.6)
Relationship to treatment
Unrelated 18 (94.7) 6 (54.5) 15 (78.9) 39 (79.6)
Unlikely to be related 0 (0.0) 5 (45.5) 4 (21.1) 9 (18.4)
Possibly related 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Probably related 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Definitely related 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unable to assessa 1 (5.3) 0 (0.0) 0 (0.0) 1 (2.0)
Number of SAEs referred to DMEC 0 (0.0) 2 (18.2) 3 (15.8) 5 (10.2)
Number of SAEs referred to REC 0 (0.0) 0 (0.0) 2 (10.5) 2 (4.1)
Event details
Involved inpatient hospitalisationb 17 (89.5) 10 (90.9) 13 (68.4) 40 (81.6)
Life-threateningb,c 0 (0.0) 1 (9.1) 6 (31.6) 7 (14.3)
Patient died 2 (10.5) 0 (0.0) 0 (0.0) 2 (4.1)
Involved persistent or significant disability
or incapacityc
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Resulted in a congenital anomaly or
birth defect
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
a Researcher was informed that the participant had recently been hospitalised but, when contacted, the patient did not
provide further information and withdrew from the study.
b One SAE was classed as both involving inpatient hospitalisation and life-threatening.
c One SAE was classed as both life-threatening and involving persistent or signification disability or incapacity.
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Data on technical support telephone calls and contacts
Information relating to technical support telephone calls and contacts was recorded for each participant.
The default mode of contact was by telephone call, with e-mails and/or texts sent if this alternative mode
of communication was specifically requested by the participant. Contact attempts (which included
telephone calls, e-mails and texts) were made to participants irrespective of their progression through the
cCBT program, meaning that participants could be contacted on a number of separate occasions while still
working through the same cCBT session.
A median of 13 contact attempts were made to both Beating the Blues (IQR 11–16) and MoodGYM
(IQR 10–16) participants. A total mean of 6.0 (IQR 3–8) technical telephone support calls were made to
participants allocated to Beating the Blues. A total mean of 6.8 (IQR 4–9) technical telephone support calls
were made to MoodGYM participants. Of the technical telephone support calls made, the mean number
of calls answered by participants allocated to Beating the Blues was 3.1 (IQR 1–5), with a mean per call
duration of 1.8 minutes (IQR 1–2 minutes). For MoodGYM participants, the mean number of technical
telephone support calls answered by participants was 3.3 (IQR 1–5), with a mean per call duration of
2.0 minutes (IQR 1–2 minutes). The total mean number of minutes of technical support calls delivered
to participants was 6.2 minutes (IQR 2–8 minutes) for participants allocated to Beating the Blues and
6.5 minutes (IQR 2–9 minutes) for participants allocated to MoodGYM. The mean number of e-mails sent
was 5.3 (IQR 2–8) and 5.0 (IQR 1–8) for Beating the Blues and MoodGYM participants, respectively.
Few texts were sent (mean of < 0.1 texts sent to both Beating the Blues and MoodGYM participants).
Summary
There was little or no evidence of statistically significant effects of Beating the Blues on the proportion of
participants who are depressed across all time points when compared with usual GP care alone. There was
some evidence of a statistically significant effect of MoodGYM on the proportion of participants who are
depressed when compared with usual GP care at 12 months but this was no longer evident at 24 months
and was not present at 4 months. The free-to-use cCBT program MoodGYM was found to be non-inferior
to the commercial pay-to-use cCBT program Beating the Blues across all time points. There was no
evidence of statistically significant effects of the interactions between patient preference and allocated
treatment across any of the comparisons.
There was no evidence of statistically significant effects on the overall (including all time points) mean
depression scores, CORE-OM scores and MCS and PCS quality of life scores of Beating the Blues when
compared with usual GP care alone; however, there was evidence of a statistically significant effect
of Beating the Blues on MCS scores at 12 months. There was no evidence of statistically significant effects
on overall (including all time points) mean depression scores and PCS quality of life scores of MoodGYM
when compared with usual GP care alone; however, there was evidence of a statistically significant effect
of MoodGYM on the mean depression scores at 12 months when compared with usual GP care. There
was evidence of statistically significant effects on the overall (including all time points) mean CORE-OM
scores and MCS quality of life scores of MoodGYM when compared with usual GP care alone, with highly
statistically significant effects of MoodGYM on CORE-OM scores at 12 months and MCS quality of life
scores at 12 and 24 months when compared with usual GP care alone.
Participant engagement with the cCBT programs was low for both Beating the Blues and MoodGYM, with
the majority of participants not completing the series of sessions. Participants were offered and received
similar levels of technical telephone support across Beating the Blues and MoodGYM programs.
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Chapter 5 Economic evaluation results
Health-care resource use
Descriptive statistics (mean, SD, median and IQR) of health-care resource use by resource category per time
period during trial follow-up, and aggregated for the full duration of the trial, are shown in Tables 23–25.
The unit costs applied to resource use items to calculate total costs are also presented within the tables. The
results presented are based on the available case data set, as multiple imputation was performed for total
costs as opposed to individual resource use items.
Regarding the completeness of data, resource use data were available for 83.9% (n= 580) of all trial
participants during the 2 years of follow-up. In general, differences between treatment groups in resource
use appeared small, and resource use estimates appeared considerably variable with large SDs. Regarding
the dispersion of the results, median estimates were smaller than means for all resource categories,
treatment groups and follow-up periods. Medians were equal to zero for all treatment groups and resource
use categories, except GP and nurse visits in both follow-up periods. This suggests that the distributions
were skewed to the right.
Costs
Mean costs from baseline to 12 months and from 12 months to 24 months by treatment arm are shown
in Table 26. The results are presented by type of services, namely primary care, hospital and other
community services. Costs of depression-related medication and cCBT are also shown. Table 27 reports
undiscounted and discounted costs aggregated for the full 24-month duration of the trial. All costs results
were estimated from the multiple imputed data sets.
Primary care services represented the largest share of health-care expenditure for all treatment groups in
both trial follow-up periods, constituting over 50% of total costs for all groups. The second largest
category of costs was hospital services, which varied from 25% to 35% across the groups.
Total (discounted) costs for the 24 months were £1186 for Beating the Blues plus usual GP care, £1121
for usual GP care alone and £1098 for MoodGYM plus usual GP care group. There is limited value in
interpreting differences in mean costs across time periods and for different treatment groups at this level,
as the results shown in Table 27 are unadjusted for baseline costs and participant covariates. The adjusted
mean differences for each cCBT treatment versus usual GP care alone and corresponding 95% CIs,
obtained through regression analysis, are reported within the cost-effectiveness results section
(see Cost-effectiveness analysis).
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Health-related quality of life
Table 28 shows the extent to which EQ-5D questionnaires were completed at each time point during trial
follow-up. Table 29 shows the corresponding information for SF-6D scores.
There was a steady decrease in completed EQ-5D questionnaires throughout trial follow-up. The rate of
questionnaire return was slightly higher for the Beating the Blues plus usual GP care treatment group but,
in general, it was similar for all treatment groups.
The pattern of response to SF-6D is similar to that of EQ-5D, with the response rate decreasing over time.
Tables 30 and 31 summarise the unadjusted HRQoL scores and QALY estimates obtained from EQ-5D and
SF-6D, respectively, from the multiple imputed data sets.
Mean QALYs estimated through EQ-5D over 24 months (discounted at 3.5% rate for QALYs accrued in the
last 12 months of follow-up) were 1.3325 for Beating the Blues plus usual GP care, 1.3888 for usual GP
care alone and 1.3564 for MoodGYM plus usual GP care. Mean QALYs estimated through SF-6D over
24 months (discounted at 3.5% rate for QALYs accrued in the last 12 months of follow-up) were 1.2464 for
Beating the Blues plus usual GP care, 1.2856 for usual GP care alone and 1.2810 for MoodGYM plus usual
GP care.
TABLE 28 Participant response to the EQ-5D questionnaire at each time point (absolute and relative frequency)
Treatment group
Time point (month), n Time point (month), %
0 4 12 24 0 4 12 24
Beating the Blues 210 157 144 129 100.00 74.7 68.57 61.43
MoodGYM 242 170 159 144 100.00 70.25 65.70 59.50
Usual GP care alone 239 167 156 143 100.00 69.87 65.27 59.83
TABLE 30 European Quality of Life – 5 Dimensions summary scores and quality-adjusted life-year estimates
Outcome Beating the Blues, mean (SE) MoodGYM, mean (SE) Usual GP care alone, mean (SE)
Baseline 0.6162 (0.0173) 0.6111 (0.0173) 0.6256 (0.0174)
4 months 0.6854 (0.0204) 0.6851 (0.0211) 0.7275 (0.0184)
12 months 0.6914 (0.0225) 0.7186 (0.0203) 0.7081 (0.0210)
24 months 0.6677 (0.0234) 0.6734 (0.0250) 0.7093 (0.0216)
QALYs 1.3325 (0.0337) 1.3564 (0.0330) 1.3888 (0.0328)
SE, standard error.
TABLE 29 Participant response to the SF-6D questionnaire at each time point (absolute and relative frequency)
Treatment group
Time point (month), n Time point (month), %
0 4 12 24 0 4 12 24
Beating the Blues 209 155 132 117 99.52 73.81 62.86 55.71
MoodGYM 242 170 155 139 100.00 70.25 64.05 57.44
Usual GP care alone 237 165 147 135 99.16 69.04 61.51 56.49
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As for total costs, HRQoL scores and QALYs estimates shown here are unadjusted means, and, therefore,
there is limited value in interpreting differences between treatments. Mean differences for each cCBT
treatment versus usual GP care alone and corresponding 95% CIs, adjusted for patient covariates by
regression analysis, are shown in the following section.
Cost-effectiveness analysis
Table 32 shows the results for the differences in mean costs and QALYs adjusted for patient covariates,
between each cCBT treatment group and usual GP care alone. In general, differences in costs and QALYs
between both cCBT groups and usual GP care alone were small with wide CIs and were not statistically
significant at a 5% significance level.
Results for the SUR models, where incremental QALYs and costs are estimated simultaneously, are
presented in Appendix 13. The estimates from the SUR model are very similar to those estimated for the
base-case analysis. The results lack statistical significance (5% level of significance) and CIs on both models
are wide (and overlap between models).
TABLE 31 Short Form questionnaire-6 Dimensions summary scores and quality-adjusted life-year estimates
Outcome Beating the Blues, mean (SE) MoodGYM, mean (SE) Usual GP care alone, mean (SE)
Baseline 0.5702 (0.0054) 0.5705 (0.0050) 0.5790 (0.0050)
4 months 0.6223 (0.0084) 0.6359 (0.0080) 0.6540 (0.0087)
12 months 0.6528 (0.0114) 0.6668 (0.0088) 0.6666 (0.0087)
24 months 0.6360 (0.0137) 0.6368 (0.0080) 0.6580 (0.0102)
QALYs 1.2464 (0.0177) 1.2810 (0.0135) 1.2856 (0.0144)
SE, standard error.
TABLE 32 Adjusted mean differences in QALYs and costs between cCBT and usual GP care alone: base case
Comparison
Adjusted
difference
in means
95% confidence limits
Lower Upper
QALYsa (n = 691)
Beating the Blues vs. usual GP care alone (n= 210 and n= 239, respectively) – 0.0435 – 0.1167 0.0297
MoodGYM vs. usual GP care alone (n= 242 and n= 239, respectively) – 0.0153 – 0.0919 0.0613
Total costsb (n = 691)
Beating the Blues vs. usual GP care alone (n= 210 and n= 239, respectively) £104.24 – £66.77 £275.26
MoodGYM vs. usual GP care alone (n= 242 and n= 239, respectively) – £106.07 – £261.65 £49.52
a On baseline EQ-5D score, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
b On costs at baseline, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
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Base-case cost-effectiveness results
Table 33 presents the fully incremental cost-effectiveness estimates and probability that each intervention
is cost-effective at a threshold of £20,000 per QALY.
Beating the Blues plus usual GP care is dominated by usual GP care alone, with higher mean costs and
lower QALYs. As both mean costs and QALYs were lower for MoodGYM plus usual GP care than for usual
GP care alone, the ICER estimated falls within the south-west quadrant of the cost-effectiveness plane. In
this quadrant, the interpretation of the ICER is estimated using the difference in costs and QALYs between
the lower-cost intervention (in this case, MoodGYM) and the higher-cost intervention (usual GP care alone).
Consequently, the ICER of £6933 per additional QALY actually represents the ICER of usual GP care alone
versus MoodGYM. As this falls within the £20,000 per QALY threshold, the conclusion is that usual GP care
alone is cost-effective when compared with MoodGYM plus usual GP care. Consequently, these main
results do not provide evidence supporting the cost-effectiveness of either Beating the Blues or MoodGYM
compared with usual GP care alone.
Table 33 also reports probabilities of cost-effectiveness for each of the treatments under comparison at a
cost-effectiveness threshold of £20,000 per QALY. The corresponding CEACs, showing the probability of
each treatment being cost-effective across a range of cost-effectiveness thresholds, are shown in Figure 9.
At a £20,000 per QALY threshold, usual GP care alone is the treatment most likely to be cost-effective
(0.545 probability of cost-effectiveness), followed by MoodGYM plus usual GP care (0.417 probability of
cost-effectiveness) and Beating the Blues plus usual GP care (0.038 probability of cost-effectiveness).
Figures 10 and 11 present the incremental cost and effectiveness estimates of the comparator (Beating the
Blues or MoodGYM) compared with usual GP care alone taken from the probabilistic sensitivity analysis.
TABLE 33 Cost-effectiveness analysis summary table: base case
Treatment group Δ costsa (£) Δ QALYsa ICERa (£ per QALY) Probability cost-effective at £20,000/QALY
Beating the Blues 104.24 – 0.0435 Dominated 0.038
MoodGYM – 106.07 – 0.0153 6933b 0.417
Usual GP care alone – – – 0.545
a Compared with usual GP care alone.
b ICER on south-west quadrant of the cost-effectiveness plane.
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Each point represents the incremental costs and effectiveness given one particular realisation of uncertainty.
The £20,000 per QALY line represents the cost-effectiveness threshold. All points south-east of this line
represent realisations of uncertainty when the comparator (Beating the Blues or MoodGYM) is cost-effective
compared with usual GP care alone at a cost-effectiveness threshold of £20,000 per QALY.
Sensitivity analysis
A series of scenario analyses were conducted to test the robustness of the base-case results to alternative
assumptions, as previously described in Chapter 2. Tables 34 and 35 show the results for scenario 1, where
SF-6D scores were used to calculate QALYs instead of EQ-5D scores. Difference in means for QALYs
(SF-6D estimated) between each cCBT treatment group compared with usual GP care alone (adjusted for
participant covariates) are presented in Table 34.
Consistent with the main analysis, Beating the Blues plus usual GP care was less effective, on average,
than usual GP care alone (– 0.0277 QALYs). In contrast to the main analysis, when QALYs were generated
using SF-6D values, MoodGYM plus usual GP care had a positive, albeit small, QALY increment (0.0058).
Nevertheless, the estimates were not statistically significant at a 5% significance level for comparison of
either cCBT program against usual GP care alone.
Table 35 reports the cost-effectiveness results for scenario 1. Although Beating the Blues remains
dominated compared with usual GP care alone, MoodGYM now appears cost-effective, resulting in lower
mean costs and higher mean QALYs compared with usual GP care alone. At a £20,000 per QALY threshold,
MoodGYM has a 0.756 probability of being the optimal intervention in terms of cost-effectiveness.
Although the results appear sensitive to the choice of whether EQ-5D or SF-6D was used to estimate QALYs,
with different conclusions reached concerning the cost-effectiveness of MoodGYM, it should be noted that
the differences between all three groups were relatively minor in terms of both costs and QALYs in both sets
of analyses. Therefore, minor differences in the assumptions can lead to different cost-effectiveness
interpretations because of relatively small impacts on the mean incremental estimates of costs and QALYs.
TABLE 35 Cost-effectiveness analysis summary table: SF-6D as HRQoL source (scenario 1)
Treatment group Δ costs (£) Δ QALYs ICER (£ per QALY) Probability of CE at £20,000/QALY
Beating the Blues 104.24 – 0.0277 Dominated 0.007
MoodGYM –106.07 0.0058 Dominant 0.756
Usual GP care alone – – – 0.237
CE, cost-effectiveness.
TABLE 34 Adjusted mean differences in SF-36v2 estimated QALYs between cCBT and usual GP care: SF-6D as
HRQoL source (scenario 1)
Comparison
Adjusted
difference
in means
95% confidence limits
Lower Upper
QALYs – SF-6Da (n = 691)
Beating the Blues vs. usual GP care alone (n= 210 and n= 239, respectively) – 0.0277 – 0.0672 0.0118
MoodGYM vs. usual GP care alone (n= 242 and n= 239, respectively) 0.0058 – 0.0294 0.0409
a On baseline SF-6D score, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
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Table 36 shows the results for scenario 2, where only depression-related treatment costs are considered
(in contrast to all health-care costs in the base case). The estimated impact of each cCBT treatment group
compared with usual GP care alone (adjusted for participant covariates) on depression-related costs is
presented. In this scenario, the results for the incremental costs were consistent with the main analysis,
albeit the magnitude of the differences between the cCBT groups and usual GP care was reduced.
Scenarios 3–5 relax the base-case assumption that data are missing at random and assume, instead, that
data are missing completely at random and analyses are, therefore, conducted on a complete case data
set. Scenario analysis 3 replicated the base-case analysis on the complete case data set. In scenario 4,
HRQoL was sourced on the SF-6D questionnaire and the analysis was performed on the correspondent
complete case data set. Finally, in scenario 5 only depression-related costs were included in the analysis
which was also conducted on the complete case data set. Results for the adjusted differences in mean
QALYs and/or costs between each cCBT treatment group compared with usual GP care are presented in
Tables 37–39.
TABLE 37 Adjusted mean differences in QALYs and costs between cCBT and usual GP care: complete case
(scenario 3)
Comparison
Adjusted
difference
in means
95% confidence limits
Lower Upper
QALYs – EQ-5Da (n = 290)
Beating the Blues vs. usual GP care alone (n= 89 and n= 101, respectively) – 0.0485 – 0.1488 0.0518
MoodGYM vs. usual GP care alone (n= 100 and n= 101, respectively) – 0.0295 – 0.1264 0.0674
Total costsb (n = 290)
Beating the Blues vs. usual GP care alone (n= 89 and n= 101, respectively – £23.62 – £247.75 £200.51
MoodGYM vs. usual GP care alone (n= 100 and n= 101, respectively) – £176.54 – £386.44 £33.37
a On baseline EQ-5D score, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
b On costs at baseline, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
TABLE 36 Adjusted mean differences in depression-related costs between cCBT and usual GP care alone:
depression-related costs (scenario 2)
Comparison
Adjusted
difference
in means
95% confidence limits
Lower Upper
Depression-related costsa (n = 691)
Beating the Blues vs. usual GP care alone (n= 210 and n= 239, respectively) £52.55 – £45.48 £150.58
MoodGYM vs. usual GP care alone (n= 242 and n= 239, respectively) – £57.15 – £142.98 £28.67
a On depression related costs at baseline, gender, age, baseline depression severity, baseline depression duration and
baseline level of anxiety.
ECONOMIC EVALUATION RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
Table 40 reports the incremental cost-effectiveness results for these three scenarios. CEACs for each
scenario are reported in Appendix 14. The results of all scenarios based on complete case data
were consistent with the findings based on the imputed data.
Subgroup analysis
Preference subgroup analysis
The cost-effectiveness estimates for the preference subgroup analysis are shown in Table 41.
In line with the corresponding subgroup analysis reported in Chapter 4, there was little evidence of an
actual interaction effect between preference and treatment allocation on treatment outcomes (costs and
QALYs), with coefficients on the interaction terms for each treatment both being non-significant at 5%
significance level.
TABLE 38 Adjusted mean differences in QALYs (SF-6D estimated) and costs between cCBT and usual GP care:
complete case and SF-6D at HRQoL source (scenario 4)
Comparison
Adjusted
difference
in means
95% confidence limits
Lower Upper
QALYs – SF-6Da (n = 265)
Beating the Blues vs. usual GP care alone (n= 77 and n= 92, respectively) – 0.0297 – 0.0791 0.0196
MoodGYM vs. usual GP care alone (n= 96 and n= 92, respectively) 0.0028 – 0.0436 0.0491
Total costsb (n = 265)
Beating the Blues vs. usual GP care alone (n= 77 and n= 92, respectively) £25.96 – £214.87 £266.80
MoodGYM vs. usual GP care alone (n= 76 and n= 92, respectively) – £157.92 – £372.00 £56.16
a On baseline SF-6D score, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
b On costs at baseline, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
TABLE 39 Adjusted mean differences in QALYs and costs between cCBT and usual GP care: complete case and
depression-related costs (scenario 5)
Comparison
Adjusted
difference
in means
95% confidence limits
Lower Upper
QALYs – EQ-5Da (n = 290)
Beating the Blues vs. usual GP care alone (n= 89 and n= 101, respectively) –0.0485 – 0.1488 0.0518
MoodGYM vs. usual GP care alone (n= 100 and n= 101, respectively) –0.0295 – 0.1264 0.0674
Depression-related costsb (n = 290)
Beating the Blues vs. usual GP care alone (n= 89 and n= 101, respectively) – £42.27 – £173.21 £88.67
MoodGYM vs. usual GP care alone (n= 100 and n= 101, respectively) – £115.35 – £234.08 £3.37
a On baseline EQ-5D score, gender, age, baseline depression severity, baseline depression duration and baseline level
of anxiety.
b On depression-related costs at baseline, gender, age, baseline depression severity, baseline depression duration and
baseline level of anxiety.
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TABLE 40 Cost-effectiveness analysis summary table: complete case scenarios
Scenario Δ costs (£) Δ QALYs ICERa (£ per QALY) Probability of CE at £20,000/QALY
Scenario 3 – complete case
Beating the Blues – 23.62 – 0.0485 487b 0.109
MoodGYM – 176.54 – 0.0295 5984b 0.290
Usual GP care alone – – – 0.601
Scenario 4 – complete case and SF-6D as HRQoL sources
Beating the Blues 25.96 – 0.0297 Dominated 0.017
MoodGYM – 157.92 0.0028 Dominant 0.662
Usual GP care alone – – – 0.321
Scenario 5 – complete case and depression-related costs
Beating the Blues – 42.27 – 0.0485 872b 0.100
MoodGYM – 115.35 – 0.0295 3910b 0.281
Usual GP care alone – – – 0.619
CE, cost-effectiveness.
a Compared with usual GP care.
b ICER on southwest quadrant of the CE plane (ICER refers to cost-effectiveness of usual GP care alone vs. intervention).
TABLE 41 Preference subgroup cost-effectiveness analysis summary table
Analysis Δ costsa (£) Δ QALYsa ICERa (£ per QALY) Probability of CE at £20,000/QALY
Base case
Beating the Blues 104.24 – 0.0435 Dominated 0.038
MoodGYM – 106.07 – 0.0153 6933b 0.417
Usual GP care alone – – – 0.545
No preference
Beating the Blues 295.26 – 0.0599 Dominated 0.124
MoodGYM 89.41 0.0117 7615 0.560
Usual GP care alone – – – 0.440
Preference
Beating the Blues – 4.62 – 0.0341 135b 0.124
MoodGYM – 210.87 – 0.0285 7390b 0.303
Usual GP care alone – – – 0.573
CE, cost-effectiveness.
a Compared with usual GP care alone.
b ICER on south-west quadrant of the CE plane (ICER refers to cost-effectiveness of usual care alone vs. intervention).
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Extrapolation
No strong evidence of difference between the treatments arms in terms of clinical effectiveness, HRQoL or
costs was found in the trial. Given the lack of difference between arms, there is no basis for inferring
that any differences might occur in the future and, therefore, that conclusions might be altered if
extrapolation was conducted. Thus, no extrapolation of the trial results has been conducted.
Evidence synthesis
External evidence was used to facilitate the inclusion of additional trial evidence on the effectiveness of
cCBT and also to incorporate additional comparators which were not included within the REEACT study.
This was undertaken as an exploratory analysis to determine the robustness of the results to external
evidence and to ascertain the generalisability of the findings to a broader decision problem which included
additional comparators. Regression analyses were used to determine the impact of changes in depression,
measured by change in PHQ-9 from baseline, rather than treatment arm on costs, excluding intervention
costs, and QALYs measured in the trial. The coefficients on the change in PHQ-9 from the regression
equations estimate the impact of changes in PHQ-9 on costs and QALYs for participants within the trial.
This approach allowed external evidence on the changes in PHQ-9 to be related to expected changes in
total costs and QALYs for a range of different comparators.
As this analysis was exploratory in nature, we did not undertake a formal systematic search of individual
RCTs. Instead we restricted our approach to including external evidence published in recent meta-analyses
of internet-based and face-to-face psychological therapies for adult patients with depression. Two
meta-analyses were identified, one on the effectiveness of internet-based treatments for depression in
adults,10 in which there was some evidence of effect for therapist-guided cCBT, and another on the
effectiveness of brief face-to-face psychological therapies for patients with depression managed in primary
care settings.79 These reported the effect of the interventions compared with usual care in terms of a SMD.
These SMDs can be converted back onto the change in PHQ-9 (ΔPHQ-9) scale by multiplying them by the
SD in ΔPHQ-9 observed in the trial, so as to estimate the incremental impact of the two interventions on
costs and QALYs in the trial population compared with usual GP care. These analyses were then combined
with estimates of the intervention-specific costs to estimate the cost-effectiveness of cCBT and other
psychological therapies compared with usual GP care alone in participants from the REEACT study.
As shown in Tables 42 and 43, a one-point reduction in PHQ-9 from baseline to 12 months resulted in a
0.02927 increase in QALYs over the trial period and a £7.07 reduction in costs over the trial period. For cCBT,
the meta-analysis10 showed supported cCBT to be the most effective, with a SMD of 0.61, which, when
converted onto the change in PHQ-9 scale, resulted in a reduction of 4.32 on the PHQ-9 score. Unsupported
cCBT had a SMD of 0.25, which resulted in a reduction of PHQ-9 score of 1.771, whereas all cCBT had a
SMD of 0.41, which resulted in a reduction of PHQ-9 score of 2.905. Costs for cCBT treatment were based on
the REEACT trial, assuming that 50% of participants would use Beating the Blues and 50% MoodGYM and
that supported cCBT would involve 1 hour’s support from a community support worker per patient.
Other psychological therapies, which included face-to-face CBT, had a SMD of 0.3179 which resulted in a
reduction in PHQ-9 score of 2.196. Treatment costs for other psychological therapies were based on the
cost of face-to-face CBT from a previous economic evaluation.84
Table 44 presents the results of the evidence synthesis analysis. As can be seen from the table, all
treatments, when compared with usual care, resulted in increased costs but also increased QALYs.
Supported cCBT was the most effective option and extendedly dominated or dominated all the other cCBT
and other psychological treatment options. Supported cCBT compared with usual care generated an ICER
of £126 per QALY and a probability of being cost-effective at a £20,000 per QALY cost-effectiveness
threshold of 0.9747.
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TABLE 42 Trial analysis, treatment effect and change in PHQ-9 parameters used to inform the evidence
synthesis analysis
Parameters Mean SE Source
From trial analysis
Incremental impact of one point reduction in PHQ-9 from
baseline to 12 months on QALYs
0.02927 0.002249 REEACT trial
Incremental impact of one point change in PHQ-9 from baseline
to 12 month on costs (excluding cCBT costs)
– £7.07 £6.7926 REEACT trial
SD of change in PHQ 7.084 – REEACT trial
Treatment effects
SMD of unsupported cCBT 0.25 0.05102 Andersson and Cuijpers (2009)10
SMD of supported cCBT 0.61 0.08163 Andersson and Cuijpers (2009)10
SMD of all cCBT 0.41 0.06120 Andersson and Cuijpers (2009)10
SMD of other psychological therapy (including face-to-face CBT) 0.31 0.07142 Cuijpers et al. (2009)79
Corresponding change in PHQ-9 compared with usual care
Unsupported cCBT 1.771 – –
Supported cCBT 4.321 – –
All cCBT 2.905 – –
Other psychological therapy 2.196 – –
SE, standard error.
TABLE 43 Treatment cost parameters used to inform the evidence synthesis analysis
Treatment costs Mean (£) Source Assumptions
Cost of unsupported cCBT 25 REEACT trial 50% split between Beating the Blues and
MoodGYM
Cost of supported cCBT 46 REEACT trial As above but assuming one hour of clinical
support from a community support worker
(based on Kaltenhaler et al.6)
Cost of all cCBT 35.50 REEACT trial Average of above two assuming 50% split
Cost of other psychological
therapies
1160 National Clinical
Practice Guideline 9084
Assuming same cost as for 18 sessions of CBT
TABLE 44 Evidence synthesis results
Comparison
Incremental
cost
Incremental
QALY ICER
Probability cost-effective
at £20,000 per QALY
Usual care 0 0 – –
Unsupported cCBT vs. usual
care
£12.67 0.05193 Extendedly dominated 0
All cCBT vs. usual care £15.33 0.08508 Extendedly dominated 0.0253
Supported cCBT vs. usual care £15.99 0.12664 £126 per QALY 0.9747
Other psychological
treatments vs. usual care
£1144.70 0.06435 Dominated 0
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The evidence synthesis analysis results suggested that, based on external evidence of effectiveness and the
impact of changes in PHQ-9 from baseline to 12 months on costs and QALYs (observed in the REEACT trial),
therapist-guided cCBT is the most cost-effective treatment option compared with usual GP care alone,
unsupported cCBT and other psychological therapies. These findings are based on exploratory analyses and,
as such, the findings should be considered tentative, as they are not based on directly randomised evidence.
Furthermore, although we sought to include evidence from published meta-analyses, we did not attempt
to critically appraise or quality assess their findings.
Summary
The within-trial results of the economic analysis suggest that neither Beating the Blues nor MoodGYM
appeared cost-effective compared with usual GP care alone. In the base-case results, Beating the Blues was
dominated by usual GP care alone (higher mean costs and lower QALYs), and mean costs and QALYs were
lower for MoodGYM than for usual GP care alone, resulting in an ICER of £6933 per additional QALY for
usual GP care alone versus MoodGYM. Usual GP care alone, compared with either cCBT intervention, was
also the cost-effective intervention in the majority of scenario analyses, and it was the intervention most
likely to be cost-effective at a £20,000 per QALY threshold (probabilities ranging across scenarios from
0.545 and 0.619). The exceptions to this were scenarios where SF-6D scores were used to estimate QALYs.
In these scenarios, MoodGYM dominated usual GP care alone (lower mean costs and higher QALYs) and
was the intervention most likely to be cost-effective at a £20,000 per QALY threshold (probabilities ranging
across scenarios from 0.662 to 0.756).
Although the cost-effectiveness conclusions appear sensitive to the choice of whether EQ-5D or SF-6D is
used to estimate them, the magnitude of the differences between all three groups was relatively low
(and non-significant) for both cost and QALY estimates across all the scenarios. Hence, minor differences in
the assumptions can lead to different cost-effectiveness interpretations because of relatively small impacts
on the mean incremental estimates of costs and QALYs and, therefore, some caution should be exercised
when interpreting these results. Results for the patient subgroup analysis were broadly consistent between
the overall population and patient preference subgroups. There was little evidence of interaction effects
between treatment allocation and patient preference.
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Chapter 6 Results from the qualitative study on
the acceptability to patients and health professionals
of computerised cognitive behaviour therapy
Patient interviews
A total of 320 trial participants were sent an invitation to take part in the qualitative study. Of these, 39
(12%) participants responded to the invitation letter and were contacted by telephone to discuss participating
in the study. A total of 36 participants were subsequently recruited to the study from across the four main
trial sites, sampling for expressed preference for cCBT prior to randomisation and self-reported engagement
with the cCBT program. Owing to a slowing in overall trial recruitment, no participants were recruited who
indicated that their primary reason for refusal to participate in the main trial prior to randomisation was
concern over using cCBT. All recruited participants received a participant information sheet about the
qualitative study and completed a consent form. Individual semistructured patient interviews were conducted
face to face in participants’ homes, except for three patient interviews with participants recruited via the
University of Sheffield, which were conducted by telephone. Patient interviews were conducted by three
qualitative researchers from the Universities of Manchester and Bristol (SK, HT, EA). Participants were
interviewed between January and October 2011, at which point data saturation was judged complete.
Participant characteristics
Details of the study participants are given in Table 45. In summary, 10 (28%) of the participants were
male. The mean age of participants was 51 years, with ages ranging from 29 to 69 years. Thirty-four
(94%) of the participants were white British, with the two remaining participants reporting any other white
background. The mean PHQ-9 score at baseline was 19, with scores ranging from 12 to 27. The participant
sample was, therefore, representative of the wider trial population regarding gender and ethnicity but the
average age of participants in the interview sample was older (51 years compared with 40 years in the trial
overall). Ten of the participants reported that they would not prefer to receive cCBT, 22 participants
indicated that they would prefer to receive cCBT and four participants gave no response. Only four
participants reported during the qualitative interview that they completed all modules of computerised
therapy (all four of whom had used the Beating the Blues program). Two-thirds of participants used the
MoodGYM program (six males, 17 females).
Main themes from patient interviews
We did not observe any specific differences in themes between the two cCBT programs (Beating the Blues
and MoodGYM). Differences in patient experience did not appear to be due to any specific features of a
particular program, but related to the broader experience of therapy delivered by computer.
Three key themes emerged from the data: acceptability; engagement and adherence; and absence of
support. Although participants varied in their reported acceptability, common issues relating to adherence
and support were reported across the whole sample.
Patient acceptability: perceived benefits and barriers
We observed in the data that participants could be classified as ‘positive’, ‘negative’ or ‘ambivalent’ based
on their perceptions of cCBT, referring to the fact that the participants’ perceptions could be clearly and
consistently grouped under the headings of positive, negative or ambivalent and particularly noting how
opinions on the same aspect of the program (e.g. its flexibility) could be seen to vary across these dimensions.
Examples of this, presented in the classifications, are shown in Figure 12. These classifications were found
to conceptualise differences usefully and were exhaustive (all participants could be clearly defined within
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Flexibility Autonomy
‘Too’ flexible – easy to avoid, difficult
to stick to:
‘When you’ve got your off days it’s
easier to not bother with the computer
whereas, you know, if you’ve got a face
to face it’s not, to me, I think it’s not
polite to not turn up. So I think yeah
it’s definitely going to work, you know,
against it being so flexible.’ (DS03)
Enforced autonomy – too demanding,
felt like ‘work’:
‘To come and have to do something
deemed as work, my mind
automatically saw as work and
effort . . . and the amount of motivation
that it takes when you’re depressed
to go and do work it just doesn’t
seem to add up at all.’ (DS08)
Appreciated flexibility but
monitoring/follow-up needed to
support use:
‘I felt because the computer is here I
thought it would be easier than going
somewhere and seeing someone; but it
didn’t work out that way . . . I just sort of
lost the oomph for it and then I kept
forgetting to go on . . . I would have felt
more obliged to do it if there was
somebody keeping an eye on me.’
(DS023)
Interrupted autonomy – didactic, 
did not feel like it was user led:
‘There’s certain parts of MoodGYM
where the computer says, no, you
know, and it was just so typical, 
I was just thinking, oh for goodness
sake! . . . if you’re wanting to get
something done, don’t put fifty
obstacles in front of them getting the
right answer, it’s just daft.’ (DS025)
Patient controls when to use:
‘You could go back on yourself, you
could go back and forward as much as
you want, you could see what you’d put
and what you were working towards,
and that you could stop at any time if
you wanted to and come back at a later
time.’ (DS045)
Supported autonomy – empowering,
encourages self determination:
‘Rather than just saying well here’s
your pills or sit there and talk to
somebody for 35 minutes . . . actually
felt like I was doing something to
help myself.’ (DSB24.5)
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Lacks empathic response:
‘If you're feeling like that, then a
computer telling you something isn't
going to make any difference.  Whereas
somebody seeing you and seeing the
state that you're in can make a big
difference . . . slight physical things,
just the words that she used . . . you know,
the verbal cuddle, which is what you
need.’ (DS11)
Isolating, enhances feeling of
loneliness:
‘You do feel very alone . . . [working
on the computer] sort of highlights it.’
(DS04)
Relational Connectedness
Lacks personalisation – too generic:
‘Some of it didn't feel like it applied
to me. I found it was most effective
and most challenging when I read
something and thought oh yes, that's
me, or I see how that works out in my
life, or I recognise that response . . . just
some way of putting in some basics
about yourself at the beginning, which
would either maybe shape or filter the
content.’ (DS015)
Disconnection from characters:
‘When they were relevant to me it
was fine, you know, but when they
weren't it was so frustrating.’
(DSB0706)
Appreciate anonymity or reduced
pressure of not being face to face:
‘(I felt) that the computer cared, and I
know that sounds absolutely ridiculous,
but it was like speaking to somebody but
different. Maybe because I wasn’t
speaking to somebody, it didn’t hurt me
to write down my feelings.’ (DS016)
Comforting – ‘always there’:
‘I think that’s really important with
people when they’re on the floor and
you’re there and you think you’re the
only one in the world and nobody’s
around, and you can get on there
and, well, it’s instant isn’t it . . . if it’s
three o’clock in the morning,
thinking is this normal, why am I
feeling like this, all that sort of thing,
you just go straight to it and it’s
there.’ (DS038) 
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FIGURE 12 Subthemes and extracts relating to perceived benefits and barriers. (a) Flexibility and autonomy;
and (b) relational and connectedness. Reproduced from Knowles et al.85 © BMJ Open 2015. This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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the groupings). It is not typical to assign qualitative data into formal groups in this manner, but the categories
are useful in the context of this pragmatic trial to understand experience and uptake of the health technology.
Seventeen participants were categorised as ‘ambivalent’ (Beating the Blues, n= 7; MoodGYM, n= 10 ), 10
were categorised as ‘negative’ (Beating the Blues, n= 2; MoodGYM, n= 8) and nine as ‘positive’ (Beating the
Blues, n= 4 ; MoodGYM, n= 5). These classifications were reached through consensus among the qualitative
team, based on the rereading of the transcripts and the identification of consistent differences that could be
classified as positive, negative or ambivalent. However, it is notable that these categorisations did not map
clearly onto expressed prior preference for cCBT. There was no consistent relationship between prior
expressed preference at baseline and whether the participant reported being positive or negative after they
had personal experience of the programs. Although numbers are too small to draw any definitive conclusions,
this may indicate that patients are not able to anticipate if computerised therapy would be appropriate for
them based on initial preferences alone.
Subthemes and extracts relating to perceived barriers and benefits are shown in Figure 12, which illustrates
both the consistency within classifications and also the contrast across the subthemes dependent on
classification. Specifically, the four subthemes presented (‘flexibility, ‘autonomy’, ‘relational’, ‘connectedness’)
illustrate how the same aspects of cCBT could be perceived both positively and negatively, depending on
individual participant experience and preference. The subthemes are further illustrated with quotations within
Figure 12.
l ‘Flexibility’ refers to the unstructured, flexible nature of the treatment, which was perceived as
advantageous by positive participants, who appreciated the greater accessibility, but as a barrier by
negative participants because of the greater responsibility placed on participants to organise and
adhere to sessions themselves. Ambivalent participants recognised the potential benefits of this
flexibility but reported that additional support or monitoring was necessary to encourage them
to engage.
l ‘Autonomy’ refers to how the independence of cCBT was experienced, with negative participants
feeling overburdened by the absence of support, in contrast to positive participants, who felt
empowered to take control of their recovery. Ambivalent participants occupied a ‘middle ground’, in
which they were willing to engage with the program independently but felt that barriers within the
content prevented them from doing so.
l ‘Relational’ refers to whether the absence of another person, such as a therapist, was perceived
positively (owing to the comfort offered by anonymity) or negatively (with participants struggling
without the relational or empathetic input of a therapist). Again, ambivalent participants had a more
moderate response, with increased personalisation being felt to be necessary for them to relate to the
characters in the program and relate the content to their own lives.
l ‘Connectedness’ refers to the degree of connection that participants experienced with the program,
with negative participants feeling that cCBT further isolated them and emphasised their loneliness, in
contrast to positive participants, who felt that the program was ‘always there’ for them. Ambivalent
participants again seemed instead frustrated by limitations of the content of these particular programs,
similar to the ‘Relational’ theme where being able to identify with the material was perceived as
important – in this case, the potential for connection with the content was hindered by inappropriate
or overly generic material.
The analysis demonstrated that although some participants clearly embraced or rejected computerised
therapy, as illustrated in Figure 12, the majority of participants (17 of the sample classed as ‘ambivalent’)
fell between these extremes. For these ‘ambivalent’ participants, cCBT was not rejected outright as with
the ‘negative’ participants or fully embraced as with the ‘positive’ participants but was considered to
require greater external support and greater personalisation of material to enable participants to engage
fully with the programs. Barriers relating specifically to experience of technology, such as problems in
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accessing the program or discomfort using computers, were not observed. This may reflect either that
patient populations are increasingly familiar with using technologies, or that only those patients
comfortable with technology were willing to enter the trial.
Patient engagement and adherence
All participants reported some difficulties with engaging with the programs, but, consistent with their
reported attitudes, there was a trend for ‘positive’ participants to report greater adherence, and three of
the four participants who reported completing the programs were in this group. ‘Negative’ participants
reported lower levels of engagement than the rest of the sample, suggesting that participant attitudes are
associated with behavioural engagement to some extent. On self-reported engagement, positive participants
reported using the program an average of 9.1 times in total, ambivalent participants reported using the
program 6.7 times in total and negative participants reported an average of 3.2 uses in total.
Participants also reported difficulties maintaining engagement when their depression was more severe and
perceived the programs to be inappropriate for patients experiencing severe episodes.
I was feeling so miserable that all those questions did was actually just hold the mirror and show me
how miserable I was and, so, I just turned the program off . . . And that was, for me, the first, kind of,
2 months really, 3 months, because I was just feeling so down.
DS025. Reproduced from Knowles et al.85 © BMJ Open 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
If you’re mildly depressed, or if you’ve turned the corner, then I think that’s when it’s appropriate. But
I think if you were deeply depressed, and still struggling, then it would be much harder . . . I think you
probably would fail and that would make you feel worse. Because the last thing you need is another
failure when you’re feeling really down.
DS017. Reproduced from Knowles et al.85 © BMJ Open 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Despite the provision of regular technical telephone support calls, participants also indicated that a greater
level of monitoring or support would have encouraged engagement, which is reflected in the third theme.
Perceived limitations of support
All participants perceived the programs to be unsupported, suggesting that the technical support and
encouragement offered via telephone support calls within the trial may not meet patient expectations
regarding level or type of support that should be provided. However, although ‘negative’ participants
appeared to disengage with the programs deliberately, both ‘positive’ and ‘ambivalent’ participants
expressed a desire for greater monitoring and follow-up, providing greater motivational support to help
them engage with and complete the programs.
Just someone being aware and sort of either saying ‘oh that’s great, you did another unit! Hey that’s
good, keep it up!’ Or ‘you haven’t done a unit for 4 weeks. Only takes an hour, how about it?’.
DSB0906
If I had somebody ringing me up every week, then I would have been more likely to have stuck with it.
DS018
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Participants reported that GPs did not tend to monitor their engagement with the programs, and
suggested that the support needed to sustain engagement was unlikely to be provided in primary care
because of lack of time in consultations and interruptions to continuity of care:
I think if they’d got the time you maybe would, but I think it’s indicative of the world we live in and
the system that we live with. The good doctors are always in demand and you go back for your repeat
prescription and you see who you see and there are maybe three of them that I would see, but you
don’t see the one that suggested this therapy in the first place. So no, I’ve never talked about it
to anybody.
DS029. Reproduced from Knowles et al.85 © BMJ Open 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
I wouldn’t have expected a GP to call me. It would have been nice, the family GP practitioner in the
countryside but we live in a city and they’ve got what 10,000 patients on their book. So yeah
I understand.
DS08. Reproduced from Knowles et al.85 © BMJ Open 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Summary of main findings from patient interviews
The patient interviews demonstrate the degree of individual difference in experience of cCBT, with a
‘negative’ subset who consider therapy by computer unacceptable because of the absence of interpersonal
support, but another subset preferring cCBT to traditional therapy because of the greater accessibility,
flexibility and anonymity. However, the majority of participants had a more mixed reaction, appreciating the
potential benefits of cCBT but struggling with the content and delivery of the intervention, specifically the lack
of personalisation of materials and the partially supported and unstructured delivery of the program. Poor
adherence and engagement with cCBT were typical and were attributed to severity of depression and
absence of follow-up support to encourage adherence. Even ‘positive’ participants reported that greater
monitoring and follow-up would be needed to help sustain their engagement. Although the data suggested
that addition of monitoring or supportive follow-up could improve engagement and completion, respondents
did not think that this additional follow-up could be provided by GPs in primary care.
There were no obvious differences in attitudes by gender or age, and technological aptitude was not
prominently reported, although it is possible that patients who would struggle with computers had already
self-selected out of the trial.
Health professional interviews
A total of 70 GP practices that had recruited participants to the main trial were sent invitations to
participate in the qualitative study. Fourteen health professionals responded to the invitation and were
contacted to discuss the study in more detail. A total of 11 GPs were subsequently recruited to the study
from 10 GP practices, across six out of the nine trial sites. No expressions of interest were received from
practice managers. All recruited GPs received a participant information sheet about the qualitative study
and completed a consent form. Individual semistructured interviews were conducted with GPs by telephone
by a qualitative researcher (SK) from the University of Manchester. GPs were interviewed between
September 2012 and February 2013.
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Health professional participant characteristics
The sample consisted of eight males and three females. Of the 11 participants, nine were white British and
two were of Asian origin.
Main themes from health professional interviews
Benefits of computerised cognitive behaviour therapy for patients
The primary benefit of having cCBT as a referral option was the speed of access, even in surgeries
supported by local IAPT, where waiting times are relatively short:
For the counselling, even though patient being seen very quickly, usually within . . . now it’s within
14 days, or something like that, there’s no guarantee the next appointment is not 6 weeks, or longer.
GP076 (York site, male)
Yeah, there is a waiting list, our counsellor, usually it’s 4 to 6 weeks, that’s the face to face in the
practice, there’s the IAPT service . . . they can be waiting a month, or so for that as well . . . so, yeah,
the computerised stuff is the fastest definitely.
GP077 (Bristol site, female)
Computerised CBT was also perceived as particularly useful for patients who might otherwise struggle to
access therapy, for example because of time restrictions or job demands:
A few people were very keen on it. That, for example, weren’t able due to work commitments to see
someone that works 9 till 5.
GP073 (York site, male)
Young people who have got work commitments that couldn’t get to somewhere, you know, that
was useful . . . a pragmatic issue of whether it was, sort of, good to fit in with their work, or their
family commitments.
GP077 (Bristol site, female)
‘Matching’ patients to computerised cognitive behaviour therapy
The interviews explored the issue of whether or not GPs referred certain types of patient to cCBT. The
primary considerations tended to be practical ones, such as access to a computer and computer literacy,
and the GPs also appeared to consider demographic factors which they judged to impact on acceptability and
ability to engage:
I think, it also depends on the education of the patient and their ability to use computers and, I guess,
their general intelligence.
GP062 (Manchester site, male)
I think younger people are more likely to respond to computer stuff . . . I think that men might be
more keen on computerised, I think they’re a bit more IT orientated generally.
GP074 (Bristol site, female)
GPs, similar to the patient interview sample, perceived cCBT as unsuitable for people with more severe
depression. However, they justified this on the basis of the level of motivation required to use cCBT, in
contrast to the patient interview sample, which reported lack of support and the difficulty of being
reminded how depressed they felt as the primary barriers for severely depressed patients:
The extremely unmotivated patients who are severely depressed, I think, I have generally stayed away
from, because of the motivation issues.
GP075 (York site, male)
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[if they have] difficulty just motivating themselves to get up in the morning, they’re not going to have
the ability to engage in a CBT thing.
GP078 (Bristol site, male)
One GP working in a community with a large South Asian population also suggested that differences in
attitudes to treatment, particularly self-help based treatments, among ethnic groups could have a role:
I think, for Asian people, explaining that your depression can be helped with an internet program
about you helping yourself, I think, a lot of them think the onus of responsibility for their health is on
someone else and not on them . . . they won’t participate in something like this, they seem to think it’s
an external thing, your health, someone else has to give you medication, it’s not in their control.
GP061 (Manchester site, female)
However, other GPs in the sample also referred to the issue of patients taking responsibility for their own
treatment as a deciding factor in their acceptance of cCBT, and they perceived engagement with cCBT as
requiring individual initiative:
I think, there’s a subgroup of these patients that want their responsibility taken away . . . some people
want to be helped, rather than help themselves.
GP062 (Manchester site, male)
It’s good for somebody who is proactive and wants to get better . . . you have to have the initiative to
actually go there every day, or turn the computer on to do the assessment. And I think that in itself
shows some life skills that I think is often lacking in people who see me for help.
GP079 (York site, male)
However, these assumptions about responsibility and preference could still be related to overarching
perceptions of education and ability, or assumptions about appropriate demographic profiles:
[People who like cCBT] tend to be people that are reasonably literate . . . people that perhaps have an
internal locus of control and enough motivation to feel they can contribute to their own recovery . . .
whereas some people whose lives are perhaps a bit more chaotic, perhaps less educated, less literate
and have a more external locus of control, you know, they don’t necessarily own their own housing,
or even pay their own rent . . . that sort of person might not take so much responsibility for their own
health care as well, including putting in the effort themselves.
GP073 (York site, male)
The websites, I think, help you, but it’s having the confidence to go for it like that and the intelligence
to be analytical like that . . . highly mobile people, intelligent people . . . they need a certain amount of
self-confidence to do that, I think.
GP078 (Bristol site, male)
Implementation in primary care
The interviews explored whether or not GPs would consider providing cCBT on site themselves, as this
model of provision had been employed in earlier trials of one of the cCBT programs (Beating the Blues).
Although some GPs were open to the possibility, they reported a range of barriers in terms of availability
of space and concerns about access to protected computer systems:
We’re really pushed for space . . . I can imagine that it would take the managers and partners a little
bit of getting their heads round it because you would have people using a system which contained
very confidential data.
GP072 (York site, male)
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One GP in the sample had set up access on site but reported it was both time-consuming and expensive:
You had to have a room for patients to come and use a computer, we had to create appointment
slots for them to book in to use the computer, we then had to get a BT line for internet for that
computer, which we ended up paying for two years’ worth, . . . the [primary care trust] said, it has
to be a specially set up computer, because patients shouldn’t be able to access anything.
GP061 (Manchester site, female)
The GPs, in fact, reported access from home as a perceived benefit, and reported that public access to
cCBT would probably be inappropriate because patients might be unfamiliar with public locations such as
libraries or depressed patients might struggle to cope with public access:
I think if you’re depressed, going to a library and logging on in a public place to do something about
depression is quite daunting, isn’t it? If they didn’t have their own computer at home . . . that was a
very potent discourager from doing it really.
GP074 (Bristol site, female)
Provision of support and follow-up in primary care
The GPs commented that patients in the trial had referred to needing more support to engage with cCBT
and suggested that such support could be provided remotely. They perceived barriers to providing such
support themselves because of time constraints.
The patients that have spoken to us about it, they talk about wanting a bit more support to engage
with it . . . from the perspective of the GP supporting the patient, you’d be concerned how high on
the priority of the GP list it would be within the consultation and their knowledge of it as well. So, I
think, the support would be better coming from an external, . . . it could just be a five-minute
telephone call every couple of weeks, or something, more often just to encourage and
motivate somebody.
GP062 (Manchester site, male)
[They’re] probably better off doing IAPT than a GP, just because of the issue of time, we have
10 minutes, by the time we’ve, kind of, reviewed their mental health, then going on to, kind of,
reviewing how they’re doing on a computer might be a bit too long.
GP075 (York site, male)
Consistent with the patient interview sample, GPs reported that they did not tend to follow up patients
who used the programs and so did not tend to know if experience had been positive or not:
I haven’t got the foggiest what’s happened to them. Probably got better because I haven’t seen them
again, or they’re so fed up with what I tried to make them do . . . We come across this sort of situation
so often in our work and in research that you just get used to it. When you don’t get hospital discharge
letters for three months you get very used to this sort of thing. No news is good news.
GP072 (York site, male)
I don’t know, you know, you wouldn’t know! I mean, the people that I saw who got on well with it,
reported positively, but then I might not have seen the people that didn’t get on with it, because they
might not have come back.
GP077 (Bristol site, female)
RESULTS FROM THE QUALITATIVE STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Several of the GPs suggested that providing such follow-up information from the program itself would
have been helpful, which is an option for practices that have purchased the Beating the Blues program,
but was not provided to GPs within the trial:
I think it would have been nice to have had just a brief discharge summary. What was it, 12 weeks or
whenever the final check was, of how that person, how that individual went, just like when I refer to
anyone else, it’s nice to get feedback.
GP073 (York site, male)
I think you need to produce some sort of review, report, if the program actually let us know at the
end, your patient didn’t complete the program, or completed the program with varying degree of
success. Generally, we don’t have any feedback, basically, unless we make the effort ourselves to ask
the patient.
GP078 (Bristol site, male)
Summary of main findings from health professional interviews
The GPs interviewed perceived the key benefits of cCBT to be its accessibility, in terms of being the quickest
treatment available to access even when IAPT services or on-site counsellors were available and also being
more accessible to certain participants because of its flexibility, such as those who work long hours. GPs
were sceptical that cCBT could be provided on site and perceived home access to be most appropriate and
also preferable for patients. The GPs suggested that cCBT would be inappropriate for patients with more
severe depression and most appropriate for patients high in computer literacy who were open to self-help
interventions (as opposed to preferring to receive treatment from others). Consistent with the patient
interviews, GPs reported that they did not tend to monitor or follow up patients using cCBT, and suggested
that incorporating a function within the program to allow them to view patients’ progress would be helpful.
Comparison of the patient and health professional interviews
A core finding from the patient interview transcripts concerned the individual differences in experience of
computerised therapy, which related to different preferences around privacy, flexibility and independent
working. The GPs tended to consider demographic or pragmatic factors in their referrals such as computer
illiteracy or inability to access therapy because of work demands. GPs may be conflating perceptions of
ability or education with perceptions of the patient as willing or able to engage with self-help therapies, or
assuming certain demographic groups will be more suitable, which contrasts with the findings of the
patient qualitative study that did not show consistent differences in age and gender. In fact, the most
positive attitudes were reported by female participants, contrary to stereotypes about preference for cCBT
among males.
Matching appropriate patients to cCBT treatment may need to be focused more on the individual needs
and preferences of the patients, although the lack of congruence between patients’ expressed prior
preference and their experience as positive or negative demonstrates the complexity of doing this. This
may indicate a need for greater GP follow-up in the early stages of use to identify more rapidly those
patients who are now struggling with the intervention, which would be consistent with the principles of
stepped care around self-correction9 when patients do not respond to minimal interventions.
Both patients and health professionals reported a lack of follow-up on use of the cCBT program in primary
care. GPs suggested that notifications from within the cCBT program about completion and assessment
would be helpful to them but did not perceive themselves to have a role in supporting engagement with the
program itself. However, patients’ desire for support was specifically related to a higher level of ongoing
support while completing the cCBT program, although the patients interviewed also questioned whether or
not it was feasible that this could be provided in primary care consultations. This suggests that support for
engagement with cCBT in primary care may need to be provided by other health professionals or provided
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as supplemental remote or face-to-face support as part of the cCBT packages. However, as noted previously,
providing earlier feedback to GPs themselves around initial engagement with the cCBT program may be
necessary to help them follow the self-correcting principles of stepped care and enable alternative referrals
for patients who are unable to complete the computerised intervention.
The majority of GPs were sceptical that computerised therapy could be provided in their practices,
demonstrating that in routine primary care it would be unlikely that cCBT would be provided to patients
on site. Given that those patients who reported positive experiences with cCBT valued the anonymity and
flexibility of access from home, this suggests that attempting to implement cCBT services within general
practice sites may lead to barriers for patient engagement as well as creating difficulties for GPs. It is
possible that those patients who struggled with the flexibility of the home-accessed treatment would
appreciate the greater structure offered by on-site access, but given the reported barriers to implementing
this, it may again be the case that more remote support or motivational support built into the intervention
would be most feasible and effective.
Limitations of the qualitative study with patients and
health professionals
The patient interview sample was predominantly female and all participants were from a white background.
This indicates that the sample is representative of the wider trial population (being consistent with the trial
population profile); but, nevertheless, further research is necessary to determine whether similar experiences
are reported by more diverse patient groups. The finding that technical aptitude was not commonly
reported as a prominent issue may be because potential participants with low computer literacy declined to
take part in the trial. Interviewing participants who decline should be attempted in future research on
computerised interventions to explore if such self-selection occurs.
The GP interview sample was predominantly male, although there did not appear to be any consistent
differences between male and female interviewees’ reports. We did not collect data on other factors that
may have influenced attitudes, such as numbers of years in practice and specialist training in mental health,
although, given the small sample size, it would have been difficult to analyse subgroups within the sample.
The reports from GPs regarding follow-up and support may not be representative of how they would
respond to patients receiving the intervention who were not part of a larger trial and should be interpreted
with caution.
Implications of findings from qualitative study
The combined interviews suggest several approaches for improving engagement and acceptability of cCBT
in primary care:
l identifying factors that impact on patient engagement, specifically personal preferences around
working alone or with the support of health professionals
l improving patient experience and engagement through greater personalisation and provision of
motivational support which could involve minimal health professional contact remotely or face to face
l encouraging early follow-up in primary care to identify which patients find the intervention unsuitable.
Some text has been reproduced from Knowles et al.85 © BMJ Open 2015. This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the
original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Chapter 7 Discussion
The REEACT trial is, to our knowledge, the largest pragmatic evaluation of the clinical effectiveness,cost-effectiveness and acceptability of cCBT in primary care. Hitherto there have been no large-scale
trials conducted independently of the developers of cCBT products and the REEACT trial was commissioned
following an earlier technology appraisal in this area.6 At the time of the design of the trial, both cCBT
products to be evaluated (MoodGYM and Beating the Blues) were recommended in NICE depression
guidelines and both remain NICE-endorsed treatments at the time of publication of this trial.86 A novel
aspect of the REEACT trial is the comparison of a free-to-use cCBT product (MoodGYM) with a
commercially available cCBT product (Beating the Blues); a comparison that addresses an important
question to commissioners of health services and to policy-makers.
The REEACT trial was unusual in comparison with earlier trial-based evaluations in that it included an
extended follow-up to 24 months. Outcomes were measured across a broad range of domains including
psychological well-being, quality of life and health state utility. Important aspects of service utilisation were
also recorded, and the REEACT trial included concurrent qualitative and economic evaluations. The REEACT
trial was also novel in measuring patient preference at baseline, thereby allowing an investigation into the
degree to which baseline preference for computer-delivered therapy might influence the effectiveness of
this intervention (a fully randomised patient preference trial).87 The delivery of the cCBT intervention was
also supported by weekly technical telephone support calls which offered a general level of motivational
enhancement to encourage the uptake of the programs by people with depression and also practical
support in the use of computer-based programs. The level of support matched and often exceeded that
which might be offered in routine NHS primary care and IAPT services, where cCBT remains a
recommended lower-intensity psychological intervention.86
The main findings of the REEACT study in relation to: (1) trial-based estimates of the clinical effectiveness
of cCBT; (2) trial- and model-based estimates of cost-effectiveness; and (3) qualitative examination of
acceptability and use of cCBT will now be discussed in turn.
Trial-based estimates of clinical effectiveness for
computer-delivered cognitive behaviour therapy
There was little or no evidence of statistically significant effects of Beating the Blues on the proportion of
participants who were depressed across all points of follow-up when compared with usual GP care alone.
For the free-to-use MoodGYM package, there was no evidence of effect in the primary outcome on the
proportion of participants who were depressed at 4 months. There was some evidence of a statistically
significant effect of MoodGYM on the proportion of participants who were depressed when compared
with usual GP care at 12 months, but this was no longer evident at 24 months. When comparing
MoodGYM and Beating the Blues, the free-to-use cCBT program MoodGYM was found to be non-inferior
to the commercial pay-to-use cCBT program Beating the Blues across all time points. It is worth noting
that, although the target sample size of 230 participants randomised to each trial arm was not achieved
in the Beating the Blues arm (n= 210), the actual number of participants required for the analysis
(n= 150 per arm) was achieved across all trial arms (Beating the Blues, n= 165; usual GP care alone,
n= 179; and MoodGYM, n= 182).
Turning to the broader range of secondary outcomes which were collected in the REEACT trial, there was
no evidence of statistically significant effects on the overall (including all time points) mean depression
scores, CORE-OM scores and MCS and PCS quality of life scores of Beating the Blues when compared with
usual GP care alone; however, there was evidence of a statistically significant effect of Beating the Blues
on the MCS scores at 12 months. There was no evidence of statistically significant effects on the overall
(including all time points) mean depression scores and PCS quality of life scores of MoodGYM when
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compared with usual GP care alone; however, there was evidence of a statistically significant effect of
MoodGYM on the mean depression scores at 12 months when compared with usual GP care alone. When
all time points were considered simultaneously in a mixed model, there was no clinical benefit for either
MoodGYM or Beating the Blues when compared with usual GP care.
The clinical significance of the small but statistically significant clinical benefit of MoodGYM at 12 months
was not clear. This finding of no benefit at 4 months followed by a small benefit at 12 months for
MoodGYM was unexpected and was difficult to interpret. The primary outcome at 4 months is the point
where any clinical benefit would most readily have been expected, and this finding is not routinely
observed in trial-based evaluations of brief psychological intervention. Based on existing research and
systematic reviews, the greatest amount of benefit would have been expected in the short term and any
short-term benefits would have been expected to have attenuated by 12 months.88,89
When baseline preference for treatment allocation was measured prior to randomisation, we found that
there was a strong preference in favour of cCBT. This baseline preference did not impact on clinical
outcomes within the trial. Computer-delivered CBT was equally ineffective for those with and those
without a strong preference for treatment.
When the process of engagement with cCBT was monitored in the trial with reference to computer
records it was found that there was low uptake and use of programs. Although the large majority of
REEACT participants logged on and used the programs at least once (modal number of sessions= 1 for
both programs), further usage was lower than that which has been reported in developer-led trials. Very
few participants completed all treatment sessions, and the most common number of sessions for either
computer program was just one session. This low usage was apparent despite the provision of regular
(weekly) technical telephone support calls.
In summary, the main finding is, therefore, that for the primary outcome of depression severity at 4 months
there was no significant additional benefit when participants were offered a technically supported form of
computerised therapy in addition to usual GP care. This finding was true for both a free-to-use package
(MoodGYM) and commercially produced cCBT (Beating the Blues).
Summary of trial- and model-based estimates of
cost-effectiveness
The within-trial results of the economic analysis suggest that neither Beating the Blues nor MoodGYM
appeared cost-effective compared with usual GP care alone. In the base-case results, Beating the Blues was
dominated by usual GP care alone (with higher mean costs and lower QALYs associated with Beating the
Blues), and mean costs and QALYs were lower for MoodGYM versus usual GP care alone, resulting in an
ICER of £6933 per additional QALY for usual GP care alone versus MoodGYM. Usual GP care alone
compared with either cCBT intervention was also the cost-effective intervention in the majority of scenario
analyses, and it was the intervention most likely to be cost-effective at a £20,000 per QALY threshold. The
exceptions to this were scenarios where SF-6D scores were used to estimate QALYs. In these scenarios,
MoodGYM dominated usual GP care alone (lower mean costs and higher QALYs) and was the intervention
most likely to be cost-effective at a £20,000 per QALY threshold.
Although the cost-effectiveness conclusions appear sensitive to the choice of whether EQ-5D or SF-6D is
used to estimate them, the magnitude of the differences between all three groups were relatively minor
(and non-significant) for both cost and QALY estimates across all the scenarios. Hence, minor differences in
the assumptions can lead to different cost-effectiveness interpretations because of relatively small impacts
on the mean incremental estimates of costs and QALYs, and some caution should be exercised when
interpreting these results.
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Results for the patient subgroup analyses were broadly consistent between the overall population and both
patient preference subgroups. There was little evidence of interaction effects between treatment allocation
and patient preference.
The evidence synthesis analysis results suggested that, based on external evidence of effectiveness and the
impact of changes in PHQ-9 from baseline to 12 months on costs and QALYs (observed in the REEACT
trial), therapist-guided cCBT may in fact be the most cost-effective treatment option compared with usual
GP care alone and less-supported cCBT. These findings are tentative and are not based on directly
randomised evidence.
Summary of main findings from qualitative examination of
acceptability and use of computerised cognitive behaviour
therapy
The qualitative patient interviews demonstrated a level of individual difference in experience of cCBT,
with a ‘negative’ subset who consider therapy by computer unacceptable because of the absence of
interpersonal therapeutic support, but another subset preferring cCBT to traditional therapy because of the
greater accessibility, flexibility and anonymity. However, the majority of participants had a more mixed
reaction. While they recognised the potential benefits of cCBT, they struggled with the content and
delivery of the intervention, particularly with the lack of personalisation of content and the limited support
and unstructured delivery of the program. Poor adherence and engagement were typical and were
attributed to severity of depression and absence of follow-up support to encourage adherence. Even
‘positive’ participants reported that greater monitoring and follow-up than was provided in weekly
supportive telephone calls would be needed to help sustain their engagement. Although the data
suggested that addition of more intensive monitoring or supportive follow-up could improve engagement
and completion, respondents did not think that this higher level of follow-up could feasibly be provided by
GPs in primary care.
When GPs were interviewed, they perceived the attraction of cCBT to be its accessibility and flexibility, in
terms of being the quickest treatment available to access, particularly to certain patients such as those who
work long hours. GPs were sceptical that cCBT could ever be provided on site and perceived home access to
be most appropriate and also preferable for patients. The GPs suggested that cCBT would be inappropriate
for patients with more severe depression and most appropriate for patients high in computer literacy who
were open to self-help interventions (as opposed to preferring to receive treatment from others).
Matching appropriate patients to cCBT treatment may need to be focused more on the individual needs
and preferences of the patients, although the lack of congruence between patients’ expressed prior
preference and their experience as positive or negative demonstrates the complexity of doing this. This
may indicate a need for greater GP follow-up in the early stages of use, to more rapidly identify those
patients who are now struggling with the intervention, which would be consistent with the principles of
stepped care around self-correction9 when patients do not respond to minimal interventions.
The qualitative evaluation also found that support for engagement with cCBT in primary care may need to
be provided by health professionals (other than GPs), or provided as supplemental remote or face-to-face
support as part of the cCBT packages. Earlier feedback to GPs themselves around initial engagement with
the cCBT program may also be necessary to help them follow the self-correcting principles of stepped care
and enable alternative referrals for patients who are unable to complete the computerised intervention.
That the majority of GPs were sceptical that computerised therapy could be provided in their own
practices demonstrates that in routine primary care it would be impractical and unlikely that cCBT would
be provided to patients on site. It is possible that those patients who struggled with the flexibility of the
home-accessed treatment would appreciate the greater structure offered by on-site access but, given the
DOI: 10.3310/hta191010 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 101
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Littlewood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
reported barriers to implementing this, it may again be the case that more remote support or motivational
support built into the intervention would be most feasible and effective.
The combined interviews suggest several approaches for improving engagement and acceptability of cCBT
in primary care.
Discussion of main findings
The REEACT trial offered an independent and pragmatic evaluation of cCBT. The clinical results of the trial
were shown to be inconsistent with a number of developer-led trials, which have been summarised in
systematic reviews90,91 and UK technology appraisals.6 In addition to the independence of the REEACT trial
from trials conducted by the developers of cCBT, there are a number of differences in the trial design of
REEACT that are important to acknowledge.
The first difference in design is that the REEACT trial was purposely conducted entirely within primary care,
which is the setting in which most cases of depression are managed. This focus on a primary care setting is
in contrast with a number of trials which have recruited either from specialist (secondary care) referral
centres or from centres that have developed specialist clinics requiring participants to be supervised in their
use of the computer package.
The second design difference is the level of support that was offered alongside cCBT. In the REEACT trial,
participants were offered regular (weekly) technical support and general encouragement to use the cCBT
programs but were purposely not offered structured psychological support over the telephone by a mental
health professional. Furthermore, the technical telephone support provided in the REEACT trial did not
involve detailed explanations of CBT and did not involve detailed review of homework or between-session
tasks. The chosen level of technical and motivational support was, therefore, less intense than other trials
where, for example, computer usage has been supervised by therapists on a 1 : 1 basis92 or where a
health-care professional has met with the user and has therefore been physically present to ensure the
user interacts successfully with the computer.7 Trials where there has been an intensive level of support
have generally demonstrated a greater level of effect than less supported programs.91 Nevertheless, the
pragmatic nature of the REEACT trial meant that the level of support that was offered is one that is at
least as intensive as the support offered in many NHS care settings and is in line with (or for MoodGYM
exceeds) the level of recommended support. As such, the REEACT trial represents a realistic evaluation of
an intervention that replicates the use of cCBT in routine primary care settings. The aim of conducting a
pragmatic effectiveness trial of cCBT was, therefore, achieved.
Another important finding in this trial is that there was relatively low uptake of cCBT, despite the provision
of technical telephone support. Other lower intensity interventions for depression have similarly shown
that dropout and failure to engage are common when such interventions are offered in primary care.79
The REEACT findings therefore serve to add to this existing evidence. However, the finding of the low
uptake of cCBT in REEACT contrasts with other developer-led trials that report good levels of uptake
and engagement.79 Here we note again that REEACT was a pragmatic trial and one which replicated a
feasible and representative primary care intervention within the context of a RCT.7,93 The REEACT trial is
a realistic evaluation of computer-delivered CBT, as it is currently offered in the NHS. Within the context of
trials, there has been limited investigation of the reasons for poor engagement and barriers to the use of
cCBT in routine care, and a concurrent qualitative evaluation in the REEACT trial explored reasons for poor
engagement in depth. It was clear that participants with significant levels of depression were not generally
motivated to engage in weekly unguided cCBT sessions. The technology was also not one which
was sufficiently attractive to ensure that participants returned to further sessions after their initial session.
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Conclusion
Computerised CBT forms a core component of stepped psychological care in the UK primary care and other
health systems. The overall conclusion of the REEACT trial is that technically supported cCBT conferred
modest or no benefit over usual GP care. This finding would therefore suggest that the routine promotion
and commissioning of cCBT be reconsidered in the light of the results of this trial. A firm conclusion of the
trial is that a commercially developed cCBT product conferred no benefit over a free-to-use product. This
finding is particularly important for those who commission services and purchase commercial products on
behalf of publicly funded health services. The REEACT trial results suggest that the routine use and purchase
of cCBT is likely to be an ineffective low-intensity form of treatment for people with depression and, as
such, an inefficient use of finite health-care resources. There are other treatments for depression that might
be considered instead of cCBT, which includes telephone-guided self-help, bibliotherapy (unguided or
standalone self-help) and therapist-delivered CBT.86 We would recommend that more large-scale pragmatic
trials of these low-intensity forms of guided self-help are conducted within routine NHS primary care services.
Implications for health care
l In this trial for patients with moderate or severe depression powered to detect non-inferiority,
technically supported cCBT in addition to usual GP care was no more effective than usual GP care alone.
Practice recommendations such as those offered by NICE and IAPT stepped models of care might
usefully be re-examined in the light of these findings.
l We consider that, where cCBT continues to be offered within the portfolio of low intensity
psychological treatment, there should be early follow-up in primary care to identify patients for whom
the intervention may be unsuitable.
l Commissioners of services should take note of our findings that commercially produced products may
add little benefit to usual GP care alone.
l We found no substantial difference in outcomes between the commercially produced product (Beating
the Blues), when offered in addition to usual GP care, and the free-to-use product (MoodGYM), which
is clearly less costly for the NHS.
l Free-to-use products such as MoodGYM could be offered in response to patient choice. However, our
overall finding of the relative lack of benefit of these programs in addition to usual GP care should also
be taken into account in this context.
Recommendations for research
l There is a clinical and economic need for brief, low-intensity self-help interventions for depression. The
finding that computer-based therapies had low uptake and were not well regarded underlines both
the need to further understand barriers to uptake of such therapies and the need for trials of
alternative forms of guided self-help or brief psychological intervention.
l Although technically supported cCBT is largely ineffective and inefficient, a more highly supported form
of cCBT with therapeutic advice, guidance and psychological support may in fact improve outcomes at
an acceptable level of cost. Further trials of more intensively supported computer-delivered guided
self-help are, therefore, required to test this hypothesis.
l Large-scale pragmatic trials of treatments such as bibliotherapy or telephone-based psychological
interventions are, therefore, needed.
l All such studies should be framed in primary care and conducted by researchers other than
product developers.
l In the longer term, if computers are to be used to deliver psychological treatment with minimal
therapist input, then there needs to be improved patient experience and engagement through greater
personalisation of treatment packages. This requires further research and innovation at the
human–computer interface.
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Appendix 1 Regulatory approvals
The REC approval was obtained for the study from the Leeds East REC on 10 July 2008. The relevantResearch and Development departments were approached and approval was given for the
relevant primary care trust (PCTs)/trusts on the dates shown in Table 46.
Approval was gained at six additional PCTs/trusts, but these sites did not recruit any participants to
the study.
TABLE 46 Research and Development trust approvals
Site PCT/Trust Research and development approval
University of Bristol Bristol PCT 21 May 2009
Gloucestershire PCT 22 June 2009
North Somerset PCT 11 November 2009
Somerset PCT 16 November 2009
South Gloucestershire PCT 21 May 2009
University of Manchester Manchester PCT 22 June 2009
Stockport PCT 22 June 2009
University of Sheffield Barnsley PCT 27 April 2009
Derbyshire County PCT 15 October 2009
Sheffield PCT 13 May 2009
University of York North Yorkshire and York PCT 27 May 2009
Durham and Darlington County Durham and Tees Valley PCT 24 November 2009
Gateshead Gateshead PCT 24 April 2009
Hull NHS East Riding of Yorkshire 3 February 2010
NHS Hull 4 November 2008
North of Tyne Northumberland Care Trust 24 April 2009
South of Tyne Sunderland PCT 24 April 2009
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Appendix 2 Details of the study sites
TABLE 47 Study site details
Site Recruitment dates
University of Bristol Recruitment via site research team (recruited first patient August 2009, last patient
January 2011)
University of Manchester Recruitment via site research team (recruited first patient September 2009, last patient
February 2011)
University of Sheffield Recruitment via site research team (recruited first patient September 2009, last patient
February 2011)
University of York Recruitment via site research team (recruited first patient August 2009, last patient
January 2011)
Durham and Darlington Recruitment via the MHRN (recruited first patient January 2010, last patient November 2010)
Gateshead Recruitment via the Primary Care Mental Health Team (recruited first patient September 2009,
last patient January 2011)
Hull Recruitment via University of Hull research nurses (recruited first patient February 2010,
last patient March 2011)
North of Tyne Recruitment via the MHRN (recruited first patient October 2009, last patient February 2011)
South of Tyne Recruitment via the MHRN (recruited first patient February 2010, last patient October 2010)
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Appendix 3 Study information for GP practices
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Appendix 4 Study information for participants
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Appendix 5 Number of participants recruited via
direct referrals and database screening methods
TABLE 48 Number (%) of participants recruited via direct referral and database screening methods
Referral method
Beating the Blues
(N= 210) MoodGYM (n= 242)
Usual GP care alone
(n= 239) Total (n= 691)
Direct referral 153 (72.9) 163 (67.4) 170 (71.1) 486 (70.3)
Record screening 57 (27.1) 79 (32.6) 69 (28.9) 205 (29.7)
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Appendix 6 Summary of participant involvement
in the trial
Research team receives ‘permission of
release of contact details form’ and contacts 
participant to discuss study and to conduct 
telephone pre-screen for eligibility
Patient ineligible
Patient’s GP
advised of outcome
Researcher calls 
randomisation service. 
Participant is allocated to:
No further action needed
Patient is not interested in
study and does not complete a
‘permission of release of
contact details form’
No further action needed
Patient ineligible
Patient’s GP advised of 
outcome
No further action needed
One of two cCBT interventions
(Beating the Blues or MoodGYM)
plus usual GP care
Researcher explains intervention and
provides participant with cCBT
program log-in details and
advises participant about telephone
support worker calls
Participant advised of outcome 
Participant’s GP advised of outcome 
Participant contacted for technical
support on a weekly basis during the
intervention period
Patient is interested in study
and completes a ‘permission
of release of contact details
form’ which is faxed (via GP
practice) or posted (by
participant) to research team
Patient eligible
Researcher arranges home
visit with participant
Home visit – researcher
obtains written consent to
pre-screen for eligibility
Patient eligible
Researcher obtains written
consent for study. Participant
completes baseline
assessment
Usual GP care
Participant advised of outcome
Participant’s GP advised of outcome
Participants contacted to complete
follow-ups at 4, 12 and 24 months
Patient receives information about the 
study via GP practice – during GP
consultation (direct referral) or via letter 
from GP (record screening)
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Appendix 7 Data collection forms
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Appendix 8 Sources and details of key unit costs
TABLE 49 Sources and details of key unit costs
Health-care
resource Unit
Cost per
unit (£) Source Details
Primary care
GP Visit 43.00 PSSRU56 Per surgery consultation lasting 11.7 minutes
GP Telephone
contact
26.00 PSSRU56 Per telephone contact lasting 7.1 minutes
GP Home visit 110.00 PSSRU56 Per home visit lasting 23.4 minutes (includes
travel time)
Practice nurse Visit 10.59 PSSRU56 Practice nurse (Band 5) cost per appointment.
Assumes 15.5 minutes visit duration
Practice nurse Telephone
contact
4.10 PSSRU56 Practice nurse (Band 5) cost per appointment.
Assumes 6 minutes contact duration, as for nurse
advanced telephone consultation (PSSRU)
Community nurse Visit 12.40 PSSRU56 Based on community nurse (Band 6) hour.
Assumes 15.5 minutes visit duration
Community nurse Telephone
contact
4.80 PSSRU56 Based on community nurse (Band 6) hour.
Assumes 6 minutes contact duration, as for nurse
advanced telephone consultation (PSSRU)
Community nurse Home visit 22.00 PSSRU56 Based on community nurse (Band 6) hour.
Assumes 27.5 minutes visit duration (includes
12 minutes of travel time, as for GP home visit)
Specialist nurse Visit 12.66 PSSRU56 Based on specialist nurse hour (Band 6) hour.
Assumes 15.5 minutes visit duration
Specialist nurse Telephone
contact
4.90 PSSRU56 Based on specialist nurse hour (Band 6).
Assumes 6 minutes contact duration, as for nurse
advanced telephone consultation (PSSRU)
Senior specialist
nurse
Visit 14.98 PSSRU56 Based on nurse advanced hour (Band 7).
Assumes 15.5 minutes visit duration
Senior specialist
nurse
Telephone
contact
5.80 PSSRU56 Based on nurse advanced hour (Band 7).
Assumes 6 minutes contact duration, as for nurse
advanced telephone consultation (PSSRU)
Mental health
nurse
Visit 10.33 PSSRU56 Based on nurse hour (mental health – Band 5).
Assumes 15.5 minutes visit duration
Mental health
nurse
Telephone
contact
4.00 PSSRU56 Based on nurse hour (mental health – Band 5)
Health visitor Visit 12.66 PSSRU56 Based on health visitor hour (Band 6). Assumes
15.5 minutes visit duration
Health visitor Telephone
contact
4.90 PSSRU56 Based on health visitor hour (Band 6). Assumes
6 minutes contact duration, as for nurse
advanced telephone consultation (PSSRU)
continued
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TABLE 49 Sources and details of key unit costs (continued )
Health-care
resource Unit
Cost per
unit (£) Source Details
Clinical support
worker
Visit 5.43 PSSRU56 Based on clinical support worker nursing
(community – Band 2) hour. Assumes
15.5 minutes visit duration
Clinical support
worker
Telephone
contact
2.10 PSSRU56 Based on clinical support worker nursing
(community – Band 2) hour. Assumes 6 minutes
contact duration
Out-of-hours
service
Visit 61.14 Primary Care
Foundation
Benchmark94
Average of cost across 84 PCTs in England
Hospital services
Inpatient Elective
Inpatient excess
bed-day
Various NHS reference
costs and
PSSRU56
Per specialty ward, activity weighted average of
corresponding health-related group
Outpatient Visit Various NHS reference
costs56,57
Activity weighted average per specialty
Mental health services
IAPT Visit 70.35 Parry et al.,
201195
Cost per visit based on cost per referral and
mean number of sessions for the Doncaster
cohort. Unit cost estimate uprated to from
2008/09 to 2011/12 cost year
CMHT Visit 44.84 PSSRU56 Based on clinical CMHT member cost per hour.
Assumes same relationship as between clinical
counsellor cost per consultation and cost
per hour
Counsellor Visit 59.00 PSSRU56 Based on clinical counsellor cost per consultation
Psychiatrist Visit 174.64 PSSRU56 Based on psychiatrist (consultant) cost per hour.
Assumes same relationship as between clinical
counsellor cost per consultation and cost
per hour
Psychologist Visit 70.08 PSSRU56 Based on clinical psychologist hour. Assumes
same relationship as between clinical counsellor
cost per consultation and cost per hour
Medication
Depression-related Item Various BNF55 Assumes larger size presentations were used
BNF, British National Formulary.
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Appendix 9 Study information for qualitative
study (patients)
DOI: 10.3310/hta191010 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 101
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Littlewood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
148
DOI: 10.3310/hta191010 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 101
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Littlewood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
DOI: 10.3310/hta191010 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 101
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Littlewood et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152
Appendix 10 Topic guides for qualitative study
(patients and health professionals)
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Appendix 11 Study information for qualitative
study (health professionals)
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Appendix 12 Details of recruiting general
practitioner practices
TABLE 50 Details of recruiting GP practices
Site GP practice PCT/Trust
Number of patients
recruited (n= 691)
University of Bristol Axbridge and Wedmore Medical
Practice
Somerset PCT 9
Barnwood Medical Practice Gloucestershire PCT 4
Bradley Stoke Surgery South Gloucestershire PCT 9
Brockway North Somerset PCT 17
Campden Surgery Gloucestershire PCT 12
Chipping Surgery Gloucestershire PCT 34
Close Farm Surgery South Gloucestershire PCT 7
Dr Burney & Partners South Gloucestershire PCT 5
Horfield Health Centre Bristol PCT 1
London Road Medical Practice Gloucestershire PCT 5
Longlevens Surgery Gloucestershire PCT 3
Orchard Medical Centre Gloucestershire PCT 2
Painswick Surgery Gloucestershire PCT 2
Portland Practice Gloucestershire PCT 1
Stoke Gifford Medical Centre South Gloucestershire PCT 16
Students’ Health Service Bristol PCT 7
The Cedars Surgery North Somerset PCT 5
The Stokes Medical Centre South Gloucestershire PCT 13
West Walk Surgery South Gloucestershire PCT 25
Yorkley Health Centre Gloucestershire PCT 6
University of
Manchester
Adshall Road Medical Practice Stockport PCT 3
Arch Medical Practice, Hulme Medical
Centre
Manchester PCT 6
Barlow Medical Centre Manchester PCT 26
Chadsfield Medical Practice Stockport PCT 1
Eastholme Surgery Stockport PCT 1
Heald Green Health Centre Stockport PCT 5
Heaton Mersey Practice Stockport PCT 2
High Lane Medical Practice Stockport PCT 1
Marple Bridge Stockport PCT 1
Ratcliffe & Chew-Graham Manchester PCT 9
continued
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TABLE 50 Details of recruiting GP practices (continued )
Site GP practice PCT/Trust
Number of patients
recruited (n= 691)
Stockport Medical Group Stockport PCT 11
The Archways Surgery Stockport PCT 2
The Avenue Medical Centre Manchester PCT 18
Wellfield Medical Manchester PCT 4
Woodlands Medical Practice Manchester PCT 11
University of
Sheffield
Avondale Surgery Derbyshire County PCT 2
Birley Health Centre Sheffield PCT 1
Devonshire Green & Hanover Medical
Centres
Sheffield PCT 8
Drs M I Kadarsha & M
Muthulingaswamy
Barnsley PCT 9
Handsworth Grange Sheffield PCT 6
Holywell Medical Group Derbyshire County PCT 11
Mill Road Surgery Sheffield PCT 1
Mosborough Health Centre Sheffield PCT 10
Richmond Medical Centre Sheffield PCT 9
Rotherham Road Medical Centre Barnsley PCT 9
The Old School Medical Centre Sheffield PCT 8
University Health Service Sheffield PCT 21
Whitehouse Surgery Sheffield PCT 4
University of York Ampleforth Surgery North Yorkshire and York PCT 1
Dr Moss & Partners – Kings Rd
Harrogate
North Yorkshire and York PCT 56
Escrick Surgery North Yorkshire and York PCT 9
Leyburn Medical Group North Yorkshire and York PCT 1
Posterngate Sugery – Selby North Yorkshire and York PCT 7
Spring Vale Medical Centre – Whitby North Yorkshire and York PCT 11
Strensall Medical Group North Yorkshire and York PCT 16
York Medical Group Acomb North Yorkshire and York PCT 16
Durham Annfield Plain County Durham and Tees
Valley PCT
7
Harbinson House County Durham and Tees
Valley PCT
4
Peaseway Medical Centre County Durham and Tees
Valley PCT
12
Station View County Durham and Tees
Valley PCT
1
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TABLE 50 Details of recruiting GP practices (continued )
Site GP practice PCT/Trust
Number of patients
recruited (n= 691)
Gateshead Elvaston Road Gateshead PCT 4
Glenpark Medical Centre Gateshead PCT 3
Oxford Terrace Medical Group Gateshead PCT 24
Hull Beeford & Leven Surgery NHS East Riding of Yorkshire 8
Church View Surgery, Hedon NHS East Riding of Yorkshire 11
Cranwell Road Medical Centre NHS East Riding of Yorkshire 36
Dr Cook, Beverley High Road NHS Hull 2
Manor Road HC, Beverley NHS East Riding of Yorkshire 2
Orchard 2000 Medical Centre NHS Hull 1
Springhead Practice NHS Hull 20
St Andrews Group Practice NHS Hull 1
The Marshes, Snaith NHS East Riding of Yorkshire 6
North of Tyne Belford Medical Practice Northumberland Care Trust 1
Bellingham Practice Northumberland Care Trust 2
Coquet Medical Group Northumberland Care Trust 12
Forum Family Practice Northumberland Care Trust 5
Ponteland Medical Group Northumberland Care Trust 7
Sele Medical Practice Northumberland Care Trust 10
South of Tyne Dr Cloak & Partners, Southwick Sunderland PCT 5
Herrington Medical Centre Sunderland PCT 2
Pennywell Medical Centre Sunderland PCT 2
Springwell Medical Group Sunderland PCT 2
Victoria Road Health Centre Sunderland PCT 1
Seventeen additional GP practices were recruited but they did not recruit any participants into the study (1 ×University of
Bristol, 4 ×University of Manchester, 8 ×University of Sheffield, 1 ×University of York, 1 ×Gateshead, 1 ×Hull and 1 ×North
of Tyne).
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Appendix 13 Results of the seemingly unrelated
regressions model: adjusted mean differences in
quality-adjusted life-years and costs between
computerised cognitive behaviour therapy and usual
general practitioner care – complete regression
output for the seemingly unrelated regressions model
(base-case assumptions)
TABLE 51 Results of SURs model: adjusted mean differences in quality-adjusted life-years and costs between cCBT
and usual GP care: complete regression output for the SURs model (base-case assumptions)
QALYs – EQ-5D (n= 691)
Adjusted difference
in means
95% confidence limits
Lower Upper
Beating the Blues vs. usual GP care alone (n= 210 and
n= 239, respectively)
– 0.0435 – 0.1162 0.0291
MoodGYM vs. usual GP care alone (n= 242 and
n= 239, respectively)
– 0.0153 – 0.0914 0.0607
Baseline EQ-5D 0.9557 0.8080 1.1034
Gender 0.0199 – 0.0407 0.0806
Age – 0.0066 – 0.0090 – 0.0041
Anxiety level 0.0022 – 0.0218 0.0261
Depression severity – 0.0081 – 0.0151 – 0.0011
Depression duration – 0.0378 – 0.0624 – 0.0133
Constant 1.2956 1.0630 1.5282
Total costs (n = 691)
Beating the Blues vs. usual GP care alone (n= 210 and
n= 239, respectively)
£102.64 – £92.56 £297.83
MoodGYM vs. usual GP care alone (n= 242 and
n= 239, respectively)
£0.72 – £202.43 £203.87
Baseline costs £2.14 £1.71 £2.56
Gender £22.59 – £149.07 £194.26
Age £12.23 £5.77 £18.69
Anxiety level £27.44 – £31.33 £86.21
Depression severity £19.33 – £2.03 £40.68
Depression duration £8.95 – £49.41 £67.31
Constant –£252.92 – £729.24 £223.41
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Appendix 14 Cost-effectiveness acceptability
curves for scenarios 1–5
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Scenario 3
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Scenario 5
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